WO2020211674A1 - 抗FXI/FXIa抗体及其用途 - Google Patents

抗FXI/FXIa抗体及其用途 Download PDF

Info

Publication number
WO2020211674A1
WO2020211674A1 PCT/CN2020/083413 CN2020083413W WO2020211674A1 WO 2020211674 A1 WO2020211674 A1 WO 2020211674A1 CN 2020083413 W CN2020083413 W CN 2020083413W WO 2020211674 A1 WO2020211674 A1 WO 2020211674A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
antigen
binding fragment
sequence
Prior art date
Application number
PCT/CN2020/083413
Other languages
English (en)
French (fr)
Inventor
田海军
刘登念
邓俗俊
崔西•马克•P
王成
郑勇
肖亮
薛彤彤
王晶翼
Original Assignee
四川科伦博泰生物医药股份有限公司
科纳思药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 四川科伦博泰生物医药股份有限公司, 科纳思药业有限公司 filed Critical 四川科伦博泰生物医药股份有限公司
Priority to US17/310,957 priority Critical patent/US20220162338A1/en
Priority to JP2021548201A priority patent/JP2022528595A/ja
Priority to EP20791510.9A priority patent/EP3957652A4/en
Priority to KR1020217026020A priority patent/KR20210151774A/ko
Priority to CN202311157496.9A priority patent/CN117186232A/zh
Priority to CN202080014807.4A priority patent/CN113474374A/zh
Publication of WO2020211674A1 publication Critical patent/WO2020211674A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Definitions

  • the present invention belongs to the field of therapeutic monoclonal antibodies. More specifically, the present invention relates to an antibody against FXI and/or FXIa; it also relates to the use of the antibody in the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism the use of.
  • thrombosis or embolism involves various organs of the body, mainly heart, brain and peripheral vascular diseases. It has the characteristics of high incidence, high disability and lethality, and is the first cause of death caused by cardiovascular diseases.
  • the prevention and treatment drugs for thrombotic diseases mainly include anticoagulant, antiplatelet and thrombolytic drugs; among them, anticoagulant drugs are mainly used to prevent and treat venous thromboembolism caused by various reasons; in addition, they can also be used Prevent stroke in patients with atrial fibrillation and anticoagulant therapy in patients with acute coronary syndrome.
  • anticoagulant drugs There is a large market demand for anticoagulant drugs, and there are drugs available for clinical use.
  • anticoagulant drugs mainly inhibits the common pathway of coagulation cascade, so bleeding is the main complication.
  • Traditional anticoagulant drugs such as warfarin, heparin, low molecular weight heparin, and new drugs that have been on the market in recent years, such as FXa inhibitors (rivaroxaban, apixaban, etc.) and thrombin inhibitors (dabigatran etexilate) , Hirudin, etc.), all have a good effect on reducing thrombosis, but they all face a common deficiency-may cause bleeding complications. Therefore, there is an urgent need for anticoagulants with low bleeding risk.
  • Factor XI participates in the endogenous coagulation cascade, and its active form is factor XIa (FXIa).
  • FXI protein is a dimer formed by two homologous monomers with a molecular weight of about 80kDa through disulfide bonds. The FXI monomer is composed of four apple domains and one catalytic domain. It is catalyzed by coagulation factor XIIa (FXIIa) to form FXIa and exposes the binding site of FIX. After binding to FIX, it promotes the conversion of FIX into active FIXa, which activates Downstream coagulation cascade.
  • the concentration of coagulation factor XI in mammalian plasma is about 25-30 nM. It is a glycoprotein in the form of zymogen. Almost all FXI forms a complex with high molecular weight kininogen (HK) and circulates in the blood. The impact of HK on FXI functions is still unclear so far. HK may assist FXI to bind to platelets or endothelial cells, indicating that HK has also been observed to inhibit FXI activation.
  • FXI The activation process of FXI is under the action of different proteases, each monomer is cleaved between its Arg369-Ile370 to produce a protein, which consists of an approximately 50kDa heavy chain containing an apple domain and an approximately 30kDa catalytic structure.
  • the domain consists of the light chain, and the heavy chain and the light chain are connected by the disulfide bond formed by Cys362-Cys482.
  • Activated FXI, FXIa usually refers to the dimer FXI each monomer is cleaved at Arg369, but there are cases where only one monomer is activated.
  • FXIa cleaves FIX with the participation of Ca 2+ , turning it into activated FIX (FIXa), which then converts coagulation factor X into its active form Xa.
  • FIXa can then mediate factor II/thrombin activation.
  • Thrombin as the terminal protease in the coagulation cascade, can further promote the production of FXIa by directly activating FXI through a feedback mechanism.
  • Both factor XIIa and FXIa (self-activation) in the coagulation cascade can convert FXI to FXIa.
  • FIX/FIXa activated FIX
  • FIX/FIXa can directly bind to platelets, promote the formation of platelet aggregates in the blood, and form distal microvascular occlusion. Therefore, FIX/FIXa promotes thrombosis through a variety of ways. And animal experiments and clinical observations show that the lack of FIX/FIXa has only a minimal risk of bleeding. Therefore, FIX/FIXa is an ideal target for preventing and treating diseases/disorders related to coagulation or thromboembolism. (Zilberman-Rudenko J.et.al. Coagulation factor XI promotes remote platelet activation and single platelet connsumpation in the bloodstream under shear flow.
  • FXIa molecules that regulate the coagulation function include, but are not limited to: the formation of FXI and/or FXIa dimers; molecules that hinder the activation of FXI, such as coagulation factor XIIa, FXIa, contact with FXI to inhibit or hinder Cut off the activation of FXI; inhibit or block the formation of complexes between FXI and HK; block the catalytic domain of FXI and/or FXIa, or induce conformational changes in the catalytic domain, thereby deactivating FXI and/or FXIa, thereby inhibiting or preventing Cut off the activation of the intrinsic coagulation pathway; inhibit or block the binding of FXI and/or FXIa to the substrate.
  • Bayer's FXIa antibody drug BAY-1213790 for venous embolism is in phase II clinical trials.
  • BAY-1213790 comes from a phage display library and binds to the FXIa catalytic domain.
  • Aronora's AB-023 (14E11) venous embolization indication is in clinical phase I
  • ESRD end-stage renal disease
  • the inventors first developed a murine antibody with excellent properties, which can specifically recognize FXI and/or FXIa. On this basis, the inventors have paid a lot of creative work to carry out in-depth research and modification of the mouse antibody, thereby developing a humanized antibody of the mouse antibody.
  • the antibodies of the present invention are extremely advantageous, which not only retain (or even improve) the functions and properties of the parent murine antibody, for example, bind to FXI and/or with high affinity and specificity.
  • FXIa thus has the potential for preventing and treating coagulation or thromboembolic disorders, and has a very high degree of humanization, and can be safely administered to human subjects without causing immunogenic reactions. Therefore, the antibody of the present invention has great clinical value.
  • the present invention provides an antibody or antigen-binding fragment thereof capable of specifically binding FXI and/or FXIa, the antibody or antigen-binding fragment thereof comprises the following:
  • CDR-L1, CDR-L2 and CDR contained in the light chain variable region (VL) shown in any one of SEQ ID NOs: 2, 18, 19, 20, 30, 32 -L3;
  • the following three light chain CDRs (a) the CDR-L1 or its variants containing amino acid mutations, (a) the CDR-L2 or its variants containing amino acid mutations, (a) The CDR-L3 described in (a) or a variant containing amino acid mutations compared with it;
  • At least one of the three heavy chain CDRs and/or three light chain CDRs described in (b) contains amino acid mutations compared with the corresponding CDRs in (a), and the amino acid mutations are one or several amino acids Substitutions, deletions or additions (for example, substitutions, deletions or additions of 1, 2, or 3 amino acids).
  • the substitutions are conservative substitutions
  • the CDR of the antibody or antigen-binding fragment thereof is defined according to the Kabat, IMGT, Chothia or AbM numbering system.
  • the antibody or antigen-binding fragment thereof further includes the framework regions (FRs) of immunoglobulin derived from human or murine.
  • FRs framework regions
  • the antibody or antigen-binding fragment thereof binds to human FXI and/or human FXIa.
  • the antibody or antigen-binding fragment thereof comprises:
  • CDR-L1, CDR-L2 and CDR-L3 contained in the light chain variable region (VL) shown in any one of SEQ ID NOs: 2, 18, 19, and 20;
  • the following three light chain CDRs (a) the CDR-L1 or its variants containing amino acid mutations, (a) the CDR-L2 or its variants containing amino acid mutations, (a) The CDR-L3 described in (a) or its variant containing amino acid mutations;
  • At least one of the three heavy chain CDRs and/or three light chain CDRs described in (b) contains amino acid mutations compared with the corresponding CDRs in (a), and the amino acid mutations are one or several amino acids Substitutions, deletions or additions (for example, substitutions, deletions or additions of 1, 2, or 3 amino acids); In certain preferred embodiments, the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises:
  • CDR-L1, CDR-L2, and CDR-L3 contained in the light chain variable region (VL) shown in any one of SEQ ID NOs: 30 and 32;
  • the following three light chain CDRs (a) the CDR-L1 or its variants containing amino acid mutations, (a) the CDR-L2 or its variants containing amino acid mutations, (a) The CDR-L3 described in (a) or its variant containing amino acid mutations;
  • At least one of the three heavy chain CDRs and/or three light chain CDRs described in (b) contains amino acid mutations compared with the corresponding CDRs in (a), and the amino acid mutations are one or several amino acids Substitutions, deletions or additions (for example, substitutions, deletions or additions of 1, 2, or 3 amino acids); In certain preferred embodiments, the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof comprises: a variable region of a heavy chain (VH) and/or a variable region of a light chain (VL).
  • VH variable region of a heavy chain
  • VL variable region of a light chain
  • the antibody or antigen-binding fragment thereof of the present invention comprises the following heavy chain variable region (VH) and/or light chain variable region (VL), wherein the CDRs are defined by the IMGT numbering system:
  • VH heavy chain variable region
  • VL The light chain variable region (VL) containing the following 3 CDRs: CDR-L1 with the sequence of SEQ ID NO: 6, CDR-L2 with the sequence of SEQ ID NO: 7, and CDR-L3 of SEQ ID NO: 8 ;
  • VH heavy chain variable region
  • VL The light chain variable region (VL) that contains the following 3 CDRs: CDR-L1 of SEQ ID NO: 36, CDR-L2 of SEQ ID NO: 37, and CDR-L3 of SEQ ID NO: 38 .
  • the antibody or antigen-binding fragment thereof of the present invention comprises the following heavy chain variable region (VH) and/or light chain variable region (VL), wherein the heavy chain variable region (VH ) And/or light chain variable region (VL) compared with the heavy chain variable region and/or light chain variable region described in (a) or (b) under the aforementioned IMGT definition, at least one CDR contains amino acids Mutation, the amino acid mutation is one or several amino acid substitutions, deletions or additions or any combination thereof (for example, 1, 2 or 3 amino acid substitutions, deletions or additions or any combination thereof); preferably, the The substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the following heavy chain variable region (VH) and/or light chain variable region (VL), wherein CDRs are defined by the AbM numbering system:
  • VH heavy chain variable region
  • VL The light chain variable region (VL) that contains the following 3 CDRs: CDR-L1 of SEQ ID NO: 12, CDR-L2 of SEQ ID NO: 13, and CDR-L3 of SEQ ID NO: 14 ;
  • VH heavy chain variable region
  • VL The light chain variable region (VL) that contains the following 3 CDRs: CDR-L1 of SEQ ID NO: 42, CDR-L2 of SEQ ID NO: 43, CDR-L3 of SEQ ID NO: 44 .
  • the antibody or antigen-binding fragment thereof of the present invention comprises the following heavy chain variable region (VH) and/or light chain variable region (VL), wherein the heavy chain variable region (VH ) And/or light chain variable region (VL) compared with the heavy chain variable region and/or light chain variable region described in (a) or (b) under the aforementioned AbM definition, at least one CDR contains amino acids Mutation, the amino acid mutation is one or several amino acid substitutions, deletions or additions or any combination thereof (for example, 1, 2 or 3 amino acid substitutions, deletions or additions or any combination thereof); preferably, the The substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the following heavy chain variable region (VH) and/or light chain variable region (VL), wherein the heavy chain variable region (VH ) And/or light chain variable region (VL) compared with the heavy chain variable region and/or light chain variable region described in (a) or (b) under the aforementioned IMGT or AbM definition, at least one CDR contains amino acid mutations, which are substitutions, deletions or additions of one or several amino acids or any combination thereof (for example, substitutions, deletions or additions of 1, 2 or 3 amino acids or any combination thereof); preferably , The substitutions are conservative substitutions.
  • the VH of the antibody or antigen-binding fragment thereof of the present invention comprises heavy chain variable region (VH) framework regions (FRs) derived from murine immunoglobulin, and/or the antibody or its
  • the VL of the antigen-binding fragment contains light chain variable region (VL) framework regions (FRs) derived from murine immunoglobulin. Therefore, in certain preferred embodiments, the antibodies or antigen-binding fragments thereof of the invention are of murine origin.
  • the VH of the antibody or antigen-binding fragment thereof of the present invention comprises heavy chain variable region (VH) framework regions (FRs) derived from human immunoglobulin, and/or the antibody or its
  • the VL of the antigen-binding fragment contains light chain variable regions (VL) framework regions (FRs) derived from human immunoglobulins. Therefore, in certain preferred embodiments, the antibodies or antigen-binding fragments thereof of the invention are humanized.
  • the heavy chain variable region FRs and/or light chain variable region FRs of the antibody or antigen-binding fragment thereof of the present invention may comprise one or more non-human (e.g., murine) amino acid residues
  • the FRs of the heavy chain framework region and/or the FRs of the light chain framework region may comprise one or more amino acid back mutations, in which there are corresponding murine amino acid residues.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the degree of humanization of the antibody or antigen-binding fragment thereof of the present invention is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%. %, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.
  • the antibody or antigen-binding fragment thereof of the invention comprises:
  • VH Heavy chain variable region
  • sequence shown in any one of SEQ ID NOs: 1, 15, 16, 17 has at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93% , At least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity sequence;
  • VL The light chain variable region (VL), which comprises an amino acid sequence selected from:
  • sequence shown in any one of SEQ ID NOs: 2, 18, 19, 20 has at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93% , At least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity sequence.
  • the antibody or antigen-binding fragment thereof of the invention comprises:
  • VH Heavy chain variable region
  • sequence shown in any one of SEQ ID NOs: 29 and 31 has at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% , At least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical sequence;
  • VL The light chain variable region (VL), which comprises an amino acid sequence selected from:
  • sequence shown in any one of SEQ ID NOs: 30 and 32 has at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% , At least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical sequence.
  • the antibody or antigen-binding fragment thereof of the present invention has the following heavy chain variable region (VH) and/or light chain variable region (VL): SEQ ID NOs: 1, 15, 16, 17 VH shown in any item, and/or VL shown in any one of SEQ ID NOs: 2, 18, 19, and 20.
  • the antibody or antigen-binding fragment thereof of the present invention has the following heavy chain variable region (VH) and/or light chain variable region (VL): SEQ ID NOs: 29, 31 VH shown, and/or VL shown in any one of SEQ ID NOs: 30 and 32.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 1, and/or the VL shown in SEQ ID NO: 2.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO:1 and/or the VL shown in SEQ ID NO: 2. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 1 and/or the VL shown in SEQ ID NO: 2.
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof).
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 15 and/or the VL shown in SEQ ID NO: 18.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 15 and/or the VL shown in SEQ ID NO: 18. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 15 and/or the VL shown in SEQ ID NO: 18.
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof).
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 15 and/or the VL shown in SEQ ID NO: 20.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 15 and/or the VL shown in SEQ ID NO: 20. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 15 and/or the VL shown in SEQ ID NO: 20.
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof).
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 16, and/or the VL shown in SEQ ID NO: 18.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 16 and/or the VL shown in SEQ ID NO: 18. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 16 and/or the VL shown in SEQ ID NO: 18.
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof).
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 17, and/or the VL shown in SEQ ID NO: 19.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 17 and/or the VL shown in SEQ ID NO: 19 %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 17 and/or the VL shown in SEQ ID NO: 19
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof.
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 17, and/or the VL shown in SEQ ID NO: 18.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 17 and/or the VL shown in SEQ ID NO: 18. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 17 and/or the VL shown in SEQ ID NO: 18
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof.
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 29, and/or the VL shown in SEQ ID NO: 30.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 29 and/or the VL shown in SEQ ID NO: 30. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 29 and/or the VL shown in SEQ ID NO: 30.
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof).
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises the VH shown in SEQ ID NO: 31, and/or the VL shown in SEQ ID NO: 32.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof of the present invention has at least 70% compared with the VH shown in SEQ ID NO: 31 and/or the VL shown in SEQ ID NO: 32. %, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, Or 100% identity.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof has one or more than the VH shown in SEQ ID NO: 31 and/or the VL shown in SEQ ID NO: 32.
  • the substitution, deletion or addition of four amino acids or any combination thereof for example, the substitution, deletion or addition of 1, 2, 3, 4, or 5 amino acids or any combination thereof).
  • the substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • VH having the sequence shown in SEQ ID NO: 15 and VL having the sequence shown in SEQ ID NO: 18;
  • VH having the sequence shown in SEQ ID NO: 16 and VL having the sequence shown in SEQ ID NO: 18;
  • VH having the sequence shown in SEQ ID NO: 31 and VL having the sequence shown in SEQ ID NO: 32.
  • the antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) and the light chain variable region (VH) Compared with the VH and VL described in any group of (a) to (h), the variable chain region (VL) has at least 70%, at least 80%, at least 85%, At least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity; and/or , Its light chain variable region (VL) has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96% , At least 97%, at least 98%, at least 99%, or 100% identity.
  • the antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) and the light chain variable region (VH) Compared with the VH and VL described in any group of (a) to (h), the variable chain region (VL) has one or several amino acid substitutions, deletions or additions or Any combination thereof (for example, substitution, deletion or addition of 1, 2, 3, 4 or 5 amino acids or any combination thereof); and/or, its light chain variable region (VL) has one or more Amino acid substitutions, deletions or additions or any combination thereof (for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions or any combination thereof); preferably, the substitutions are conservative substitutions .
  • the antibody or antigen-binding fragment thereof of the present invention may further comprise a constant region sequence derived from a mammalian (e.g., murine or human) immunoglobulin or a variant thereof.
  • the heavy chain of the antibody or antigen-binding fragment thereof of the present invention comprises the heavy chain constant region (CH) of a human or murine immunoglobulin or a variant thereof, and the variant is derived from the wild type Sequence comparisons have one or more amino acid substitutions, deletions or additions or any combination thereof (for example, up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions or additions or any combination thereof; For example, 1, 2, 3, 4, or 5 amino acid substitutions, deletions or additions or any combination thereof); and/or, the light chain of the antibody or antigen-binding fragment thereof of the present invention comprises human or murine immunoglobulin
  • the heavy chain of the antibody or antigen-binding fragment thereof of the present invention comprises the heavy chain constant region (CH) of a human immunoglobulin or a variant thereof, and the variant is derived from the wild type Conservative substitutions of up to 20 amino acids compared to the sequence (for example, conservative substitutions of up to 15, up to 10, or up to 5 amino acids; for example, conservative substitutions of 5, 4, 3, 2, or 1 amino acid)
  • the light chain of the antibody or antigen-binding fragment thereof of the present invention comprises the light chain constant region (CL) of a human immunoglobulin or a variant thereof, which has the wild-type sequence from which it is derived Conservative substitutions of up to 20 amino acids (e.g., conservative substitutions of up to 15, up to 10, or up to 5 amino acids; for example, 5, 4, 3, 2, or 1 amino acid conservative substitutions).
  • the heavy chain of the antibody or antigen-binding fragment thereof of the present invention comprises the heavy chain constant region (CH) of murine immunoglobulin or a variant thereof, which is similar to the wild-type sequence from which it is derived.
  • the ratio has conservative substitutions of up to 20 amino acids (e.g., conservative substitutions of up to 15, at most 10, or at most 5 amino acids; for example, conservative substitutions of 5, 4, 3, 2, or 1 amino acid).
  • the light chain of the antibody or antigen-binding fragment thereof of the present invention comprises the light chain constant region (CL) of murine immunoglobulin or a variant thereof, which is similar to the wild-type sequence from which it is derived.
  • the ratio has conservative substitutions of up to 20 amino acids (e.g., conservative substitutions of up to 15, at most 10, or at most 5 amino acids; for example, conservative substitutions of 5, 4, 3, 2, or 1 amino acid).
  • the constant region is altered, such as by amino acid mutations, to modify the properties of the anti-FXI and/or FXIa antibody molecule (e.g., to change one or more of the following properties: Fc receptor binding, antibody glycosylation , The number of cysteine residues, effector cell function or complement function).
  • a functional change can be produced by replacing at least one amino acid residue in the constant region of an antibody with a different residue, for example, changing the affinity of the antibody to an effector ligand (such as FcR or complement C1q), thereby changing the effector function (such as reducing ).
  • the Fc region of an antibody mediates several important effector functions, such as ADCC, phagocytosis, CDC, etc.
  • the antibody or antigen-binding fragment thereof of the present invention has a heavy chain constant region (Fc), which is selected from, for example, IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE. Region; preferably selected from, for example, the heavy chain constant region of IgG1, IgG2, IgG3, and IgG4, more preferably selected from the heavy chain constant region of IgG1 or IgG4 (for example, human IgG1 or IgG4).
  • Fc heavy chain constant region
  • the antibody or antigen-binding fragment thereof of the present invention has a light chain constant region selected from, for example, kappa or lambda light chain constant regions, preferably kappa light chain constant regions (e.g., human kappa light chain).
  • the antibody or antigen-binding fragment thereof comprises a heavy chain constant region selected from: (1) a human IgG1 heavy chain constant region; or (2) a human IgG4 heavy chain constant region.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • Heavy chain constant region which comprises an amino acid sequence selected from the following:
  • sequence shown in SEQ ID NO: 21 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, Sequences that are at least 97%, at least 98%, at least 99%, or 100% identical;
  • sequence shown in SEQ ID NO: 22 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, A sequence that is at least 97%, at least 98%, at least 99%, or 100% identical.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain constant region (CH) as shown in SEQ ID NO: 21 and a light chain constant region (CL) as shown in SEQ ID NO: 22 ).
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the sequence shown in (i) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence;
  • a light chain which comprises an amino acid sequence selected from:
  • sequence shown in (vi) and (iv) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the sequence shown in (i) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence;
  • a light chain which comprises an amino acid sequence selected from:
  • sequence shown in (vi) and (iv) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the sequence shown in (i) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence;
  • a light chain which comprises an amino acid sequence selected from:
  • sequence shown in (vi) and (iv) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the sequence shown in (i) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence;
  • a light chain which comprises an amino acid sequence selected from:
  • sequence shown in (vi) and (iv) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the sequence shown in (i) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence;
  • a light chain which comprises an amino acid sequence selected from:
  • sequence shown in (vi) and (iv) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody or antigen-binding fragment thereof of the present invention comprises:
  • the sequence shown in (i) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence;
  • a light chain which comprises an amino acid sequence selected from:
  • sequence shown in (vi) and (iv) has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97 %, at least 98%, at least 99%, or 100% identity sequence.
  • substitutions described in (ii) or (v) are conservative substitutions.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 1 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 2 and the light chain of the constant region (CL) shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 15 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 18 and the light chain of the constant region (CL) of the light chain shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 15 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 20 and the light chain of the constant region (CL) of the light chain shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 16 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 18 and the light chain of the constant region (CL) of the light chain shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 17 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 19 and the light chain of the light chain constant region (CL) shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 17 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 18 and the light chain of the constant region (CL) of the light chain shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 29 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 30 and the light chain of the light chain constant region (CL) shown in SEQ ID NO: 22.
  • the antibody of the present invention comprises: a heavy chain comprising the VH shown in SEQ ID NO: 31 and the heavy chain constant region (CH) shown in SEQ ID NO: 21, and, comprising SEQ ID The VL shown in NO: 32 and the light chain of the constant region (CL) of the light chain shown in SEQ ID NO: 22.
  • the antibodies of the invention are chimeric antibodies or humanized antibodies.
  • the antibody or antigen-binding fragment thereof of the present invention is selected from ScFv, Fab, Fab', (Fab') 2 , Fv fragments, disulfide-linked Fv (dsFv), diabody ), bispecific antibodies, and multispecific antibodies.
  • the antibody or antigen-binding fragment thereof has reduced ADCC activity.
  • the antibody or antigen-binding fragment thereof has reduced CDC activity.
  • the antibody or antigen-binding fragment thereof does not have CDC activity.
  • the antibody or antigen-binding fragment thereof does not have ADCC activity.
  • the antibody or antigen-binding fragment thereof has reduced ADCC and reduced CDC activity.
  • the antibody or antigen-binding fragment thereof does not have ADCC nor CDC activity.
  • the antibody or antigen-binding fragment thereof of the present invention has at least one of the following characteristics:
  • Binding FXI and/or FXIa e.g., human FXI and/or human FXIa
  • a KD of less than about 100 nM, such as less than about 10 nM, 1 nM, 0.1 nM or less; preferably, the K D can pass through the field Measured by well-known techniques, such as biofilm interference technology (BLI) (such as ForteBio ) Measured;
  • BLI biofilm interference technology
  • Binding FXI with an EC50 of less than about 500nM for example, less than about 100nM, 10nM, 1nM, 0.9nM, 0.8nM, 0.7nM, 0.6nM, 0.5nM, 0.4nM, 0.3nM, 0.2nM, 0.1nM or less
  • FXIa for example, human FXI and/or human FXIa
  • the EC50 can be measured by a technique known in the art, for example, by flow cytometry or cell competition ELISA;
  • the antibody or antigen-binding fragment thereof has reduced ADCC and/or CDC activity
  • the antibody or antigen-binding fragment thereof does not have ADCC and/or CDC activity
  • the antibody or antigen-binding fragment thereof of the invention prevents the FXI catalytic domain from assuming an active conformation when bound to FXI. In certain preferred embodiments, the antibody or antigen-binding fragment thereof of the present invention, when bound to FXI, prevents the FXI catalytic domain from exhibiting an active conformation by inducing a conformational change in the zymogen structure, thereby further inhibiting binding to FIX.
  • the antibody or antigen-binding fragment thereof of the present invention can be derivatized, for example linked to another molecule (for example another polypeptide or protein).
  • another molecule for example another polypeptide or protein.
  • the derivatization (eg, labeling) of an antibody or antigen-binding fragment thereof will not adversely affect its binding to FXI and/or FXIa (especially human FXI and/or FXIa). Therefore, the antibodies or antigen-binding fragments thereof of the present invention are also intended to include such derivatized forms.
  • the antibody or antigen-binding fragment thereof of the present invention can be functionally linked (by chemical coupling, gene fusion, non-covalent linkage or other means) to one or more other molecular groups, such as another antibody (for example, to form Bispecific antibodies), detection reagents, pharmaceutical reagents, and/or proteins or polypeptides capable of mediating the binding of an antibody or antigen-binding fragment to another molecule (for example, avidin or polyhistidine tag).
  • another antibody for example, to form Bispecific antibodies
  • detection reagents for example, to form Bispecific antibodies
  • pharmaceutical reagents for example, to form Bispecific antibodies
  • proteins or polypeptides capable of mediating the binding of an antibody or antigen-binding fragment to another molecule (for example, avidin or polyhistidine tag).
  • bispecific antibody is produced by cross-linking two or more antibodies (of the same type or different types).
  • Methods for obtaining bispecific antibodies are well known in the art, and examples thereof include, but are not limited to, chemical cross-linking methods, cell engineering methods (hybrid hybridoma methods), or genetic engineering methods.
  • Another type of derivatized antibody is a labeled antibody.
  • the antibody or antigen-binding fragment of the present invention can be linked to a detectable label.
  • the detectable label of the present invention can be any substance that can be detected by fluorescence, spectroscopy, photochemistry, biochemistry, immunology, electrical, optical or chemical means.
  • Such labels are well known in the art, examples of which include, but are not limited to, enzymes (for example, horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.), radioactive nuclear (E.g., 3 H, 125 I, 35 S, 14 C, or 32 P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC) , Phycoerythrin (PE), Texas red, rhodamine, quantum dots or cyanine dye derivatives (e.g.
  • enzymes for example, horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.
  • radioactive nuclear E.g., 3 H, 125 I, 35 S, 14 C, or 32 P
  • radioactive labels can be detected using photographic film or a scintillation calculator, and fluorescent labels can be detected using a light detector to detect the emitted light.
  • Enzyme markers are generally detected by providing a substrate to the enzyme and detecting reaction products produced by the action of the enzyme on the substrate, and calorimetric markers are detected by simply visualizing colored markers.
  • such labels can be suitable for immunological detection (e.g., enzyme-linked immunoassay, radioimmunoassay, fluorescent immunoassay, chemiluminescence immunoassay, etc.).
  • the detectable label as described above can be connected to the antibody or antigen-binding fragment thereof of the present invention through linkers of different lengths to reduce potential steric hindrance.
  • the antibody or antigen-binding fragment thereof of the present invention can also be derivatized with chemical groups, such as polyethylene glycol (PEG), methyl or ethyl, or sugar groups. These groups can be used to improve the biological properties of antibodies, for example to increase serum half-life.
  • chemical groups such as polyethylene glycol (PEG), methyl or ethyl, or sugar groups.
  • the present invention provides a conjugate.
  • the conjugate includes any antibody or antigen-binding fragment thereof that specifically binds to FXI and/or FXIa of the present invention, and a coupling portion, wherein the coupling portion is a detectable label, such as The above-mentioned radioisotopes, fluorescent substances, luminescent substances, colored substances or enzymes.
  • the coupling moiety is a therapeutic agent; optionally, the therapeutic agent binds to one or more of the antibody or antigen-binding fragment thereof of the present invention through a linker.
  • the therapeutic agent is bound to the antibody or antigen-binding fragment thereof of the present invention through a linker.
  • the therapeutic agent is selected from any one of the uses, treatment methods and pharmaceutical compositions in the present disclosure.
  • the linker does not significantly affect the binding biological activity of the antibody or antigen-binding fragment thereof of the present invention.
  • the present invention provides a multispecific antibody comprising the antibody or antigen-binding fragment thereof that specifically binds FXI and/or FXIa of the present invention, and another antibody or Antigen-binding fragments, or antibody analogs.
  • the multispecific antibody is a conjugate comprising the antibody or antigen-binding fragment thereof of the present invention that specifically binds FXI and/or FXIa and another antibody or antigen-binding fragment thereof, or antibody analog Things.
  • the multispecific antibody is formed by coupling the antibody or antigen-binding fragment thereof that specifically binds to FXI and/or FXIa of the present invention and another antibody or antigen-binding fragment or antibody analog thereof, and Wherein each antibody or its antigen-binding fragment or antibody analogue maintains the original binding specificity.
  • the multispecific antibody is a bispecific antibody or a trispecific antibody or a tetraspecific antibody.
  • the antibody of the present invention can be prepared by various methods known in the art, for example, obtained by genetic engineering recombinant technology.
  • DNA molecules encoding the heavy chain and light chain genes of the antibody of the present invention are obtained by chemical synthesis or PCR amplification.
  • the resulting DNA molecule is inserted into the expression vector and then transfected into the host cell. Then, the transfected host cell is cultured under specific conditions, and the antibody of the present invention is expressed.
  • the antigen-binding fragments of the present invention can be obtained by hydrolyzing intact antibody molecules (see Morimoto et al., J.Biochem.Biophys.Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)) .
  • these antigen-binding fragments can also be directly produced by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11:548-557 (1999); Little et al., Immunol. Today, 21:364-370 (2000) )).
  • Fab' fragments can be obtained directly from host cells; Fab' fragments can be chemically coupled to form F(ab') 2 fragments (Carter et al., Bio/Technology, 10:163-167 (1992)).
  • Fv, Fab or F(ab') 2 fragments can also be directly isolated from the recombinant host cell culture medium.
  • the present invention provides an isolated nucleic acid molecule comprising nucleotides encoding the antibody of the present invention or its antigen-binding fragment, or its heavy chain variable region and/or light chain variable region. Sequence, or one or more CDRs thereof.
  • the nucleotide sequence can be replaced based on the codon degeneracy.
  • the nucleotide sequence is codon optimized.
  • the isolated nucleic acid molecule comprises: a first nucleic acid and a second nucleic acid respectively encoding the heavy chain variable region and the light chain variable region of the antibody or antigen-binding fragment thereof of the present invention, or The first nucleic acid respectively encoding the heavy chain variable region and the heavy chain constant region of the antibody or antigen-binding fragment thereof of the present invention, and the second nucleic acid of the light chain variable region and the light chain constant region, or respectively encoding the antibody of the present invention Or the first nucleic acid and the second nucleic acid of the heavy chain and the light chain of the antigen-binding fragment thereof.
  • the antibody of the present invention described above is selected from any one of the following group: 36G9.10, 36G9.10-hz43, 36G9.10-hz73, 36G9.10-hz74, 36G9 .10-hz92, 36G9.10-hz93, 7B2, 7B2-hz11.
  • the first nucleic acid and the second nucleic acid comprise nucleic acids having substantially the same sequence as the first nucleic acid and the second nucleic acid described above.
  • the isolated nucleic acid molecule may comprise the nucleotide sequence shown in SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28 in the sequence listing or a sequence substantially identical thereto .
  • the substantially identical sequence refers to a sequence having at least about 85%, 90%, 95%, 99% or higher identity or a sequence having one or more nucleotide substitutions, Or a sequence that does not differ by more than 3, 6, 15, 30 or 45 nucleotides).
  • the present invention provides an isolated nucleic acid molecule comprising a nucleic acid molecule encoding an antibody heavy chain variable region, and/or a nucleic acid molecule encoding an antibody light chain variable region, wherein,
  • the nucleic acid molecule encoding the variable region of the antibody heavy chain has a nucleotide sequence selected from: (a). The nucleotide sequence shown in SEQ ID NO: 23, or (b).
  • nucleotide sequence e.g., a sequence that has at least about 85%, 90%, 95%, 99% or more identity compared with the nucleotide sequence of (a), Or a sequence with one or more nucleotide substitutions), or (c).
  • the nucleic acid molecule encoding the variable region of the antibody light chain has a sequence selected from the following: (d). The nucleotide sequence shown in SEQ ID NO: 24, or (e). and (d).
  • the nucleotide sequence is substantially the same sequence (for example, compared with the nucleotide sequence described in (d), a sequence that has at least about 85%, 90%, 95%, 99% or more identity, or has a Or more nucleotide substitutions), or (f).
  • the nucleotide sequence described in (d) does not differ by more than 3, 6, 15, 30 or 45 nucleotides.
  • the present invention provides an isolated nucleic acid molecule comprising a nucleic acid molecule encoding an antibody heavy chain variable region, and/or a nucleic acid molecule encoding an antibody light chain variable region, wherein,
  • the nucleic acid molecule encoding the variable region of the antibody heavy chain has a nucleotide sequence selected from: (a). The nucleotide sequence shown in SEQ ID NO: 27, or (b).
  • nucleotide sequence that is substantially the same as the nucleotide sequence (e.g., a sequence that has at least about 85%, 90%, 95%, 99% or more identity compared with the nucleotide sequence of (a), Or a sequence with one or more nucleotide substitutions), or (c).
  • the nucleic acid molecule encoding the variable region of the antibody light chain has a nucleotide sequence selected from the following: (d). The nucleotide sequence shown in SEQ ID NO: 28, or (e). and (d).
  • the isolated nucleic acid molecule of the present invention comprises the nucleic acid molecule encoding the variable region of the antibody heavy chain as shown in SEQ ID NO: 23, and/or the encoding as shown in SEQ ID NO: 24 The nucleic acid molecule of the variable region of the antibody light chain.
  • the isolated nucleic acid molecule of the present invention comprises the nucleic acid molecule encoding the variable region of the antibody heavy chain as shown in SEQ ID NO: 27, and/or the encoding as shown in SEQ ID NO: 28 The nucleic acid molecule of the variable region of the antibody light chain.
  • the present invention provides an isolated nucleic acid molecule comprising a nucleic acid molecule encoding an antibody heavy chain, and/or a nucleic acid molecule encoding an antibody light chain, wherein the encoding antibody heavy chain
  • the nucleic acid molecule has a nucleotide sequence selected from the following: (a). The nucleotide sequence shown in SEQ ID NO: 25, or (b).
  • the nucleotide sequence described in (a) is substantially the same (E.g., a sequence having at least about 85%, 90%, 95%, 99% or higher identity compared with the nucleotide sequence described in (a), or having one or more nucleoside Acid substitution sequence), or (c).
  • nucleic acid molecule of the chain has a nucleotide sequence selected from the following: (d) the nucleotide sequence shown in SEQ ID NO: 26, or the nucleotide sequence described in (e) and (d) basically The same sequence (for example, a sequence having at least about 85%, 90%, 95%, 99% or higher identity compared with the nucleotide sequence described in (d)., or having one or more Nucleotide substitution sequence), or (f).
  • the nucleotide sequence described in (d) does not differ by more than 3, 6, 15, 30 or 45 nucleotides.
  • the isolated nucleic acid molecule of the present invention comprises the nucleic acid molecule encoding the antibody heavy chain as shown in SEQ ID NO: 25, and/or the antibody light chain encoding the antibody light chain as shown in SEQ ID NO: 26 Of nucleic acid molecules.
  • a vector (such as a cloning vector or expression vector) is provided, which comprises the isolated nucleic acid molecule of the present invention.
  • the vectors of the present invention are, for example, plasmids, cosmids, bacteriophages, lentiviruses and the like.
  • the vector is capable of expressing the antibody or antigen-binding fragment thereof of the present invention in a subject (such as a mammal, such as a human).
  • a host cell which contains the isolated nucleic acid molecule of the present invention or the vector of the present invention.
  • the host cell may be a eukaryotic cell (e.g., mammalian cell, insect cell, yeast cell) or a prokaryotic cell (e.g., Escherichia coli).
  • Suitable eukaryotic cells include, but are not limited to, NS0 cells, Vero cells, Hela cells, COS cells, CHO cells, HEK293 cells, BHK cells, and MDCKII cells.
  • Suitable insect cells include but are not limited to Sf9 cells.
  • the host cell of the present invention is a mammalian cell, such as CHO (e.g., CHO-K1, CHO-S, CHO DXB11, CHO DG44).
  • a method for preparing the antibody or antigen-binding fragment thereof of the present invention which comprises culturing the host cell of the present invention under conditions that allow the expression of the antibody or antigen-binding fragment thereof, and obtaining The antibody or antigen-binding fragment thereof is recovered from the host cell culture.
  • a pharmaceutical composition which comprises the antibody of the present invention or an antigen-binding fragment thereof, an isolated nucleic acid molecule, a vector, a host cell, a multispecific antibody or conjugate, and a pharmaceutically acceptable carrier And/or excipients.
  • the pharmaceutical composition of the present invention comprises the antibody or antigen-binding fragment thereof of the present invention, and a pharmaceutically acceptable carrier and/or excipient.
  • the pharmaceutical composition of the present invention comprises the isolated nucleic acid molecule, vector or host cell of the present invention, and a pharmaceutically acceptable carrier and/or excipient.
  • the host cell contains an isolated nucleic acid molecule or vector as previously described.
  • the pharmaceutical composition may also contain additional pharmaceutically active agents.
  • the additional pharmaceutically active agent is an antiplatelet drug, an anticoagulant drug or a thrombolytic drug.
  • the antibody or antigen-binding fragment thereof of the present invention and the additional pharmaceutically active agent are provided as separate components or as components of the same composition. Therefore, the antibody or antigen-binding fragment thereof of the present invention and the additional pharmaceutically active agent can be administered simultaneously, separately or sequentially.
  • the pharmaceutical composition may also contain additional pharmaceutically active agents.
  • the additional pharmacologically active agent is selected from aspirin, clopidogrel, prasugrel, ticagrelor, abciximab, eptifibatide, vorapasa, unfractionated heparin, heparin, low molecular weight heparin, warfarin Lin, fondaparinux, edoxaban, betrixaban, rivaroxaban, apixaban, dabigatran etexilate, argatroban, bivalirudin, streptokinase, urokinase, Alteplase, prourokinase, or any combination thereof.
  • the antibody or antigen-binding fragment, isolated nucleic acid molecule, vector, host cell, multispecific antibody or conjugate in the pharmaceutical composition of the present invention is sufficient to produce at least one of the following biology in a subject active:
  • the pharmaceutical composition of the present invention further comprises a second antibody or a nucleic acid encoding the second antibody, wherein the second antibody is another antibody that recognizes a different epitope of FXI or FXIa, or is a specific binding option
  • the use of the antibody or antigen-binding fragment, isolated nucleic acid molecule, vector, host cell, multispecific antibody, conjugate or pharmaceutical composition of the present invention in the preparation of medicines is provided. in:
  • the host cell when the isolated nucleic acid molecule, vector or host cell of the present invention is used to prepare a medicine, the host cell contains the isolated nucleic acid molecule or vector as described above.
  • the medicament when used to prepare a medicament, the medicament is used to prevent and/or treat diseases related to coagulation or thromboembolism in a subject (such as a human) Or illness.
  • the subject is a mammal. In certain preferred embodiments, the subject is a human.
  • the medicament when used to prepare a medicament, the medicament is used to delay the occurrence of diseases or disorders related to coagulation or thromboembolism in a subject (such as a human) .
  • the medicament when used to prepare a medicament, the medicament is used to reduce or inhibit diseases or disorders related to coagulation or thromboembolism in a subject (such as a human) relapse.
  • the vector or host cell of the present invention when used to prepare a drug, the drug is used in a subject (such as a human).
  • the antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, vectors, host cells, multispecific antibodies, conjugates, or pharmaceutical compositions of the present invention are related to blood coagulation or thrombosis.
  • Embolism-related diseases or conditions are selected from: thrombosis, thrombotic stroke, atrial fibrillation, atrial fibrillation-related stroke prevention (SPAF), deep vein thrombosis, venous thromboembolism, acute coronary syndrome (ACS) , Ischemic stroke, acute limb ischemia, chronic thromboembolism, pulmonary hypertension, systemic embolism, myocardial infarction (MI), acute myocardial infarction (AMI), stable angina, unstable angina, recurrence after coronary intervention Occlusion and restenosis, peripheral arterial occlusive disease (PAOD), renal vein thrombosis, transient ischemic attack (TIA), pulmonary thromboembolism, diffuse intravascular coagulation, and
  • the present invention provides a method of preventing and/or treating diseases or disorders related to coagulation or thromboembolism in a subject. In another aspect, the present invention provides a method for delaying the onset of a disease or condition related to coagulation or thromboembolism in a subject. In another aspect, the present invention provides a method for reducing or inhibiting the recurrence of a disease or condition related to coagulation or thromboembolism in a subject. The method described above includes administering an effective amount of the antibody or antigen-binding fragment thereof, vector, host cell, multispecific antibody, conjugate, or pharmaceutical composition of the present invention to a subject in need thereof.
  • the host cell of the present invention contains the isolated nucleic acid molecule or vector as described above.
  • the above method further comprises administering a second therapy to the subject, the second therapy being selected from antiplatelet drugs, anticoagulant drugs, and thrombolytic drugs.
  • the second therapy is selected from aspirin, clopidogrel, prasugrel, ticagrelor, abciximab, eptifibatide, vorapasa, unfractionated heparin, heparin , Low molecular weight heparin, warfarin, fondaparinux, edoxaban, betrixaban, rivaroxaban, apixaban, dabigatran etexilate, argatroban, bivalirudin , Streptokinase, urokinase,reteplase, prourokinase and any combination thereof.
  • the antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, vectors, host cells, multispecific antibodies, conjugates, or pharmaceutical compositions of the present invention are related to blood coagulation or thrombosis.
  • Embolism-related diseases or conditions are selected from thrombosis, thrombotic stroke, atrial fibrillation, atrial fibrillation-related stroke prevention (SPAF), deep vein thrombosis, venous thromboembolism, acute coronary syndrome (ACS), Ischemic stroke, acute limb ischemia, chronic thromboembolism, pulmonary hypertension, systemic embolism, myocardial infarction (MI), acute myocardial infarction (AMI), stable angina, unstable angina, reocclusion after coronary intervention And restenosis, peripheral arterial occlusive disease (PAOD), renal vein thrombosis, transient ischemic attack (TIA), pulmonary thromboembolism, diffuse intravascular coagulation, thromboembolic disorders caused
  • the antibody or antigen-binding fragment thereof of the present invention, and the pharmaceutical composition of the present invention can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders , Granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injections and concentrated solutions for injections), inhalants, sprays, etc.
  • the preferred dosage form depends on the intended mode of administration and therapeutic use.
  • the pharmaceutical composition of the present invention should be sterile and stable under production and storage conditions.
  • a preferred dosage form is injection. Such injection may be a sterile injection solution.
  • a sterile injection solution can be prepared by the following method: incorporating the necessary dose of the recombinant protein of the present invention in a suitable solvent, and optionally, simultaneously incorporating other desired ingredients (including but not limited to, pH adjustment Agents, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filtration and sterilization.
  • the sterile injection solution can be prepared as a sterile lyophilized powder (for example, by vacuum drying or freeze drying) for storage and use.
  • sterile lyophilized powder can be dispersed in a suitable carrier, such as sterile pyrogen-free water, before use.
  • the antibody or antigen-binding fragment thereof of the present invention may be present in a pharmaceutical composition in a unit dosage form for easy administration.
  • the antibodies or antigen-binding fragments thereof and pharmaceutical compositions of the present invention can be administered by any suitable method known in the art, including but not limited to oral, oral, sublingual, ocular, topical, parenteral, rectal, intralobular sheath , Intracytoplasmic reticulum, groin, bladder, topical (eg powder, ointment or drops), or nasal route.
  • the preferred route/mode of administration is parenteral administration (eg, intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection).
  • the antibody or antigen-binding fragment thereof, pharmaceutical composition of the present invention is administered by intravenous infusion or injection.
  • the pharmaceutical composition of the present invention may include "therapeutically effective amount” or “prophylactically effective amount” of the antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host cell, multispecific antibody or conjugate of the present invention.
  • “Prophylactically effective amount” refers to an amount sufficient to prevent, prevent, or delay the occurrence of a disease.
  • “Therapeutically effective amount” refers to an amount sufficient to cure or at least partially prevent the disease and its complications in patients who have already suffered from the disease.
  • the therapeutically effective amount of the antibody or antigen-binding fragment thereof of the present invention may vary according to the following factors: the severity of the disease to be treated, the overall state of the patient’s own immune system, the patient’s general conditions such as age, weight and sex, and drug Mode of administration, and other treatments administered simultaneously, etc.
  • the dosage regimen can be adjusted to obtain the best objective response (for example, therapeutic or preventive response).
  • it can be administered in a single dose, can be administered multiple times over a period of time, or the dose can be reduced or increased proportionally to the urgency of the treatment situation.
  • the typical non-limiting range of the therapeutically or preventively effective amount of the recombinant protein of the present invention is 0.02-100 mg/kg, such as 0.1-100 mg/kg, 0.1-50 mg/kg, or 1-50 mg/kg. It should be noted that the dosage may vary depending on the type and severity of the symptoms to be treated. In addition, those skilled in the art understand that for any specific patient, the specific dosing regimen should be adjusted over time according to the needs of the patient and the professional evaluation of the doctor; the dosage range given here is for illustrative purposes only, and is not limited Use or scope of the pharmaceutical composition of the present invention.
  • the subject may be a mammal, such as a human.
  • the antibody or antigen-binding fragment thereof of the present invention can specifically bind to FXI and/or FXIa (for example, human FXI and/or human FXIa), and thus can be used to detect the presence or level of FXI and/or FXIa in a sample.
  • FXI and/or FXIa for example, human FXI and/or human FXIa
  • the present invention provides a kit comprising the antibody or antigen-binding fragment thereof of the present invention.
  • the antibody or antigen-binding fragment thereof of the present invention bears a detectable label.
  • the kit further includes a second antibody, which specifically recognizes the antibody of the present invention or an antigen-binding fragment thereof.
  • the second antibody further includes a detectable label.
  • the detectable label may be any substance that can be detected by fluorescence, spectroscopy, photochemical, biochemical, immunological, electrical, optical or chemical means. It is particularly preferable that such a label can be applied to immunological detection (for example, enzyme-linked immunoassay, radioimmunoassay, fluorescence immunoassay, chemiluminescence immunoassay, etc.).
  • immunological detection for example, enzyme-linked immunoassay, radioimmunoassay, fluorescence immunoassay, chemiluminescence immunoassay, etc.
  • Such labels include, but are not limited to, enzymes (for example, horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.), radionuclides (for example, , 3 H, 125 I, 35 S, 14 C or 32 P), fluorescent dyes (for example, fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin Protein (PE), Texas Red, Rhodamine, quantum dots or cyanine dye derivatives (e.g.
  • enzymes for example, horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.
  • radionuclides for example, , 3 H, 125 I, 35 S, 14 C or 32 P
  • fluorescent dyes for example, fluorescein is
  • radioactive labels can be detected using photographic film or a scintillation calculator, and fluorescent labels can be detected using a light detector to detect the emitted light.
  • Enzyme markers are generally detected by providing a substrate to the enzyme and detecting reaction products produced by the action of the enzyme on the substrate, and calorimetric markers are detected by simply visualizing colored markers.
  • the detectable label as described above can be attached to the antibody or antigen-binding fragment thereof of the present invention through linkers of different lengths to reduce potential steric hindrance.
  • the present invention provides a method for detecting the presence or level of FXI and/or FXIa (such as human FXI and/or human FXIa) in a sample, which includes the step of using the antibody or antigen-binding fragment thereof of the present invention .
  • the antibody or antigen-binding fragment thereof of the present invention also bears a detectable label.
  • the method further comprises using a reagent with a detectable label to detect the antibody or antigen-binding fragment thereof of the present invention.
  • the method can be used for diagnostic purposes, or for non-diagnostic purposes (for example, the sample is a cell sample, not a sample from a patient).
  • the present invention provides a method for detecting the presence or level of FXI and/or FXIa (such as human FXI and/or human FXIa) in a sample, and the method includes allowing the antibody or antigen-binding fragment thereof Or under the condition that a complex is formed between the conjugate and FXI and/or FXIa, the sample is contacted with the antibody or antigen-binding fragment thereof of the present invention, and the formation of the complex is detected.
  • FXI and/or FXIa such as human FXI and/or human FXIa
  • the present invention provides a diagnostic or therapeutic kit, which includes one or more of the following substances that the present invention can provide: the antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, vector, host Cells, multispecific antibodies, conjugates, or pharmaceutical compositions.
  • the diagnostic or therapeutic kit also includes instructions for use.
  • the antibody or antigen-binding fragment of the present invention has high binding affinity to FXI and/or FXIa and has extremely strong specificity. Therefore, the antibody or antigen-binding fragment of the present invention is suitable for preventing and/or treating diseases or disorders related to blood coagulation or thromboembolism.
  • the humanized antibody of the present invention retains the functions and properties of the parental murine antibody. Moreover, the humanized antibody of the present invention has a high degree of humanization, so that it can be safely administered to human subjects without triggering an immunogenic reaction. In addition, the antibodies or antigen-binding fragments of the present invention have no or little risk of bleeding. Therefore, the antibody or antigen-binding fragment of the present invention has great clinical value.
  • FR Antibody framework region amino acid residues in the variable region of the antibody other than CDR residues
  • Kabat The immunoglobulin comparison and numbering system proposed by Elvin A. Kabat (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991 ).
  • Chothia The immunoglobulin numbering system proposed by Chothia et al. is a classic rule for identifying the boundaries of CDR regions based on the position of structural loop regions (see, for example, Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. People (1989) Nature 342:878-883).
  • IMGT is based on the international immunogenetics information system (The international ImMunoGeneTics information) initiated by Lefranc et al. (IMGT)) for the numbering system, please refer to Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003.
  • FXIa Activates human coagulation factor 11
  • FXI protein As used herein, the terms "FXI protein”, “FXI antigen” and “FXI” are used interchangeably and refer to coagulation factor XI proteins of various species.
  • FXIa protein As used herein, the terms “FXIa protein”, “FXIa antigen” and “FXIa” are used interchangeably and refer to activated coagulation factor XI proteins of various species.
  • the terms “FXI” and “FXIa” include mutants and variants of natural FXI and FXIa proteins, respectively, which have the same primary structure (amino acid sequence) as described in the present invention. Substantially the same amino acid sequence.
  • coagulation and coagulation cascade referring to the coagulation pathway through a proteolytic cascade to finally produce thrombin, which then converts soluble fibrinogen into formation The fibrin of the clot.
  • Various enzymes of this pathway exist in the plasma in the form of zymogen (inactive form), which undergo proteolytic division when activated to release active coagulation factors.
  • the process of thrombin production can be divided into three stages: internal and external pathways, and the final common pathway.
  • antibody refers to an immunoglobulin molecule usually composed of two pairs of polypeptide chains (each pair has a light chain (LC) and a heavy chain (HC)).
  • Antibody light chains can be classified into kappa (kappa) and lambda (lambda) light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 3 or more amino acids.
  • Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the heavy chain constant region is composed of 3 domains (CH1, CH2, and CH3).
  • Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
  • the light chain constant region consists of a domain CL. Constant domains are not directly involved in the binding of antibodies and antigens, but exhibit a variety of effector functions, such as mediating immunoglobulins and host tissues or factors, including various cells of the immune system (for example, effector cells) and classical complement Combination of the first component (C1q) of the system.
  • VH and VL regions can also be subdivided into regions with hyperdenaturation (called complementarity determining regions (CDR)), interspersed with more conservative regions called framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL consists of 3 CDRs and 4 FRs arranged from the amino terminal to the carboxy terminal in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions (VH and VL) of each heavy chain/light chain pair respectively form an antigen binding site.
  • the assignment of amino acids in each region or domain can follow the numbering system definitions such as IMGT, Kabat, Chothia or AbM.
  • antibody includes not only intact antibodies but also antigen-binding fragments of antibodies.
  • CDR complementarity determining region
  • the precise boundaries of these amino acid residues can be defined according to various numbering systems known in the art, for example, according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), Chothia numbering system (Chothia & Lesk (1987) J.Mol. Biol. 196:901-917; Chothia et al.
  • framework region or "FR” residues refers to those amino acid residues in the variable region of an antibody other than the CDR residues as defined above.
  • germline antibody gene is an immunoglobulin sequence encoded by non-lymphocytes that has not undergone the process of genetic rearrangement and maturation leading to the expression of specific immunoglobulins.
  • One advantage provided by various embodiments of the present invention is derived from the recognition that germline antibody genes retain more important amino acid sequence structures characteristic of individual animal species than mature antibody genes. Therefore, when applied therapeutically to this species, it is less recognized as a foreign substance by this species.
  • antibody is not limited by any specific method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies.
  • the antibodies can be antibodies of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.
  • the term "antigen-binding fragment" of an antibody refers to a polypeptide that is a full-length or partial fragment of an antibody, such as a polypeptide that is a fragment of a full-length antibody, which retains the ability to specifically bind to the same antigen that the full-length antibody binds , And/or compete with the full-length antibody for specific binding to the antigen, which is also called the "antigen-binding portion".
  • a polypeptide that is a full-length or partial fragment of an antibody such as a polypeptide that is a fragment of a full-length antibody, which retains the ability to specifically bind to the same antigen that the full-length antibody binds , And/or compete with the full-length antibody for specific binding to the antigen, which is also called the "antigen-binding portion”.
  • Antigen-binding fragments of antibodies are produced by enzymatic or chemical cleavage of intact antibodies.
  • Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, dAb and complementarity determining region (CDR) fragments , Single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, linear antibodies, nanobodies (technology from Domantis), domain antibodies (technology from Ablynx), and enough to have full-length antibodies A small fragment of polypeptide with specific antigen binding ability.
  • the engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23:1126-1136.
  • full-length antibody means an antibody composed of two “full-length heavy chains” or “heavy chains” and two “full-length light chains” or “light chains”.
  • full-length heavy chain or “heavy chain” refers to a polypeptide chain that consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, and a hinge region ( HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain; and, when the full-length antibody is of the IgE isotype, it optionally also includes a heavy chain constant region CH4 domain.
  • the "full-length heavy chain” is a polypeptide chain composed of VH, CH1, HR, CH2 and CH3 in the N-terminal to C-terminal direction.
  • a “full-length light chain” or “light chain” is a polypeptide chain composed of a light chain variable region (VL) and a light chain constant region (CL) in the N-terminal to C-terminal direction.
  • the two pairs of full-length antibody chains are connected by a disulfide bond between CL and CH1 and a disulfide bond between the HR of the two full-length heavy chains.
  • the full-length antibody of the present invention can be from a single species, such as human; it can also be a chimeric antibody or a humanized antibody.
  • the full-length antibody of the present invention contains two antigen binding sites formed by a pair of VH and VL respectively, and the two antigen binding sites specifically recognize/bind the same antigen.
  • the term “Fd fragment” means an antibody fragment composed of VH and CH1 domains;
  • the term “dAb fragment” means an antibody fragment composed of VH domains (Ward et al., Nature 341:544 546 (1989));
  • the term “Fab fragment” means an antibody fragment composed of VL, VH, CL and CH1 domains;
  • the term “F(ab') 2 fragment” means a fragment comprising a disulfide bridge connected by a hinge region The antibody fragment of two Fab fragments;
  • the term “Fab'fragment” means the fragment obtained by reducing the disulfide bond connecting the two heavy chain fragments in the F(ab') 2 fragment, consisting of a complete light chain and heavy chain The Fd fragment (consisting of VH and CH1 domains) is composed.
  • Fv fragment means an antibody fragment composed of the VL and VH domains of a single arm of an antibody. Fv fragments are generally considered to be the smallest antibody fragments that can form a complete antigen binding site. It is generally believed that the six CDRs confer antigen binding specificity to an antibody. However, even a variable region (such as an Fd fragment, which contains only three antigen-specific CDRs) can recognize and bind antigen, although its affinity may be lower than the complete binding site.
  • Fc fragment means that the second and third constant regions of the first heavy chain of an antibody are formed by disulfide bonding of the second and third constant regions of the second heavy chain. Antibody fragments. The Fc fragment of an antibody has many different functions, but does not participate in antigen binding.
  • scFv refers to a single polypeptide chain comprising VL and VH domains, wherein the VL and VH are connected by a linker (see, for example, Bird et al., Science 242:423 -426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Roseburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)).
  • Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH.
  • a suitable prior art linker consists of a repeated GGGGS amino acid sequence or variants thereof.
  • a linker having an amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448).
  • Other linkers that can be used in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol.
  • di-scFv refers to an antibody fragment formed by linking two scFvs.
  • the term "diabody” means that its VH and VL domains are expressed on a single polypeptide chain, but a linker that is too short is used to allow it to be between the two domains of the same chain. Pairing, thereby forcing the domain to pair with the complementary domain of the other chain and creating two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993) ), and Poljak RJ et al., Structure 2:1121-1123 (1994)).
  • Each of the aforementioned antibody fragments maintains the ability to specifically bind to the same antigen that the full-length antibody binds, and/or competes with the full-length antibody for specific binding to the antigen.
  • multispecific antibody refers to antibodies with multiple different antigen binding specificities, including, for example, bispecific antibodies, trispecific antibodies, and tetraspecific antibodies.
  • Bispecific antibody refers to an antibody with two different antigen binding specificities, which is formed by a first antibody (or a fragment thereof) and a second antibody (or a fragment thereof) or antibody analogs through a coupling arm Conjugates, coupling methods include but are not limited to chemical reaction, gene fusion, protein fusion, polypeptide fusion and enzymatic reaction.
  • Trispecific antibodies are antibodies with three different antigen binding specificities
  • tetraspecific antibodies are antibodies with four different antigen binding specificities.
  • antibody mimetic refers to the same specific binding as an antibody, but without the structure of an antibody. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa.
  • DARPin and fynomer are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa.
  • the designed ankyrin repeat protein (DARPin) can be linked to IgG antibody, scFv-Fc antibody fragment or a combination thereof, as described in CN104341529A.
  • the anti-IL-17a fynomer binds to the anti-IL-6R antibody, as described in WO2015141862A1.
  • immunoglobulin may refer to a type of protein that functions as an antibody. Antibodies expressed by B cells are sometimes called antigen receptors. The five members included in this class of proteins are IgA, IgG, IgM, IgD, and IgE, with IgG being the most common circulating antibody. It is the most effective immunoglobulin in agglutination, complement fixation, and other antibody responses, and is important in defense against bacteria and viruses.
  • the technique for obtaining antibodies can use conventional techniques known to those skilled in the art (for example, recombinant DNA technology or enzymatic or chemical fragmentation) to obtain the antigen of the antibody from a given antibody (for example, the antibody provided by the present invention) Binding fragments (for example, the above-mentioned antibody fragments), and specifically screening for antigen-binding fragments of antibodies in the same manner as used for intact antibodies.
  • a given antibody for example, the antibody provided by the present invention
  • Binding fragments for example, the above-mentioned antibody fragments
  • the terms “monoclonal antibody”, “monoclonal antibody”, and “mAb” have the same meaning and are used interchangeably, which refers to one of a group of highly homologous antibody molecules.
  • An antibody or a fragment of an antibody that is, a group of identical antibody molecules except for natural mutations that may occur spontaneously.
  • the monoclonal antibody has high specificity for a single epitope on the antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen.
  • the modifier "monoclonal” only indicates that the antibody is characterized as being obtained from a group of highly homologous antibodies, and cannot be understood as requiring any specific method to prepare the antibody.
  • the monoclonal antibodies of the present invention can be prepared by various techniques, such as hybridoma technology (see, for example, Kohler et al. Nature, 256:495,1975), recombinant DNA technology (see, for example, U.S. Patent Application 4,816,567), or phage Antibody library technology (see, for example, Clackson et al. Nature352:624-628, 1991, or Marks et al. J. Mol. Biol. 222:581-597, 1991).
  • monoclonal antibodies can be prepared as follows. First immunize mice or other suitable host animals with immunogen (add adjuvant when necessary).
  • the injection method of immunogen or adjuvant is usually subcutaneous multi-point injection or intraperitoneal injection.
  • the immunogen can be pre-conjugated to certain known proteins, such as serum albumin or soybean trypsin inhibitor, to enhance the immunogenicity of the antigen in the host.
  • the adjuvant may be Freund's adjuvant or MPL-TDM.
  • lymphocytes can also be obtained by in vitro immunization.
  • hybridoma cells prepared above can be inoculated into a suitable culture medium for growth, and the culture medium preferably contains one or more substances capable of inhibiting the growth of unfused, parental myeloma cells.
  • HGPRT hypoxanthine guanine phosphotransferase
  • HAT medium hypoxanthine, aminopterin, and thymine
  • the preferred myeloma cells should have the characteristics of high fusion rate, stable antibody secretion ability, and sensitivity to HAT medium.
  • murine myeloma such as MOP-21 or MC-11 mouse tumor-derived strains (THE Salk Institute Cell Distribution Center, San Diego, Calif.
  • Methods for determining the binding specificity of monoclonal antibodies produced by hybridoma cells include, for example, immunoprecipitation or in vitro binding assays such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunosorbent assay
  • the Scatchard assay described by Munson et al., Anal. Biochem. 107:220 (1980) can be used to determine the affinity of monoclonal antibodies.
  • the target cell line can pass the standards described in (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103, Academic Press, 1996). Dilution method for subcloning.
  • a suitable culture medium can be DMEM or RPMI-1640.
  • hybridoma cells can also grow in animals in the form of ascites tumors.
  • immunoglobulin purification methods such as protein A agarose gel, hydroxyapatite chromatography, gel electrophoresis, dialysis or affinity chromatography, etc.
  • the monoclonal antibodies secreted by subclonal cells can be removed from the cell culture medium, Isolated from ascites or serum.
  • Monoclonal antibodies can also be obtained through genetic engineering recombination technology. Using nucleic acid primers that specifically bind to the heavy and light chain genes of the monoclonal antibody for PCR amplification, DNA molecules encoding the heavy and light chain genes of the monoclonal antibody can be isolated from hybridoma cells. Insert the resulting DNA molecule into an expression vector, then transfect host cells (such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin), and culture them under appropriate conditions. A recombinantly expressed target antibody can be obtained.
  • host cells such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin
  • Antibodies can be purified by known techniques, such as affinity chromatography using protein A or protein G.
  • the specific antigen (the target molecule recognized by the antibody) or its epitope can be immobilized on a column, and the immunospecific antibody can be purified by immunoaffinity chromatography.
  • the purification of immunoglobulin can refer to, for example, D. Wilkinson (The Scientific, published by The Engineer, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).
  • murine antibody refers to the fusion of B cells from immunized mice with myeloma cells, followed by screening of murine hybrid fusion cells that can proliferate indefinitely and secrete antibodies. Further screening, antibody preparation, and antibody purification are performed to obtain antibodies; or, after antigen invades the mouse body, B cells differentiate and proliferate to form plasma cells, which can produce secreted antibodies.
  • chimeric antibody refers to an antibody whose light chain or/and part of its heavy chain is derived from an antibody (which may be derived from a specific species or belong to a certain A specific antibody class or subclass), and another part of the light chain or/and heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but no matter However, it still retains the binding activity to the target antigen (US Patent 4,816,567 to Capability et al.; Proc. Natl. Acad. Sci. USA, 81: 6851 6855 (1984)).
  • chimeric antibody may include antibodies (e.g., human-mouse chimeric antibodies) in which the heavy and light chain variable regions of the antibody are derived from the first antibody (e.g., murine antibody), and the heavy and The light chain constant region is derived from a second antibody (e.g., a human antibody).
  • first antibody e.g., murine antibody
  • second antibody e.g., a human antibody
  • humanized antibody refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase homology with the sequence of a human antibody.
  • CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (for example, variable region FR and/or constant region) is derived from human source.
  • Immunoglobulin (receptor antibody) Humanized antibodies generally retain the expected properties of donor antibodies, including but not limited to antigen specificity, affinity, reactivity, ability to improve immune cell activity, and ability to enhance immune response.
  • the donor antibody may be a mouse, rat, rabbit, or non-human primate with the desired properties (eg, antigen specificity, affinity, reactivity, ability to improve immune cell activity and/or ability to enhance immune response) Animal-like (eg, cynomolgus monkey) antibodies.
  • Humanized antibodies can not only retain the expected properties of non-human donor antibodies (such as murine antibodies), but also effectively reduce the immunogenicity of non-human donor antibodies (such as murine antibodies) in human subjects. Therefore, it is particularly advantageous.
  • the expected properties of the humanized antibody eg, antigen specificity, affinity, reactivity, ability to improve immune cell activity, and/or The ability to enhance immune response
  • a high degree of humanization for example, at least 75%, at least 80%, at least 85%, at least 90%, At least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% humanization degree
  • the framework region (FR) of the humanized antibody of the present invention can include both the amino acid residues of the human acceptor antibody and the corresponding non-human donor antibody.
  • the chimeric antibody or humanized antibody of the present invention can be prepared based on the sequence of the murine monoclonal antibody prepared above.
  • DNA encoding the heavy and light chains can be obtained from target murine hybridomas and engineered using standard molecular biology techniques to contain non-mouse (e.g., human) immunoglobulin sequences.
  • chimeric antibodies To prepare chimeric antibodies, methods known in the art can be used to link murine immunoglobulin variable regions to human immunoglobulin constant regions (see, for example, U.S. Patent No. 4,816,567 to Cabilly et al.).
  • the DNA encoding VH is operably linked to another DNA molecule encoding the heavy chain constant region to obtain a full-length heavy chain gene.
  • the sequence of the human heavy chain constant region gene is known in the art (see, for example, Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242 ), DNA fragments containing these regions can be obtained by standard PCR amplification.
  • the heavy chain constant region may be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region, but is generally preferably an IgG1 or IgG4 constant region.
  • DNA encoding VL is operably linked to another DNA molecule encoding the light chain constant region CL to obtain a full-length light chain gene (and Fab light chain gene).
  • the sequence of the human light chain constant region gene is known in the art (see, for example, Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242 ), DNA fragments containing these regions can be obtained by standard PCR amplification.
  • the light chain constant region may be a kappa or lambda constant region, but is generally preferably a kappa constant region.
  • mouse CDR regions can be inserted into human framework sequences using methods known in the art (see US Patent Nos. 5,225,539 to Winter; US Patent Nos. 5,530,101 to Queen et al.; 5,585,089; 5,693,762 and 6,180,370; And Lo, Benny, KC, editor, in Antibody Engineering: Methods and Protocols, volume 248, Humana Press, New Jersey, 2004).
  • transgenic animals can also be used, which can produce no endogenous immunoglobulin after immunization and can produce a complete human antibody library.
  • JH antibody heavy chain joining region
  • Non-limiting examples of the above-mentioned transgenic animals include HuMAb mice (Medarex, Inc.), which contain human immunoglobulin genes encoding unrearranged human heavy chain ( ⁇ and ⁇ ) and ⁇ light chain immunoglobulin sequences. Locus (miniloci), plus targeted mutations that inactivate endogenous mu and kappa chain loci (see, for example, Lonberg et al. (1994) Nature 368(6474):856-859); or carrying human heavy chain transgenes and human The light chain transchromosome "KM MouseTM” (see patent application WO02/43478). Other methods of antibody humanization include phage display technology (Hoogenboom et al., 1991, J. Mol. Biol. 227: 381; Marks et al., J. Mol. Biol. 1991, 222: 581-597; Vaughan et al., 1996 , Nature Biotech 14: 309).
  • degree of humanization is an index used to evaluate the number of non-human amino acid residues in a humanized antibody.
  • the degree of humanization of a humanized antibody can be predicted by the IMGT website DomainGapAlign to predict the homology of the variable region sequence and the human V domain.
  • homologous antibody refers to a variant of an antibody that contains the amino acid sequence of the variable region of the heavy chain and light chain and the amino acid sequence of the antibody or antigen-binding fragment thereof provided herein. It is homologous and wherein the variant retains the desired functional properties of the anti-FXI and/or FXIa antibodies of the invention.
  • the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen it targets.
  • the strength or affinity of a specific binding interaction can be expressed by the equilibrium dissociation constant (KD) or half-maximum effect concentration (EC50) of the interaction.
  • the specific binding properties between two molecules can be determined using methods known in the art.
  • One method involves measuring the rate of antigen binding site/antigen complex formation and dissociation.
  • Both the "binding rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and the actual rate of association and dissociation (see Malmqvist M, Nature, 1993, 361 :186-187).
  • the ratio of kdis/kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473). Any effective method can be used to measure KD, kon and kdis values.
  • bioluminescence interferometry e.g., ForteBio's Octet method
  • surface plasmon resonance technology such as Biacore
  • Kinexa can be used to measure the dissociation constant.
  • the term "vector” refers to a nucleic acid delivery vehicle into which polynucleotides can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into the host cell through transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
  • Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1 derived artificial chromosomes (PAC) ; Phage such as lambda phage or M13 phage and animal viruses.
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillary viruses.
  • Polyoma vacuole virus (such as SV40).
  • a vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes.
  • the vector may also contain an origin of replication site.
  • Expression and cloning vectors contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells. Generally, in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and it includes an origin of replication or an autonomously replicating sequence.
  • expression vector refers to a vector containing a recombinant polynucleotide, which contains an expression control sequence operatively linked to the nucleotide sequence to be expressed.
  • the expression vector contains sufficient cis-acting elements for expression; other elements for expression can be provided by host cells or in vitro expression systems.
  • Expression vectors include all those known in the art, such as cosmids, plasmids (e.g. naked or contained in liposomes), and viruses (e.g., lentivirus, retrovirus, adenovirus, and adeno-associated virus).
  • the term "host cell” refers to a cell that can be used to introduce a vector, which includes, but is not limited to, prokaryotic cells such as Escherichia coli or subtilis, fungal cells such as yeast cells or Aspergillus, etc. Insect cells such as S2 fruit fly cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as Escherichia coli or subtilis
  • fungal cells such as yeast cells or Aspergillus
  • Insect cells such as S2 fruit fly cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • identity is used to refer to the matching of sequences between two polypeptides or between two nucleic acids.
  • a certain position in the two sequences to be compared is occupied by the same base or amino acid monomer subunit (for example, a certain position in each of two DNA molecules is occupied by adenine, or two A certain position in each of the polypeptides is occupied by lysine)
  • each molecule is the same at that position.
  • the "percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions to be compared ⁇ 100. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% identity.
  • the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of 6 positions match).
  • the comparison is made when two sequences are aligned to produce maximum identity.
  • Such alignment can be achieved by using, for example, the method of Needleman et al. (1970) J. Mol. Biol. 48:443-453 which can be conveniently performed by a computer program such as the Align program (DNAstar, Inc.). You can also use the algorithms of E. Meyers and W. Miller (Comput.
  • the Needleman and Wunsch (J MoI Biol. 48:444-453 (1970)) algorithms in the GAP program integrated into the GCG software package can be used, and the Blossum 62 matrix or PAM250 matrix and gap weights of 16, 14, 12, 10, 8, 6, or 4 and length weights of 1, 2, 3, 4, 5, or 6 to determine the percent identity between two amino acid sequences .
  • the term "conservative substitution” means an amino acid substitution that does not adversely affect or change the expected properties of the protein/polypeptide comprising the amino acid sequence.
  • the variants of the antibody obtained by conservatively substituting amino acids sufficiently retain their origin The biological activity of the sequence, such as specifically binding to FXI or FXIa.
  • conservative substitutions can be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions of amino acid residues with similar side chains, such as those that are physically or functionally similar to the corresponding amino acid residue (e.g., have similar size, shape, charge, chemical properties, including The ability to form covalent bonds or hydrogen bonds, etc.) residues.
  • Families of amino acid residues with similar side chains have been defined in the art. These families include basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g. aspartic acid, glutamate), uncharged polar side chains (e.g., glycine , Asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g.
  • alanine, valine, leucine, isoleucine Acid, proline, phenylalanine, methionine), beta branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, Phenylalanine, tryptophan, histidine) amino acids. Therefore, it is preferred to replace the corresponding amino acid residue with another amino acid residue from the same side chain family.
  • Methods for identifying conservative substitutions of amino acids are well known in the art (see, for example, Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999) ; And Burks et al. Proc. Natl Acad. Set USA 94:412-417 (1997), which is incorporated herein by reference).
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient that is pharmacologically and/or physiologically compatible with the subject and the active ingredient, It is well-known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes but not limited to: pH regulators, surfactants, adjuvants, and ionic strength enhancement Agents, diluents, agents for maintaining osmotic pressure, agents for delaying absorption, preservatives.
  • pH adjusting agents include, but are not limited to, phosphate buffer.
  • Surfactants include but are not limited to cationic, anionic or nonionic surfactants, such as Tween-80.
  • Ionic strength enhancers include, but are not limited to, sodium chloride.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid and the like.
  • Agents for maintaining osmotic pressure include but are not limited to sugar, NaCl and the like.
  • Agents that delay absorption include, but are not limited to, monostearate and gelatin.
  • Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol) and the like.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, paraben, chlorobutanol, phenol, sorbic acid and the like.
  • Stabilizers have the meaning commonly understood by those skilled in the art, which can stabilize the desired activity of the active ingredients in the drug, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose) , Lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin or casein) or their degradation products (such as lactalbumin hydrolysate).
  • prevention refers to a method implemented to prevent or delay the occurrence of a disease or condition or symptom (for example, a disease or condition related to blood clotting or thromboembolism) in a subject.
  • treatment refers to a method implemented in order to obtain beneficial or desired clinical results.
  • beneficial or desired clinical results include, but are not limited to, alleviating symptoms, narrowing the scope of the disease, stabilizing (ie, no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the disease State, relief of symptoms (regardless of part or all), relief or improvement of prognosis, reduction or inhibition of disease recurrence, etc., whether detectable or undetectable.
  • treatment can also refer to prolonging survival compared to expected survival (if not receiving treatment).
  • the term "subject” refers to a mammal, such as a primate mammal, such as a human.
  • the subject e.g., human
  • an effective amount refers to an amount sufficient to obtain or at least partially obtain the desired effect.
  • an effective amount for preventing a disease refers to an amount sufficient to prevent, prevent, or delay the occurrence of a disease (for example, a disease or condition related to coagulation or thromboembolism);
  • a therapeutically effective amount refers to an amount sufficient to cure or at least partially prevent the disease and its complications in patients who have already suffered from the disease. It is completely within the abilities of those skilled in the art to determine such an effective amount.
  • the effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient’s own immune system, the patient’s general conditions such as age, weight and sex, the way the drug is administered, and other treatments that are simultaneously administered and many more.
  • effector function refers to those biological activities attributable to the Fc region (natural sequence Fc region or amino acid sequence variant Fc region) of an antibody, and which vary with the antibody The same type varies.
  • antibody effector functions include but are not limited to: Fc receptor binding affinity, antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) , Down-regulation of cell surface receptors (such as B cell receptors), B cell activation, cytokine secretion, half-life/clearance of antibodies and antigen-antibody complexes, etc.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • Down-regulation of cell surface receptors such as B cell receptors
  • B cell activation such as B cell activation
  • cytokine secretion half-life/clearance of antibodies and antigen-antibody complexes, etc.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • cytotoxic cells such as natural killer (NK) cells, neutral
  • FcR Fc receptor
  • the method for detecting the ADCC activity of an antibody is known in the art, for example, it can be evaluated by measuring the binding activity between the antibody to be tested and the Fc receptor (for example, CD16a).
  • complement-dependent cytotoxicity refers to a form of cytotoxicity that activates the complement cascade by binding complement component C1q to antibody Fc.
  • Methods for detecting the CDC activity of an antibody are known in the art. For example, it can be evaluated by measuring the binding activity between the antibody to be tested and an Fc receptor (for example, C1q).
  • FXI and/or FXIa-mediated refers to the fact that FXI and/or FXIa directly or indirectly activates coagulation factor IX (also known as FIX), coagulation factor X (FX) and/or Or thrombin and/or mediate activation of the endogenous coagulation pathway by binding to platelet receptors.
  • coagulation factor IX also known as FIX
  • FX coagulation factor X
  • thrombin thrombin
  • disease or disorder related to blood coagulation or thromboembolism refers to a condition or disease caused by abnormal activation or non-natural inactivation of the coagulation pathway (for example, in the absence of therapeutic means).
  • thrombosis thrombotic stroke, atrial fibrillation, atrial fibrillation-related stroke prevention (SPAF), deep vein thrombosis, venous thromboembolism, acute coronary syndrome (ACS) , Ischemic stroke, acute limb ischemia, chronic thromboembolism, pulmonary hypertension, systemic embolism, myocardial infarction (MI), acute myocardial infarction (AMI), stable angina, unstable angina, recurrence after coronary intervention Occlusion and restenosis, peripheral arterial occlusive disease (PAOD), renal vein thrombosis, transient ischemic attack (TIA), pulmonary thromboembolism, diffuse intravascular coagulation, and thromboembolic disorders caused by medical devices (such as catheters) , Severe systemic inflammatory response syndrome, metastatic cancer, infectious diseases, organ failure (such as renal failure), toxicity caused by the administration of therapeutic proteins in the body, multiple trauma, isch
  • Catheter-induced thromboembolic disorders include the formation of thromboembolism in the catheter (for example, Hickman catheter in tumor patients, and the use of extracorporeal membrane oxidation (ECMO) may cause clots).
  • ECMO extracorporeal membrane oxidation
  • prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism may refer to one of the following conditions that the anti-FXI and/or FXIa antibody or antigen-binding fragment thereof of the present invention can be used to prevent or treat kind or more:
  • arrhythmia such as thromboembolism in individuals with sudden, permanent or permanent atrial fibrillation or atrial fibrillation;
  • SPAF atrial fibrillation
  • PCI percutaneous coronary intervention
  • VTE -Acute venous thromboembolic event
  • -Venous thrombosis which includes (but does not exclude) treatment and secondary prevention of deep or superficial venous thrombosis in the lower or upper part, abdominal and thoracic vein thrombosis, sinus thrombosis and jugular vein thrombosis;
  • CTEPH -Chronic Thromboembolic Pulmonary Hypertension
  • -Arterial thrombus on ruptured atherosclerotic plaque thrombus on intra-arterial assistive devices or catheters, and thrombus in normal arteries on the surface.
  • This condition includes (but is not limited to) acute coronary syndrome, ST elevated myocardium Infarction, non-ST elevation myocardial infarction, unstable colic, stent thrombosis, thrombus on any artificial surface in the arterial system, and thrombus in the pulmonary artery of individuals with or without pulmonary hypertension;
  • PCI percutaneous coronary intervention
  • -Cardiac thrombosis and thromboembolism including (but not exclusively) cardiac thrombosis after myocardial infarction, related to conditions such as cardiac aneurysm, myocardial fibrosis, cardiac enlargement and dysfunction, myocarditis and artificial surfaces in the heart Heart thrombosis;
  • coagulation factor V Leiden coagulation factor V Leiden
  • prothrombin mutation coagulation factor V XIII mutation
  • family fibrin Dystrophy congenital plasminogen deficiency
  • congenital plasminogen deficiency increased coagulation factor XI content
  • sickle cell disease antiphospholipid syndrome
  • autoimmune disease chronic bowel disease
  • nephrotic syndrome hemolytic uremic disease
  • myelodysplasia Diseases disseminated intravascular coagulation
  • paroxysmal nocturnal hemoglobinuria and heparin-induced thrombocytopenia coagulation factor V Leiden, prothrombin mutation, antithrombin III, protein C and protein S deficiency
  • coagulation factor XIII mutation family fibrin Dystrophy
  • congenital plasminogen deficiency increased coagulation factor XI content
  • sickle cell disease antiphospholipid syndrome
  • autoimmune disease chronic bowel disease
  • nephrotic syndrome hemo
  • the term "pharmaceutically acceptable” means that when the molecular body, molecular fragment or composition is properly administered to animals or humans, they will not produce adverse, allergic or other adverse reactions.
  • Specific examples of substances that can be used as pharmaceutically acceptable carriers or components thereof include sugars (such as lactose), starch, cellulose and its derivatives, vegetable oils, gelatin, polyols (such as propylene glycol), alginic acid, and the like.
  • combination therapy includes combining anti-FXI and/or FXIa antibodies or antigen-binding fragments thereof with one or more additional active therapeutic agents (e.g., chemotherapeutics) or other prophylactic or therapeutic modes of the second therapy (e.g., antiplatelet drugs, anticoagulant drugs, thrombolytic drugs) are used in combination.
  • additional active therapeutic agents e.g., chemotherapeutics
  • additional prophylactic or therapeutic modes of the second therapy for example, antiplatelet drugs, anticoagulant drugs, thrombolytic drugs
  • An exemplary antiplatelet drug for the second therapy is selected from aspirin, clopidogrel, prasugrel, ticagrelor, abciximab, eptifibatide, vorapasa or any combination thereof.
  • the exemplary anticoagulant of the second therapy is selected from unfractionated heparin, heparin, low molecular weight heparin, warfarin, fondaparinux, edoxaban, betrixaban, rivaroxaban, apixaban , Dabigatran etexilate, argatroban, bivalirudin or any combination thereof.
  • An exemplary thrombolytic drug for the second therapy is selected from streptokinase, urokinase,reteplase or prourokinase.
  • Combination therapy may allow the dosage of one or more of the agents to be reduced to reduce or eliminate adverse effects associated with one or more of the agents.
  • Such combination therapies can have a synergistic therapeutic or preventive effect on underlying diseases, disorders or conditions.
  • “combination” includes therapies that can be administered separately, such as separately formulated for separate administration (for example, can be provided in a kit), and therapies that can be administered together as a single formulation (ie, "co-formulation") .
  • the anti-FXI and/or FXIa antibodies or antigen-binding fragments thereof of the present invention can be administered sequentially.
  • the anti-FXI and/or FXIa antibodies or antigen-binding fragments thereof can be administered simultaneously.
  • the anti-FXI and/or FXIa antibody or antigen-binding fragment thereof of the present invention can be used in any combination with at least one other (active) agent.
  • Figure 2A-2B Detection of clotting time of anti-human FXI/FIXa mouse monoclonal antibody by APTT method
  • FIG. 3 BIOPHEN method to detect the anticoagulant function of anti-human FXI/FXIa mouse monoclonal antibody
  • FIG. 4 Anti-human FXI/FXIa murine monoclonal antibody specifically blocks the biological activities of FXI and FXIa
  • FIG. 6 BIOPHEN method to detect the anticoagulant function of anti-human FXI/FXIa humanized monoclonal antibody
  • Figure 7A ELISA to detect the affinity of anti-human FXI/FXIa humanized antibody and FXIa
  • Figure 7B ELISA to detect the affinity of anti-human FXI/FXIa humanized antibody and FXI
  • FIG. 8 Anti-human FXI/FXIa humanized antibody competes with control antibody BAY-1213790 for binding to FXIa detection
  • Figure 9A Detecting the anticoagulant activity of anti-human FXI/FXIa humanized antibody in human blood by measuring activated partial thromboplastin time (APTT)
  • Figure 9B Detect the anticoagulant activity of anti-human FXI/FXIa humanized antibody in monkey blood by measuring activated partial thromboplastin time (APTT)
  • Figure 9C Detection of anticoagulant activity of anti-human FXI/FXIa humanized antibody in dog blood by measuring activated partial thromboplastin time (APTT)
  • Figure 9D Detection of anticoagulant activity of anti-human FXI/FXIa humanized antibody in rabbit blood by measuring activated partial thromboplastin time (APTT)
  • Figure 9E Detect the anticoagulant activity of anti-human FXI/FXIa humanized antibody in rat blood by measuring activated partial thromboplastin time (APTT)
  • Figure 11A In vivo pharmacodynamics (PD) APTT activity detection of anti-human FXI/FXIa humanized antibody in cynomolgus monkeys
  • Figure 11B Detection of pharmacodynamic (PD) PT activity of anti-human FXI/FXIa humanized antibody in cynomolgus monkeys
  • the molecular biology experimental methods and immunoassay methods used in the present invention basically refer to J. Sambrook et al., Molecular Cloning: Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FMAusubel et al., Compiled Molecular Biology Experiment Guide, 3rd Edition, John Wiley & Sons, Inc., 1995.
  • Those skilled in the art know that the embodiments describe the present invention by way of example, and are not intended to limit the scope of protection claimed by the present invention.
  • the booster immunization is emulsified with IFA (Incomplete Freund’s adjuvant, manufacturer: Sigma, product number: F5881). After three immunizations, the serum titer was measured by ELISA. Boost immunization was performed 3-5 days before fusion, and mice with higher titer were selected for intraperitoneal immunization with 10 ⁇ g FXIa and 10 ⁇ g FXI. The standard fusion process was used to fuse mouse spleen cells and Sp2/0-Ag14 (ATCC, Cat#CRL-1581) mouse myeloma cells with PEG, and then HAT (manufacturer: Sigma, catalog number: H0262- 10VL) pressurized screening, and ELISA screening 14 days later.
  • IFA Complete Freund’s adjuvant
  • Boost immunization was performed 3-5 days before fusion, and mice with higher titer were selected for intraperitoneal immunization with 10 ⁇ g FXIa and 10 ⁇ g F
  • ELISA screening method 0.5 ⁇ g/mL biotin-labeled FXI (manufacturer: Haematologic Technologies, item number: HCXI-0150-B) 100 ⁇ L/well, coated with an ELISA plate (manufacturer: Thermo Fisher Sci., item number: 5129) 1 hour. Wash three times with 200 ⁇ L washing buffer (1 ⁇ TBS containing 0.05% Tween-20), add 100 ⁇ L hybridoma supernatant, and incubate at 37°C for 1 hour. Use 200 ⁇ L of washing buffer to wash 3 times, add 100 ⁇ L of Streptavidin-HRP (Pierce, Cat#21130) diluted 1:8000 and incubate at 37°C for 1 hour.
  • the supernatants of 24,000 hybridoma clones were screened by ELISA, and 100 hybridoma clones capable of recognizing biotin-labeled FXI were obtained and transferred to a 24-well plate. After 7-10 days, the hybridoma supernatant was tested by the APTT function detection method. The best 22 clones were subcloned by limiting dilution method to obtain monoclonal hybridomas. Monoclonal hybridomas use the APTT function detection method to detect anticoagulant activity, and use the activated partial thromboplastin time (APTT) kit (Activated Partial Thromboplastin Time Kit, manufacturer: Thermo Fisher Sci, catalog number 100402) for detection.
  • APTT activated partial thromboplastin time
  • the specific steps are as follows: add 100 ⁇ L of normal human plasma (purchased from Alternative Research, Cat#IPLA-N) to the preheated test tube, and then add 100 ⁇ L of APTT reagent (purchased from Thermo Fisher Sci.Cat#100402TS) and 100 ⁇ L of test sample to mix well Incubate at 37°C for 5 minutes, then add 100 ⁇ L of calcium chloride (purchased from Thermo Fisher Sci.Cat#100304, 20mM), measure the OD405 reading, and calculate the clotting time by curve fitting.
  • the Sp2/0-Ag14 cell supernatant is negative Contrast. 14E11 is a positive control antibody (prepared with reference to Aronora patent US8388959B2).
  • the value of the multiple in the APTT experiment result is the ratio of the clotting time measured by the sample with the experimental antibody to the clotting time measured by the control sample without the antibody. 1 times or less indicates that the coagulation time is not delayed or accelerated, and more than 1 times indicates that the coagulation time is prolonged.
  • APTT tested a total of 5 subclonal hybridoma supernatants. Among them, 36G9.10 prolonged APTT time and had significant anticoagulant function, which can be used for further analysis. Other clones 6B6.9, The prolonged clotting time of 28A8.3, 36C3, 40F6.9 is not much different from the negative control. The hybridoma 7B2 with prolonged APTT duration was obtained through the same screening and used for further analysis.
  • Monoclonal hybridomas 36G9.10 and 7B2 were expanded to 100-150mL without serum. The supernatant was purified by Protein G packing, and the purified mouse antibody was tested by HPLC-SEC, and the purity was greater than 97%. The purified murine antibody can be used for further functional verification.
  • the antibody was diluted to concentrations of 2.00, 1.00, 0.50, and 0.25 ⁇ g/mL to compare 36G9.10 with the positive control antibody BAY-1213790 (refer to M007-H04 prepared in Bayer patent WO2013167669) ) And 14E11, PBS buffer is a negative control.
  • the candidate murine antibody 36G9.10 significantly prolonged the clotting time than the control antibodies BAY-1213790 and 14E11 at each concentration.
  • the control antibodies BAY-1213790 and 14E11 under the condition of antibody concentration of 5 ⁇ g/mL, compare 7B2 with positive control antibody 14E11.
  • PBS buffer is used as negative control.
  • the result is shown in Figure 2B.
  • candidate mouse antibody 7B2 significantly prolongs the clotting time and the positive control antibody 14E11. The clotting time is comparable.
  • Anti-human FXI/FXIa mouse antibody inhibits the activity of FXIa to catalyze the production of FXa and the determination of its anticoagulant function
  • BIOPHEN Factor XIa kit Hyphen BioMed, article number 220412 was used to test according to its kit instructions, and the release of para-nitroaniline (pNA) products was measured by OD405nm to further confirm the activity of anti-FXI/FXIa antibodies to inhibit FXIa from catalyzing FXa.
  • the detection concentration of all antibodies is 0.25 ⁇ g/mL. The stronger the anti-FXI/FXIa antibody blocking the FXI/FXIa activity, the lower the OD405nm signal value of the pNA product.
  • Octet It is widely used in the detection of antibody-antigen dynamic affinity.
  • Candidate mouse antibody 36G9.10 and control antibodies BAY1213790 and 14E11 use this method to determine the dynamic affinity with FXIa.
  • the specific experimental steps are as follows: the probe of streptavidin first binds with the biotin-labeled antibody to be tested to a response signal value of 0.8nm, and then with FXIa protein (3.2, 1.6, 0.8, 0.4, 0.2, 0.1, 0.05 and 0 ⁇ g/ mL) bind for 5 minutes, then dissociate for 7 minutes, using the bivalent analysis model and all fitting analysis.
  • 36G9.10 has a faster binding rate than the control antibody 14E11 and BAY-1213790 (as shown by the Kon value), while the dissociation rate is slower than BAY-1213790 (as shown by the Kdis value), and its affinity is higher than that of the control.
  • Antibodies 14E11 and BAY-1213790 are 1.7 and 2.5 times stronger, respectively.
  • Anti-human FXI/FXIa murine antibody specifically blocks the biological activities of FXI and FXIa
  • the Pierce Rapid Isotyping kit purchased from Thermo Fisher Sci.Cat#26179 was used to identify the antibody subtype of the 36G9.10 and 7B2 candidate clones.
  • the identification results showed that the heavy chain of the candidate clone was of IgG1 subtype, and the light chain was of Kappa subtype.
  • the number of hybridoma cells was cultured to about 8000, the cells were lysed and the first strand cDNA was synthesized using a cDNA reverse transcription kit (purchased from Thermo Fisher Sci.Cat#18080-200). Special primers were used to amplify VH and VK genes from cDNA by PCR. The PCR products were purified by DNA purification kit (purchased from Qiagen, Cat#28104) and ligated to TOPO vector (purchased from Thermo Fisher Sci.Cat#K457540) ). In each ligation reaction, approximately 12 clones were picked for sequencing.
  • the sequence was analyzed by Vector NTI 11.5 (purchased from Thermo Fisher Sci.) and Sequencer 5.4.6 (purchased from Genecodes), and the variable region sequence and CDR sequence of the anti-FXI/FXIa mouse antibody were obtained as shown in the sequence information table.
  • the heavy chain variable region of the 36G9.10 murine antibody is SEQ ID NO: 1, and the light chain variable region is SEQ ID NO: 2; the heavy chain variable region of the 7B2 murine antibody is SEQ ID NO: 29, the light chain The variable region is SEQ ID NO: 30.
  • 36G9.10 and 7B2 chimeric antibodies 36G9.10-hz00 and 7B2-hz00 were constructed respectively, which grafted the heavy chain variable region sequence of 36G9.10 or 7B2 to the mutant human IgG1 heavy chain constant region ( N297A mutant) (SEQ ID NO: 21), obtained by grafting the light chain variable region sequence of 36G9.10 or 7B2 to the human Kappa light chain constant region (SEQ ID NO: 22).
  • the mouse antibody 36G9.10, 7B2 was humanized by the CDR grafted antibody humanization method.
  • the humanization transformation involves the following steps: compare the amino acid sequence of the mouse monoclonal antibody with the amino acid sequence of the human germline antibody to find a sequence with high homology and better physical and chemical properties, and use it as a human embryonic line Framework sequence; analyze and investigate HLA-DR affinity, select the human embryonic framework sequence with low affinity; then transplant the six CDRs of the mouse antibody to the selected heavy chain and light chain framework sequences.
  • the heavy chain humanization template of 36G9.10 is human germline gene sequence IGHV1-2*02 (see IMGT accession number X62106) and IGHV1-69-2*01 (see IMGT accession number KF698734), light chain humanization template human Germline gene sequence IGKV1-33*01 (see IMGT accession number M64856) and IGKV1-16*01 (see IMGT accession number J00248).
  • the heavy chain humanization template of 7B2 is the human germline gene sequence IGHV1-69-2*01 (see IMGT accession number KF698734), and the light chain humanization template is the human germline gene sequence IGKV1-39*01 (see IMGT accession number X59315 ).
  • molecular docking was used to analyze the variable region and its surrounding framework amino acid sequence to investigate its three-dimensional combination.
  • electrostatic force van der Waals force, hydrophobicity and entropy value
  • the heavy chain constant region of each antibody is a human IgG1 heavy chain constant region (N297A mutant) (SEQ ID NO: 21).
  • a humanized antibody 7B2-hz11 was constructed.
  • the heavy chain constant regions are all mutant human IgG1 heavy chain constant regions (N297A mutant type) (SEQ ID NO: 21).
  • the light chain constant region sequences of antibodies 36G9.10-hz73, 36G9.10-hz74, 36G9.10-hz43, 36G9.10-hz92, 36G9.10-hz93 and 7B2hz11 are SEQ ID NO: 22, none of which have ADCC and CDC effect.
  • amino acid sequences of the variable and constant regions of the humanized antibodies are shown in Table 2.
  • the affinity of chimeric and humanized antibodies was determined.
  • the main measurement steps are: first fix the chimeric and humanized antibodies (concentration of 0.3 ⁇ g/mL) to the AHC (anti-human-Fc) sensor, and then perform the FXI test with the initial concentration of 3.2 ⁇ g/mL. : 2 gradient dilutions to determine the binding and dissociation rate of chimeric and humanized antibodies. Analyze the data obtained by Octet data analysis software.
  • the anticoagulant activity of the humanized antibody was detected using the APTT coagulation test kit, and the specific detection method is shown in Example 1. The results are shown in Figure 5. The average and standard deviation were calculated by 4 measurements.
  • the chimeric antibody 36G9.10-hz00, the humanized antibody 36G9.10-hz43, 36G9.10-hz73, 36G9.10-hz74, 36G9 .10-hz92, 36G9.10-hz93 prolonged blood coagulation time is greater than the positive control antibody 14E11 and BAY-1213790.
  • Biophen Factor XIa kit purchased from Aniara Cat#220412 was used to detect the anticoagulant activity of the humanized antibody. See Example 2 for the specific method.
  • the test results are shown in Figure 6, the chimeric antibody 36G9.10-hz00, the humanized antibody 36G9.10-hz43, 36G9.10-hz73, 36G9.10-hz74, 36G9.10-hz92, 36G9.10-hz93
  • Antibodies 14E11 and BAY-1213790 can effectively reduce the production of FXa.
  • Antibodies 36G9.10-hz43, 36G9.10-hz73, 36G9.10-hz92, 36G9.10-hz93 are more effective than control antibodies 14E11 and BAY-1213790. Effectively reduce the production of FXa, indicating its superior anticoagulant activity.
  • ELISA method was used to detect the affinity of 36G9.10-hz73 with human FXIa.
  • the specific steps are as follows: Dilute FXIa with CBS coating solution (weigh 0.32g Na 2 CO 3 , 0.59g NaHCO 3 , dissolve in deionized water, and dilute to 200ml) Antigen (Haematologic Technologies, HCMIA-160) to 1 ⁇ g/mL, 100 ⁇ L per well coated with FXIa antigen, overnight at 4°C; the next day, discard the liquid in the well and wash it with 300 ⁇ L PBS; add 100 ⁇ L PBS (containing 2% BSA, BOVOGEN, BSAS 1.0), blocked at 37°C for 2 hours; Dilute 36G9.10-hz73 and BAY-1213790 antibodies (10 ⁇ g/mL starting, 4-fold dilution, 12 concentration points) with PBS (containing 2% BSA), take 100 ⁇ L Add to the corresponding well, incubate at 37°C for 2 hours; wash with 300 ⁇ L
  • ELISA method was used to detect the affinity of 36G9.10-hz73 with human FXI, and FXI antigen was diluted with CBS coating solution (purchased PMD-F11 plasmid from Yiqiao Shenzhou, cloned into PLVX-TRES-PURO vector and transfected into 293F cell for expression) to 1 ⁇ g/mL, 100 ⁇ L per well was coated overnight at 4°C, the rest of the steps are as shown in the previous section, the initial antibody concentration is 0.37 ⁇ g/mL, 3-fold dilution, 9 concentration points.
  • CBS coating solution purchased PMD-F11 plasmid from Yiqiao Shenzhou, cloned into PLVX-TRES-PURO vector and transfected into 293F cell for expression
  • the specific steps are as follows: Dilute human FXIa to 1nM with a buffer containing 50mM Tris/HCl, 100mM NaCl, 5mM CaCl 2 and 0.1% BSA, and use this as the mother liquor to serially dilute 36G9.10-hz73 and BAY-1213790 antibodies, 20 ⁇ g /mL, 4-fold dilution, 14 concentration points; add 10 ⁇ L of diluted antibody to each well of a 384-well plate (purchased from Coring, 4514) and incubate at 37°C for 1 hour; add to each well after incubation 10 ⁇ L of the fluorescent substrate I-1575 with a concentration of 2 ⁇ M, and immediately on the machine after mixing, use a microplate reader to continuously read the fluorescence value at 360/465nm, and import Graphpad Prism for curve fitting.
  • Example 10 Detecting the anticoagulant activity of anti-human FXI/FXIa antibodies by measuring activated partial thromboplastin time (APTT)
  • APTT is used to detect human FXI/FXIa The anticoagulant activity of the chemical antibody.
  • the specific steps are as follows: Take venous blood from human, monkey, dog, rabbit, and rat respectively, take 2 to 3 samples from each species, take 4 tubes of blood samples for each sample (1.8ml per tube), use 3.2% sodium citrate Anticoagulant, after centrifugation at 2500 ⁇ g at 4°C for 10 minutes, take the plasma and store it at 4°C (the plasma of each sample is combined); dilute the antibody to be tested with normal saline, starting at 1500 ⁇ g/mL, and 3 concentration points as 10 ⁇ The mother solution of the antibody to be tested; the sample detection system is 150 ⁇ l at high concentration, take 135 ⁇ l of plasma, add 15 ⁇ l of the mother solution of the antibody to be tested (that is, the mother solution of the antibody to be tested is diluted 10 times), and then use the automatic coagulation analyzer (purchased from Greek Senmeikang CA1500) detects APTT.
  • the sample detection system is 150 ⁇ l at high concentration, take 135 ⁇ l of plasma, add 15 ⁇ l of the mother solution of the antibody
  • the sample detection system is 75 ⁇ l. Take 67.5 ⁇ l of plasma and add 7.5 ⁇ l of the mother solution of the antibody to be tested (ie, the mother solution of the antibody to be tested is diluted by 10 times), and then the APTT is detected with an automatic coagulation analyzer.
  • 36G9.10-hz73 only prolonged APTT clotting time in monkey plasma, while BAY-1213790 prolonged APTT clotting time in monkey and rabbit plasma, and 14E11 prolonged APTT in monkey, rabbit, and rat plasma.
  • the prothrombin time (PT) test mainly reflects the condition of the exogenous coagulation system.
  • the multiple value in the PT test result is the coagulation time measured by the sample with the experimental antibody and the coagulation measured by the control sample without the antibody.
  • the ratio of time. 1 times or less indicates that the coagulation time is not delayed or accelerated, and more than 1 times indicates that the coagulation time is prolonged.
  • Antibody name people monkey dog rabbit Rat 36G9.10-hz73 0.96 ⁇ 0.04 1.00 ⁇ 0.01 1.03 ⁇ 0.01 0.99 ⁇ 0.01 0.99 ⁇ 0.01 0.99 ⁇ 0.01 BAY-1213790 0.95 ⁇ 0.05 1.00 ⁇ 0.01 1.02 ⁇ 0.01 0.99 ⁇ 0.01 0.99 ⁇ 0.01 14E11 0.95 ⁇ 0.05 / / 1.00 ⁇ 0.01 1.00 ⁇ 0.01 BMS-962212 0.97 ⁇ 0.06 0.99 ⁇ 0.01 1.01 ⁇ 0.01 1.00 ⁇ 0.00 1.00 ⁇ 0.01
  • Example 4 Dilute the 36G9.10-hz73 antibody with 20mM His-HCl (hydrochloric acid-histidine buffer) (containing 0.03% Tween-20, pH5.5) to a concentration of 11.5mg/mL, and place them at 40°C and 25°C respectively After 14 days and 28 days, the APTT assay method in Example 4 was used to detect the anticoagulant activity of the sample after acceleration, and the purity of the antibody after acceleration was detected by SEC.
  • His-HCl hydrochloric acid-histidine buffer
  • Placement conditions SEC detection purity (%) APTT detection (EC50, nM) 0 days 99.4 18.36 25°C-28 days 99.8 17.36 40°C-14 days 97.9 20.33 40°C-28 days 94.4 26.89
  • a single intravenous injection (IV) or subcutaneous injection (SC) was used to give different doses of 36G9.10-hz73 antibody to cynomolgus monkeys, and blood samples were taken at different time points.
  • PK and APTT activity The specific administration groups and dosages are shown in Table 7.
  • the volume of a single intravenous injection or subcutaneous administration is 2 mL/kg, the intravenous injection site is the vein of the limbs, and the subcutaneous injection site is the back of the neck.
  • the 36G9.10-hz73 antibody was used as the standard, and the antibody concentration standard curve was drawn using the ELISA method in Example 7. The standard curve was used to determine 36G9.10-hz73 at each time point under the same conditions. The blood concentration of the antibody, and finally the measured blood concentration was imported into Graphpad Prism for curve fitting, and the PK of 36G9.10-hz73 in the cynomolgus monkey was calculated.
  • Example 10 the method in Example 10 was used to detect APTT, and finally all time point data was imported into Graphpad Prism for curve fitting, and the PD of 36G9.10-hz73 in the cynomolgus monkey was calculated.
  • the PD test results show that 36G9.10-hz73 can be used for intravenous injection and subcutaneous administration to achieve a good effect of prolonging APTT.
  • Figure 11A the dose-effect relationship between the two intravenous dose groups is clear.
  • the subcutaneous injection of 3 mg/kg has a slightly better prolonging APTT effect than intravenous injection, and it still has about 1.3 times the APTT prolonging effect at 1008 hours;
  • Figure 11B none of the three dose groups prolonged PT, indicating that there was no effect on exogenous coagulation. Therefore, the 36G9.10-hz73 antibody has the potential clinical advantage of not causing the risk of bleeding.

Abstract

本发明属于治疗性单克隆抗体领域，具体而言提供了抗FXI/FXIa的抗体或其抗原结合片段，编码它们的核酸分子，制备它们的方法。本发明的抗FXI/FXIa抗体或其抗原结合片段对FXI/FXIa具有特异性和高亲和力，能够有效抑制FXI/FXIa的活性。因此，本发明进一步提供了包含所述抗体或其抗原结合片段的药物组合物，以及其在制备药物中的用途，所述药物用于预防和/或治疗与凝血或血栓栓塞相关的疾病或病症。

Description

抗FXI/FXIa抗体及其用途 技术领域
本发明属于治疗性单克隆抗体领域，更具体地，本发明涉及一种针对FXI和/或FXIa的抗体；还涉及所述抗体在预防和/或治疗与凝血或血栓栓塞相关的疾病或病症中的用途。
技术背景
血栓形成或栓塞涉及全身各系统器官，主要是心、脑和外周血管疾病，具有高发、高致残和致死性特点，是心血管疾病导致死亡的第一位死因。目前，血栓性疾病的防治药物主要包括抗凝血、抗血小板和溶栓这三类药物；其中，抗凝药物临床主要用于预防与治疗各种原因引起的静脉血栓栓塞；此外，还可用于预防房颤患者的脑卒中及急性冠脉综合征患者的抗凝治疗。抗凝药物市场需求大，已有药物可供临床选用，但是目前临床使用的抗凝药物主要抑制凝血级联反应的共同途径，因此出血是主要的并发症。传统的抗凝药物，如华法林、肝素、低分子量肝素，以及近年上市的新药，如FXa抑制剂(利伐沙班、阿哌沙班等)和凝血酶抑制剂(达比加群酯、水蛭素等)，对减少血栓形成均具有较好效果，但都面临着共同的不足——可能引起出血并发症。因此，临床急切需求出血风险小的抗凝药物。
凝血因子XI(FXI)参与内源性凝血级联反应，其活性形式为凝血因子XIa(FXIa)。FXI蛋白是由两个分子量大约80kDa的同源单体通过二硫键形成的二聚体。FXI单体由四个苹果结构域和一个催化结构域组成，并由凝血因子XIIa(FXIIa)催化形成FXIa后暴露出FIX的结合位点，与FIX结合后促进FIX转变为有活性的FIXa，激活下游凝血级联反应。凝血因子XI在哺乳动物血浆中浓度大约是25-30nM，是一种以酶原形式存在的糖蛋白，几乎所有的FXI与高分子量激肽原(HK)形成复合物并在血液中循环。HK对FXI功能的影响目前为止还是不是很清楚。HK可能协助FXI结合到血小板或内皮细胞表明，也有研究观察到HK抑制FXI的活化。FXI的活化过程是在不同的蛋白酶的作用下，每个单体在其Arg369-Ile370之间裂解，产生一个蛋白，该蛋白由一个大约50kDa含有苹果结构域的重链和一个大约30kDa含有催化结构域的轻链组成，重链和轻链之间由Cys362-Cys482形成的二硫键连接。活化的FXI，既FXIa，通常指的二聚体FXI的每个单体都在Arg369裂解,但也有只有一个单体被活化的情况。FXIa在Ca 2+ 参与下裂解FIX，使其变成活化的FIX(FIXa)，其随后转化凝血因子X成其活性形式Xa。Xa接着可介导凝血因子II/凝血酶活化。凝血酶作为凝血级联中的末端蛋白酶，可通过以反馈机制直接活化FXI来进一步促成FXIa产生。凝血级联中的凝血因子XIIa与FXIa(自身活化)都能使FXI转化为FXIa。
此外，活化的FIX(FIXa)能直接与血小板结合，促进血液中血小板聚集物形成，并在形成远端微血管闭塞。因此，FIX/FIXa通过多种途径促进血栓形成。并且动物实验和临床观察表明FIX/FIXa的缺失只有极小的出血风险。所以，FIX/FIXa是理想的预防和治疗与凝血或血栓栓塞相关的疾病/病症的极好靶点。(Zilberman-Rudenko J.et.al.Coagulation factor XI promotes distal platelet activation and single platelet connsumpation in the bloodstream under shear flow.Arterioscler Thromb Vasc Biol.2016 March；36(3):510–517.)通过干预FXI和/或FXIa分子从而调节凝血功能的因素包括，但不限于：FXI和/或FXIa二聚体的形成；阻碍能使FXI活化的分子，如凝血因子XIIa，FXIa，与FXI接触，从而抑制或阻断FXI的活化；抑制或阻断FXI与HK形成复合物；封闭FXI和/或FXIa的催化结构域，或诱导催化结构域构象发生变化，从而使FXI和/或FXIa失活，进而抑制或阻断内在凝血途径的激活；抑制或阻断FXI和/或FXIa与底物的结合。
目前，拜耳公司的FXIa抗体药物BAY-1213790静脉栓塞适应症正处于II期临床试验。BAY-1213790来自噬菌体展示文库，并与FXIa催化结构域结合。另外Aronora公司的AB-023(14E11)静脉栓塞适应症处于临床I期，终末期肾病(ESRD)适应症处于临床II期。
目前并无靶向FXIa抗体药物上市，因此，发展具有更高的特异性、更低的毒副作用、更优的临床药效、更方便给药方式的抗FXI和/或FXIa抗体是迫切而必要的，这将给患者提供更多的用药选择。
发明内容
在本申请中，发明人首先开发了具有优良性质的鼠源抗体，其能够特异性识别FXI和/或FXIa。在此基础上，发明人又付出了大量的创造性劳动，对该鼠源抗体进行了深入的研究和改造，从而开发了该鼠源抗体的人源化抗体。
本发明的抗体(特别是人源化抗体)是极为有利的，其不仅保留了(或甚至提高了)亲本鼠源抗体的功能和性质，例如以很高的亲和力和特异性结合FXI和/或FXIa，从而具 有用于预防和治疗凝血或血栓栓塞病症的潜力，而且具有极高的人源化程度，可安全地施用给人受试者，而不引发免疫原性反应。所以本发明的抗体具有重大的临床价值。
本发明的抗体
在一个方面，本发明提供了一种能够特异性结合FXI和/或FXIa的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含如下的：
(a)如下的三个重链CDRs：如SEQ ID NOs:1、15、16、17、29、31任一项所示的重链可变区(VH)所含的CDR-H1、CDR-H2以及CDR-H3；和/或
如下的三个轻链CDRs：如SEQ ID NOs:2、18、19、20、30、32任一项所示的轻链可变区(VL)所含的CDR-L1、CDR-L2以及CDR-L3；
或，
(b)如下的三个重链CDRs：(a)中所述的CDR-H1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H3或与其相比含有氨基酸突变的变体；和/或
如下的三个轻链CDRs：(a)中所述的CDR-L1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L3或与其相比含有氨基酸突变的变体；
其中(b)中所述的三个重链CDRs和/或三个轻链CDRs中至少一个CDR，与(a)中相应的CDR相比含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)。
在某些优选地实施方案中，所述的置换是保守置换；
在某些优选地实施方案中，所述抗体或其抗原结合片段的CDR根据Kabat，IMGT，Chothia或AbM编号系统定义。
在某些优选地实施方案中，所述抗体或其抗原结合片段还包括来自人或鼠的免疫球蛋白的构架区(FRs)。
在某些优选地实施方案中，所述抗体或其抗原结合片段结合人FXI和/或人FXIa。
在某些实施方案中，所述抗体或其抗原结合片段包含：
(a)如下的三个重链CDRs：如SEQ ID NOs:1、15、16、17任一项所示的重链可变区(VH)所含的CDR-H1、CDR-H2以及CDR-H3；和/或
如下的三个轻链CDRs：如SEQ ID NOs:2、18、19、20任一项所示的轻链可变区(VL) 所含的CDR-L1、CDR-L2以及CDR-L3；
或，
(b)如下的三个重链CDRs：(a)中所述的CDR-H1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H3或与其相比含有氨基酸突变的变体；和/或
如下的三个轻链CDRs：(a)中所述的CDR-L1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L3或与其相比含有氨基酸突变的变体；
其中(b)中所述的三个重链CDRs和/或三个轻链CDRs中至少一个CDR,与(a)中相应的CDR相比含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)；在某些优选地实施方案中，所述的置换是保守置换。
在某些实施方案中，所述抗体或其抗原结合片段包含：
(a)如下的三个重链CDRs：如SEQ ID NOs:29、31任一项所示的重链可变区(VH)所含的CDR-H1、CDR-H2以及CDR-H3；和/或
如下的三个轻链CDRs：如SEQ ID NOs:30、32任一项所示的轻链可变区(VL)所含的CDR-L1、CDR-L2以及CDR-L3；
或，
(b)如下的三个重链CDRs：(a)中所述的CDR-H1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H3或与其相比含有氨基酸突变的变体；和/或
如下的三个轻链CDRs：(a)中所述的CDR-L1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L3或与其相比含有氨基酸突变的变体；
其中(b)中所述的三个重链CDRs和/或三个轻链CDRs中至少一个CDR,与(a)中相应的CDR相比含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)；在某些优选地实施方案中，所述的置换是保守置换。
在某些实施方案中，所述抗体或其抗原结合片段包含：重链可变区(VH)和/或轻链可 变区(VL)。
在某些实施方案中，本发明的抗体或其抗原结合片段包含下述重链可变区(VH)和/或轻链可变区(VL)，其中CDR按IMGT编号系统定义：
(a)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：3的CDR-H1，序列为SEQ ID NO：4的CDR-H2，序列为SEQ ID NO：5的CDR-H3；和/或，
包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：6的CDR-L1，序列为SEQ ID NO：7的CDR-L2，序列为SEQ ID NO：8的CDR-L3；
或
(b)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：33的CDR-H1，序列为SEQ ID NO：34的CDR-H2，序列为SEQ ID NO：35的CDR-H3；和/或，
包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：36的CDR-L1，序列为SEQ ID NO：37的CDR-L2，序列为SEQ ID NO：38的CDR-L3。
在某些实施方案中，本发明的抗体或其抗原结合片段包含下述重链可变区(VH)和/或轻链可变区(VL)，其中，所述重链可变区(VH)和/或轻链可变区(VL)与前述IMGT定义下的(a)或(b)中所述的重链可变区和/或轻链可变区相比，至少一个CDR含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个或3个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换为保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含下述重链可变区(VH)和/或轻链可变区(VL)，其中CDR按AbM编号系统定义：
(a)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：9的CDR-H1，序列为SEQ ID NO：10的CDR-H2，序列为SEQ ID NO：11的CDR-H3；和/或，
包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：12的CDR-L1，序列为SEQ ID NO：13的CDR-L2，序列为SEQ ID NO：14的CDR-L3；
或
(b)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：39的CDR-H1，序列为SEQ ID NO：40的CDR-H2，序列为SEQ ID NO：41的CDR-H3；和/或，
包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：42的CDR-L1，序列为SEQ ID NO：43的CDR-L2，序列为SEQ ID NO：44的CDR-L3。
在某些实施方案中，本发明的抗体或其抗原结合片段包含下述重链可变区(VH)和/ 或轻链可变区(VL)，其中，所述重链可变区(VH)和/或轻链可变区(VL)与前述AbM定义下的(a)或(b)中所述的重链可变区和/或轻链可变区相比，至少一个CDR含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个或3个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换为保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含下述重链可变区(VH)和/或轻链可变区(VL)，其中，所述重链可变区(VH)和/或轻链可变区(VL)与前述IMGT、或AbM定义下的(a)或(b)中所述的重链可变区和/或轻链可变区相比，至少一个CDR含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个或3个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换为保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段的VH包含来源于鼠免疫球蛋白的重链可变区(VH)构架区(FRs)，和/或所述抗体或其抗原结合片段的VL包含来源于鼠免疫球蛋白的轻链可变区(VL)构架区(FRs)。因此，在某些优选的实施方案中，本发明的抗体或其抗原结合片段是鼠源的。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段的VH包含来源于人免疫球蛋白的重链可变区(VH)构架区(FRs)，和/或所述抗体或其抗原结合片段的VL包含来源于人免疫球蛋白的轻链可变区(VL)构架区(FRs)。因此，在某些优选的实施方案中，本发明的抗体或其抗原结合片段是人源化的。在此类实施方案中，本发明的抗体或其抗原结合片段的重链可变区FRs和/或轻链可变区FRs可以包含一个或多个非人源(例如，鼠源)氨基酸残基，例如所述重链构架区FRs和/或轻链构架区FRs可以包含一或多个氨基酸回复突变，在这些回复突变中有相应的鼠源氨基酸残基。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)人免疫球蛋白的重链构架区或其变体，所述变体与其所源自的胚系抗体基因序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如1个，2个，3个，4个或5个氨基酸的保守置换)；和/或
(b)人免疫球蛋白的轻链构架区或其变体，所述变体与其所源自胚系抗体基因的序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如1个，2个，3个，4个或5个氨基酸的保守置换)。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段的人源化程度为至少75％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至 少96％、至少97％、至少98％、至少99％或100％。
在某些实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链可变区(VH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NOs：1、15、16、17任一项所示的序列；
(ii)与SEQ ID NOs：1、15、16、17任一项所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与SEQ ID NOs：1、15、16、17任一项所示的序列具有至少75％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NOs：2、18、19、20任一项所示的序列；
(v)与SEQ ID NOs：2、18、19、20任一项所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与SEQ ID NOs：2、18、19、20任一项所示的序列具有至少75％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链可变区(VH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NOs：29、31任一项所示的序列；
(ii)与SEQ ID NOs：29、31任一项所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与SEQ ID NOs：29、31任一项所示的序列具有至少75％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链可变区(VL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NOs：30、32任一项所示的序列；
(v)与SEQ ID NOs：30、32任一项所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与SEQ ID NOs：30、32任一项所示的序列具有至少75％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些实施方案中，本发明的抗体或其抗原结合片段具有如下的重链可变区(VH)和/或轻链可变区(VL)：SEQ ID NOs：1、15、16、17任一项所示的VH，和/或,SEQ ID NOs：2、18、19、20任一项所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段具有如下的重链可变区(VH)和/或轻链可变区(VL)：SEQ ID NOs：29、31任一项所示的VH，和/或,SEQ ID NOs：30、32任一项所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：1所示的VH，和/或,SEQ ID NO：2所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：1所示的VH和/或SEQ ID NO：2所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：1所示的VH和/或SEQ ID NO：2所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：15所示的VH，和/或,SEQ ID NO：18所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：15 所示的VH和/或SEQ ID NO：18所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：15所示的VH和/或SEQ ID NO：18所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：15所示的VH，和/或,SEQ ID NO：20所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：15所示的VH和/或SEQ ID NO：20所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：15所示的VH和/或SEQ ID NO：20所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：16所示的VH，和/或,SEQ ID NO：18所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：16所示的VH和/或SEQ ID NO：18所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：16所示的VH和/或SEQ ID NO：18所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：17所示的VH，和/或,SEQ ID NO：19所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：17所示的VH和/或SEQ ID NO：19所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：17所示的VH和/或SEQ ID NO：19所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：17所示的VH，和/或,SEQ ID NO：18所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：17所示的VH和/或SEQ ID NO：18所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：17所示的VH和/或SEQ ID NO：18所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：29所示的VH，和/或,SEQ ID NO：30所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：29所示的VH和/或SEQ ID NO：30所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：29所示的VH和/或SEQ ID NO：30所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。 在优选的实施方案中，所述的置换是保守置换。
在某些实施方案中，本发明的抗体或其抗原结合片段包含SEQ ID NO：31所示的VH，和/或,SEQ ID NO：32所示的VL。
在某些实施方案中，本发明的抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：31所示的VH和/或SEQ ID NO：32所示的VL相比，具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些实施方案中，所述抗体或其抗原结合片段的VH和/或VL与SEQ ID NO：31所示的VH和/或SEQ ID NO：32所示的VL相比，具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)。在优选的实施方案中，所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)具有如SEQ ID NO：1所示的序列的VH和具有如SEQ ID NO：2所示的序列的VL；
(b)具有如SEQ ID NO：15所示的序列的VH和具有如SEQ ID NO：18所示的序列的VL；
(c)具有如SEQ ID NO：15所示的序列的VH和具有如SEQ ID NO：20所示的序列的VL；
(d)具有如SEQ ID NO：16所示的序列的VH和具有如SEQ ID NO：18所示的序列的VL；
(e)具有如SEQ ID NO：17所示的序列的VH和具有如SEQ ID NO：19所示的序列的VL；
(f)具有如SEQ ID NO：17所示的序列的VH和具有如SEQ ID NO：18所示的序列的VL；
(g)具有如SEQ ID NO：29所示的序列的VH和具有如SEQ ID NO：30所示的序列的VL；或，
(h)具有如SEQ ID NO：31所示的序列的VH和具有如SEQ ID NO：32所示的序列的VL。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含重链可变区(VH)和 轻链可变区(VL)，其中所述重链可变区(VH)和轻链可变区(VL)与(a)至(h)任一组中所述的VH和VL相比，其重链可变区(VH)具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性；和/或，其轻链可变区(VL)具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含重链可变区(VH)和轻链可变区(VL)，其中所述重链可变区(VH)和轻链可变区(VL)与(a)至(h)任一组中所述的VH和VL相比，其重链可变区(VH)具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；和/或，其轻链可变区(VL)具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换是保守置换。
在以上任一方面中，本发明的抗体或其抗原结合片段可以进一步包含来源于哺乳动物(例如，鼠或人)免疫球蛋白的恒定区序列或其变体。在某些实施方案中，本发明的抗体或其抗原结合片段的重链包含人或鼠免疫球蛋白的重链恒定区(CH)或其变体，所述变体与其所源自的野生型序列相比具有一个或多个氨基酸的置换、缺失或添加或其任意组合(例如，至多20个、至多15个、至多10个、或至多5个氨基酸的置换、缺失或添加或其任意组合；例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；和/或，本发明的抗体或其抗原结合片段的轻链包含人或鼠免疫球蛋白的轻链恒定区(CL)或其变体，所述变体与其所源自的野生型序列相比具有一个或多个氨基酸的置换、缺失或添加或其任意组合(例如，至多20个、至多15个、至多10个、或至多5个氨基酸的置换、缺失或添加或其任意组合；例如5个，4个，3个，2个或1个氨基酸的置换、缺失或添加或其任意组合)。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段的重链包含人免疫球蛋白的重链恒定区(CH)或其变体，所述变体与其所源自的野生型序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如5个，4个，3个，2个或1个氨基酸的保守置换)；和/或，本发明的抗体或其抗原结合片段的轻链包含人免疫球蛋白的轻链恒定区(CL)或其变体，所述变体与其所源自的野生型序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守 置换；例如5个，4个，3个，2个或1个氨基酸的保守置换)。
在某些实施方案中，本发明的抗体或其抗原结合片段的重链包含鼠免疫球蛋白的重链恒定区(CH)或其变体，所述变体与其所源自的野生型序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如5个，4个，3个，2个或1个氨基酸的保守置换)。在某些实施方案中，本发明的抗体或其抗原结合片段的轻链包含鼠免疫球蛋白的轻链恒定区(CL)或其变体，所述变体与其所源自的野生型序列相比具有至多20个氨基酸的保守置换(例如至多15个、至多10个、或至多5个氨基酸的保守置换；例如5个，4个，3个，2个或1个氨基酸的保守置换)。
在一些实施方案中，恒定区被改变，例如被氨基酸突变，以修饰抗FXI和/或FXIa抗体分子的性质(例如改变下列中的一个或更多个特性：Fc受体结合、抗体糖基化、半胱氨酸残基的数目、效应细胞功能或补体功能)。可以通过将抗体恒定区中的至少一个氨基酸残基替换为不同残基，产生功能改变，例如，改变抗体对效应子配体(如FcR或补体C1q)的亲和力，从而改变效应子功能(例如降低)。抗体的Fc区介导几种重要的效应子功能，例如ADCC、吞噬作用、CDC等。
在某些实施方案中，本发明的抗体或其抗原结合片段具有重链恒定区(Fc)，其选自例如IgG1、IgG2、IgG3、IgG4、IgM、IgA1、IgA2、IgD和IgE的重链恒定区；优选地选自例如IgG1、IgG2、IgG3和IgG4的重链恒定区，更优选地选自IgG1或IgG4(例如是人IgG1或IgG4)的重链恒定区。在一些实施方案中，本发明的抗体或其抗原结合片段具有轻链恒定区，其选自例如κ或λ的轻链恒定区，优选κ轻链恒定区(例如人κ轻链)。
在一些优选的实施方案中，所述抗体或其抗原结合片段包含选自下列的重链恒定区：(1)人IgG1重链恒定区；或(2)人IgG4重链恒定区。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链恒定区(CH)，其包含选自下列的氨基酸序列：
(i)SEQ ID NO:21所示的序列；
(ii)与SEQ ID NO:21所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与SEQ ID NO:21所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或 100％的同一性的序列；
和/或
(b)轻链恒定区(CL)，其包含选自下列的氨基酸序列：
(iv)SEQ ID NO:22所示的序列；
(v)与SEQ ID NO:22所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与SEQ ID NO:22所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明抗体或其抗原结合片段包含如SEQ ID NO：21所示的重链恒定区(CH)和如SEQ ID NO：22所示的轻链恒定区(CL)。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链，其包含选自下列的氨基酸序列：
(i)包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的CH的序列；
(ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链，其包含选自下列的氨基酸序列：
(iv)包含SEQ ID NO：18所示的VL序列和SEQ ID NO：22所示的CL序列的序列；
(v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至 少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链，其包含选自下列的氨基酸序列：
(i)包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的CH的序列；
(ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链，其包含选自下列的氨基酸序列：
(iv)包含SEQ ID NO：20所示的VL和SEQ ID NO：22所示的CL的序列；
(v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链，其包含选自下列的氨基酸序列：
(i)包含SEQ ID NO：16所示的VH和SEQ ID NO：21所示的CH的序列；
(ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链，其包含选自下列的氨基酸序列：
(iv)包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的CL的序列；
(v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链，其包含选自下列的氨基酸序列：
(i)包含SEQ ID NO：17所示的VH和SEQ ID NO：21所示的CH的序列；
(ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链，其包含选自下列的氨基酸序列：
(iv)包含SEQ ID NO：19所示的VL和SEQ ID NO：22所示的CL的序列；
(v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至 少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链，其包含选自下列的氨基酸序列：
(i)包含SEQ ID NO：17所示的VH和SEQ ID NO：21所示的CH的序列；
(ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链，其包含选自下列的氨基酸序列：
(iv)包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的CL的序列；
(v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段包含：
(a)重链，其包含选自下列的氨基酸序列：
(i)包含SEQ ID NO：31所示的VH和SEQ ID NO：21所示的CH的序列；
(ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
和/或
(b)轻链，其包含选自下列的氨基酸序列：
(iv)包含SEQ ID NO：32所示的VL和SEQ ID NO：22所示的CL的序列；
(v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
(vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列。
在某些优选的实施方案中，(ii)或(v)中所述的置换是保守置换。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：1所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：2所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：20所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：16所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：17所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：19所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：17所示的VH和SEQ ID  NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：29所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：30所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体包含：包含SEQ ID NO：31所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：32所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
在某些优选的实施方案中，本发明的抗体是嵌合抗体或人源化抗体。在某些优选的实施方案中，本发明的抗体或其抗原结合片段选自ScFv、Fab、Fab’、(Fab’) 2、Fv片段、二硫键连接的Fv(dsFv)、双抗体(diabody)、双特异性抗体、和多特异性抗体。
在某些实施方案中，所述抗体或其抗原结合片段具有降低的ADCC活性。
在某些实施方案中，所述抗体或其抗原结合片段具有降低的CDC活性。
在某些实施方案中，所述抗体或其抗原结合片段不具有CDC活性。
在某些实施方案中，所述抗体或其抗原结合片段不具有ADCC活性。
在某些优选的实施方案中，所述抗体或其抗原结合片段具有降低的ADCC和降低CDC活性。
在某些优选的实施方案中，所述抗体或其抗原结合片段不具有ADCC也不具有CDC活性。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段具备以下特性中的至少一项：
(a)以小于约100nM，例如小于约10nM、1nM、0.1nM或更低的KD结合FXI和/或FXIa(例如，人FXI和/或人FXIa)；优选地，所述K D可以通过领域里公知的技术测得，例如通过生物薄膜干涉技术(BLI)(如ForteBio
Figure PCTCN2020083413-appb-000001
)测得；
(b)以小于约500nM，例如小于约100nM、10nM、1nM、0.9nM、0.8nM、0.7nM、0.6nM、0.5nM、0.4nM、0.3nM、0.2nM、0.1nM或更小的EC50结合FXI和/或FXIa(例如，人FXI和/或人FXIa)；优选地，所述EC50可以通过领域里公知的技术测得，例如，通过流式细胞技术或细胞竞争ELISA技术测得；
(c)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa与底物的结合，从而延长凝血时间；
(d)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa对底物的催化作用；
(e)所述抗体或其抗原结合片段与FXI和/或FXIa的结合不影响外源性凝血；
(f)所述抗体或其抗原结合片段具有降低的ADCC和/或CDC活性；
(g)所述抗体或其抗原结合片段不具有ADCC和/或CDC活性；
(h)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa各自二聚体的形成；
(i)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa与HK形成复合物；
(j)结合至FXI和/或FXIa的催化结构域，和/或诱导其构象变化；
(k)抑制或阻断FXI和/或FXIa与血小板受体结合；或
(l)(a)-(k)的任意组合。
在某些优选的实施方案中，本发明的抗体或其抗原结合片段在结合至FXI时防止FXI催化结构域呈现活性构象。在某些优选的实施方案中，本发明的抗体或其抗原结合片段在结合至FXI时通过诱导酶原结构中的构象变化防止该FXI催化结构域呈现活性构象，进一步抑制与FIX的结合。
衍生的抗体
本发明的抗体或其抗原结合片段可进行衍生化，例如被连接至另一个分子(例如另一个多肽或蛋白)。通常，抗体或其抗原结合片段的衍生化(例如，标记)不会对其与FXI和/或FXIa(特别是人FXI和/或FXIa)的结合产生不利影响。因此，本发明的抗体或其抗原结合片段还意欲包括此类衍生化的形式。例如，可以将本发明的抗体或其抗原结合片段功能性连接(通过化学偶合、基因融合、非共价连接或其它方式)于一个或多个其它分子基团，例如另一个抗体(例如，形成双特异性抗体)，检测试剂，药用试剂，和/或能够介导抗体或抗原结合片段与另一个分子结合的蛋白或多肽(例如，抗生物素蛋白或多组氨酸标签)。
一种类型的衍生化抗体(例如，双特异性抗体)是通过交叉连接2个或多个抗体(属于同一类型或不同类型)而产生的。获得双特异性抗体的方法是本领域公知的，其实例包括但不限于，化学交联法、细胞工程法(杂交杂交瘤法)或基因工程法。
另一种类型的衍生化抗体是标记的抗体。例如，可以将本发明的抗体或其抗原结合片 段连接至可检测的标记。本发明所述的可检测的标记可以是可通过荧光、光谱、光化学、生物化学、免疫学、电学、光学或化学手段检测的任何物质。这类标记是本领域熟知的，其实例包括但不限于，酶(例如，辣根过氧化物酶、碱性磷酸酶、β-半乳糖苷酶、脲酶、葡萄糖氧化酶，等)、放射性核素(例如， 3H、 125I、 35S、 14C或 32P)、荧光染料(例如，异硫氰酸荧光素(FITC)、荧光素、异硫氰酸四甲基罗丹明(TRITC)、藻红蛋白(PE)、德克萨斯红、罗丹明、量子点或花菁染料衍生物(例如Cy7、Alexa 750)、吖啶酯类化合物、磁珠(例如，
Figure PCTCN2020083413-appb-000002
)、测热标记物例如胶体金或有色玻璃或塑料(例如，聚苯乙烯、聚丙烯、乳胶，等)珠、以及用于结合上述标记物修饰的亲和素(例如，链霉亲和素)的生物素。教导该标记物的使用的专利包括，但不限于，美国专利3,817,837；3,850,752；3,939,350；3,996,345；4,277,437；4,275,149；及4,366,241(全部通过引用并入本文)。如上所述的可检测的标记可通过本领域已知的方法检测。例如，放射性标记可使用摄影胶片或闪烁计算器检测，荧光标记物可使用光检测器检测，以检测发射的光。酶标记物一般通过给酶提供底物及检测通过酶对底物的作用产生的反应产物来检测，及测热标记物通过简单可视化着色标记物来检测。在某些实施方案中，此类标记能够适用于免疫学检测(例如，酶联免疫测定法、放射免疫测定法、荧光免疫测定法、化学发光免疫测定法等)。在某些实施方案中，可通过不同长度的接头(linker)将如上所述的可检测的标记连接至本发明的抗体或其抗原结合片段，以降低潜在的位阻。
此外，本发明的抗体或其抗原结合片段还可以用化学基团进行衍生，例如聚乙二醇(PEG)，甲基或乙基，或者糖基。这些基团可用于改善抗体的生物学特性，例如增加血清半衰期。
作为抗体的衍生物之一，本发明提供一种缀合物。在某些实施方案中，所述缀合物包括任一本发明的特异性结合FXI和/或FXIa的抗体或其抗原结合片段以及偶联部分，所述偶联部分为可检测的标记，如上述放射性同位素、荧光物质、发光物质、有色物质或酶。在某些实施方案中，所述偶联部分为治疗剂；可选地，所述治疗剂通过接头与本发明的抗体或其抗原结合片段的一个或多个结合。可选地，所述治疗剂剂通过连接子与本发明的抗体或其抗原结合片段结合。所述治疗剂选自本公开中用途、治疗方法和药物组合物中的任何一种药物。连接子显著不影响本发明的抗体或其抗原结合片段结合的生物学活性。
作为抗体的衍生物之一，本发明提供一种多特异性抗体，所述多特异性抗体包含本发明的特异性结合FXI和/或FXIa的抗体或其抗原结合片段，和另外的抗体或其抗原结合片段，或抗体类似物。在某些实施方案中，所述多特异性抗体是包含本发明的特异性结合FXI 和/或FXIa的抗体或其抗原结合片段以及另外的抗体或其抗原结合片段、或抗体类似物的缀合物。
在某些实施方案中，所述多特异性抗体由本发明的特异性结合FXI和/或FXIa的抗体或其抗原结合片段与另外的抗体或其抗原结合片段或抗体类似物通过偶联形成，并且其中各抗体或其抗原结合片段或抗体类似物保持原结合特异性。某些优选的实施方案中，所述多特异性抗体为双特异性抗体或三特异性抗体或四特异性抗体。
抗体的制备
本发明的抗体可以本领域已知的各种方法来制备，例如通过基因工程重组技术来获得。例如，通过化学合成或PCR扩增获得编码本发明抗体的重链和轻链基因的DNA分子。将所得DNA分子插入表达载体内，然后转染宿主细胞。然后，在特定条件下培养转染后的宿主细胞，并表达本发明的抗体。
本发明的抗原结合片段可以通过水解完整的抗体分子获得(参见Morimoto et al.,J.Biochem.Biophys.Methods 24:107-117(1992)and Brennan et al.,Science 229:81(1985))。另外，这些抗原结合片段也可以直接由重组宿主细胞产生(reviewed in Hudson,Curr.Opin.Immunol.11:548-557(1999)；Little et al.,Immunol.Today,21:364-370(2000))。比如，Fab’片段可以直接从宿主细胞中获得；可以将Fab’片段化学偶联形成F(ab’) 2片段(Carter et al.,Bio/Technology,10:163-167(1992))。另外，Fv、Fab或F(ab’) 2片段也可以直接从重组宿主细胞培养液中直接分离得到。本领域的普通技术人员完全知晓制备这些抗原结合片段的其它技术。
因此，在另一个方面，本发明提供了一种分离的核酸分子，其包含编码本发明的抗体或其抗原结合片段，或其重链可变区和/或轻链可变区的核苷酸序列，或其一个或多个CDR。根据本领域已知的密码子简并性，在某些实施方案中，所述核苷酸序列是可以根据密码子简并性进行替换的。在某些实施方案中，所述核苷酸序列是密码子最优化的。
在某些优选的实施方案中，所述分离的核酸分子包含：分别编码本发明的抗体或其抗原结合片段的重链可变区和轻链可变区的第一核酸和第二核酸，或分别编码本发明的抗体或其抗原结合片段的重链可变区和重链恒定区的第一核酸，和轻链可变区和轻链恒定区的第二核酸，或分别编码本发明的抗体或其抗原结合片段的重链和轻链的第一核酸和第二核酸。在某些优选的实施方案中，以上所述的本发明的抗体选自下组中的任意一种：36G9.10，36G9.10-hz43，36G9.10-hz73，36G9.10-hz74，36G9.10-hz92，36G9.10-hz93，7B2， 7B2-hz11。在某些优选的实施方案中，所述第一核酸和第二核酸包含与上述第一核酸和第二核酸具有基本上相同序列的核酸。例如，所述分离的核酸分子可以包含序列表中SEQ ID NO:23,SEQ ID NO:24,SEQ ID NO:27,SEQ ID NO:28所示的核苷酸序列或与其基本上相同的序列。例如，所述与其基本上相同的序列是指与其相比具有至少大约85％、90％、95％、99％或更高同一性的序列或具有一个或更多个核苷酸取代的序列，或相差不超过3、6、15、30或45个核苷酸的序列)。
在某些优选的实施方案中，本发明提供了一种的分离的核酸分子，其包含编码抗体重链可变区的核酸分子，和/或编码抗体轻链可变区的核酸分子，其中，所述编码抗体重链可变区的核酸分子具有选自下列的核苷酸序列：(a).如SEQ ID NO:23所示的核苷酸序列，或(b).与(a)所述的核苷酸序列基本上相同的序列(例如，与(a)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或(c).与(a)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列；所述编码抗体轻链可变区的核酸分子具有选自下列的序列：(d).如SEQ ID NO:24所示的核苷酸序列，或(e).与(d)所述的核苷酸序列基本上相同的序列(例如，与(d)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或(f).与(d)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列。
在某些优选的实施方案中，本发明提供了一种的分离的核酸分子，其包含编码抗体重链可变区的核酸分子，和/或编码抗体轻链可变区的核酸分子，其中，所述编码抗体重链可变区的核酸分子具有选自下列的核苷酸序列：(a).如SEQ ID NO:27所示的核苷酸序列，或(b).与(a)所述的核苷酸序列基本上相同的序列(例如，与(a)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或(c).与(a)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列；所述编码抗体轻链可变区的核酸分子具有选自下列的核苷酸序列：(d).如SEQ ID NO:28所示的核苷酸序列，或(e).与(d)所述的核苷酸序列基本上相同的序列(例如，与(d)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或(f).与(d)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列。
在某些优选的实施方案中，本发明的分离的核酸分子包含如SEQ ID NO:23所示的编码抗体重链可变区的核酸分子，和/或如SEQ ID NO:24所示的编码抗体轻链可变区的核酸分 子。
在某些优选的实施方案中，本发明的分离的核酸分子包含如SEQ ID NO:27所示的编码抗体重链可变区的核酸分子，和/或如SEQ ID NO:28所示的编码抗体轻链可变区的核酸分子。
在某些优选的实施方案中，本发明提供了一种的分离的核酸分子，其包含编码抗体重链的核酸分子，和/或编码抗体轻链的核酸分子，其中，所述编码抗体重链的核酸分子具有选自下列的核苷酸序列：(a).如SEQ ID NO:25所示的核苷酸序列，或(b).与(a)所述的核苷酸序列基本上相同的序列(例如，与(a)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或(c).与(a)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列，和/或，所述编码抗体轻链的核酸分子具有选自下列的核苷酸序列：(d).如SEQ ID NO:26所示的核苷酸序列，或(e).与(d)所述的核苷酸序列基本上相同的序列(例如，与(d).所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或(f).与(d)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列。
在某些优选的实施方案中，本发明的分离的核酸分子包含如SEQ ID NO:25所示的编码抗体重链的核酸分子，和/或如SEQ ID NO:26所示的编码抗体轻链的核酸分子。
本发明另一方面，提供了一种载体(例如克隆载体或表达载体)，其包含本发明的分离的核酸分子。在某些优选的实施方案中，本发明的载体是例如质粒，粘粒，噬菌体，慢病毒等。在某些优选的实施方案中，所述载体能够在受试者(例如哺乳动物，例如人)体内表达本发明的抗体或其抗原结合片段。
本发明另一方面，提供了一种宿主细胞，其包含本发明的分离的核酸分子或本发明的载体。宿主细胞可以是真核细胞(例如哺乳动物细胞、昆虫细胞、酵母细胞)或原核细胞(例如大肠杆菌)。合适的真核细胞包括但不限于NS0细胞、Vero细胞、Hela细胞、COS细胞、CHO细胞、HEK293细胞、BHK细胞、和MDCKII细胞。适宜的昆虫细胞包括但不限于Sf9细胞。在某些优选的实施方案中，本发明的宿主细胞是哺乳动物细胞，例如CHO(例如CHO-K1、CHO-S、CHO DXB11、CHO DG44)。
本发明另一方面，提供了制备本发明的抗体或其抗原结合片段的方法，其包括，在允许所述抗体或其抗原结合片段表达的条件下，培养本发明的宿主细胞，和从培养的宿主细胞培养物中回收所述抗体或其抗原结合片段。
用途、治疗方法和药物组合物
本发明另一方面，提供了药物组合物，其包含本发明的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体或缀合物，以及药学上可接受的载体和/或赋形剂。
在某些优选的实施方案中，本发明的药物组合物包含本发明的抗体或其抗原结合片段，以及药学上可接受的载体和/或赋形剂。
在某些优选的实施方案中，本发明的药物组合物包含本发明的分离的核酸分子，载体或宿主细胞，以及药学上可接受的载体和/或赋形剂。在此类实施方案中，所述宿主细胞包含如前所述的分离的核酸分子或载体。
在某些优选的实施方案中，所述药物组合物还可以包含另外的药学活性剂。在某些优选的实施方案中，所述另外的药学活性剂是抗血小板类药物、抗凝类药物或溶栓药物。
在某些优选的实施方案中，在所述药物组合物中，本发明的抗体或其抗原结合片段与所述另外的药学活性剂作为分离的组分或作为同一组合物的组分提供。因此，本发明的抗体或其抗原结合片段与所述另外的药学活性剂可以同时、分开或相继施用。
在某些优选的实施方案中，所述药物组合物还可以包含另外的药学活性剂。所述另外的药学活性剂选自阿司匹林、氯吡格雷、普拉格雷、替格瑞洛、阿昔单抗、依替巴肽、沃拉帕沙、普通肝素、肝素、低分子肝素、华法林、磺达肝癸钠、依度沙班、贝曲西班、利伐沙班、阿哌沙班、达比加群酯、阿加曲班、比伐卢定、链激酶、尿激酶、阿替普酶、尿激酶原，或其任意组合。
另一方面，本发明的药物组合物中的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体或者缀合物足以在受试者中产生至少一项以下生物学活性：
(a)结合至FXI和/或FXIa的催化结构域，和/或诱导其构象变化；
(b)抑制或阻断FXI和/或FXIa与底物结合；
(c)抑制或阻断FXI和/或FXIa与血小板受体结合；
(d)抑制或阻断FXI和凝血因子XIIa(FXIIa)结合，从而抑制或阻断FXI转变为有活性的FXIa；
(e)抑制或阻断FXIa和凝血因子FIX结合，从而抑制或阻断FIX转变为有活性的FIXa；
(f)抑制或阻断FXI和/或FXIa介导的内源凝血途径的活化；
(g)抑制或阻断FXI和/或FXIa在血栓形成中的活性；
(h)延长FXI和/或FXIa介导的凝血时间；
(i)抑制血栓形成；
(j)预防和/或治疗FXI和/或FXIa介导的与凝血或血栓栓塞相关的病症或疾病；或
(k)(a)-(j)的任意组合。
另一方面，本发明的药物组合物还包含第二抗体或编码所述第二抗体的核酸，其中所述第二抗体是识别FXI或FXIa不同表位的另一抗体，或者是特异性结合选自以下受体或配体的抗体：凝血酶(thrombin)、抗纤维蛋白溶酶(Antiplasmin)、因子十二(Factor XII)、因子八(Factor VIII)、因子七(Factor VII)、因子十(Factor X)、因子九(Factor IX)、因子二(Factor II)、组织因子(Tissue Factor)、P-选择素及其配体、L-选择素及其配体，及以上抗体的任意组合。
本发明另一方面，提供本发明的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体、缀合物或者药物组合物在制备药物中的用途，所述药物用于：
(a)结合至FXI和/或FXIa的催化结构域，和/或诱导其构象变化；
(b)抑制或阻断FXI和/或FXIa与底物结合；
(c)抑制或阻断FXI和/或FXIa与血小板受体结合；
(d)抑制或阻断FXI和凝血因子XIIa(FXIIa)结合，从而抑制FXI转变为有活性的FXIa；
(e)抑制或阻断FXIa和凝血因子FIX结合，从而抑制FIX转变为有活性的FIXa；
(f)抑制或阻断FXI和/或FXIa介导的内源凝血途径的活化；
(g)抑制或阻断FXI和/或FXIa在血栓形成中的活性；
(h)延长FXI和/或FXIa介导的凝血时间；
(i)抑制血栓形成；
(j)预防和/或治疗FXI和/或FXIa介导的与凝血或血栓栓塞相关的疾病或病症；或
(k)(a)-(j)的任意组合。
在某些优选的实施方案中，当本发明的分离的核酸分子、载体或宿主细胞用于制备药物时，所述宿主细胞包含如前所述的分离的核酸分子或载体。
在某些优选的实施方案中，当本发明的载体或宿主细胞用于制备药物时，所述药物用于在受试者(例如人)中预防和/或治疗与凝血或血栓栓塞相关的疾病或病症。
在某些实施方案中，所述受试者是哺乳动物。在某些优选的实施方案中，所述受试者是人。
在某些优选的实施方案中，当本发明的载体或宿主细胞用于制备药物时，所述药物用于在受试者(例如人)中延迟与凝血或血栓栓塞相关的疾病或病症的发生。
在某些优选的实施方案中，当本发明的载体或宿主细胞用于制备药物时，所述药物用于在受试者(例如人)中降低或抑制与凝血或血栓栓塞相关的疾病或病症复发。
在某些优选的实施方案中，当本发明的载体或宿主细胞用于制备药物时，所述药物用于在受试者(例如人)。
在某些优选的实施方案中，本发明所述的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体、缀合物、或者药物组合物涉及的与凝血或血栓栓塞相关的疾病或病症选自：血栓形成、血栓性中风、心房纤维性颤动、心房纤维性颤动有关的中风预防(SPAF)、深层静脉血栓形成、静脉血栓栓塞、急性冠状动脉综合征(ACS)、缺血性中风、急性肢体局部缺血、慢性血栓栓塞肺高血压、全身栓塞、心肌梗死(MI)、急性心肌梗死(AMI)、稳定型心绞痛、不稳定型心绞痛、冠状动脉介入后的再闭塞和再狭窄、外周动脉闭塞性疾病(PAOD)、肾静脉血栓形成、短暂性脑缺血发作(TIA)、肺血栓栓塞、弥漫性血管内凝血、医疗装置(如导管)引发的血栓栓塞病症、重度全身性炎性反应综合症、转移性癌症、感染性疾病、器官衰竭(如肾衰竭)、体内施用治疗性蛋白质引起的毒性、多发性创伤、缺血再灌注损伤、局部纤维蛋白沉积，成人肺泡蛋白沉积症，关节置换(TKA)手术术前术后的血栓栓塞事件(VTE)，冠心病，心梗后血栓栓塞，非瓣膜房颤患者脑卒中，慢性肾病中的血栓形成及血栓栓塞，经受血液透析的患者及经受体外膜氧化的患者的血栓及血栓栓塞，深静脉血栓形成(DVT)，或肺栓塞(PE)。
在另一个方面，本发明提供了一种在受试者中预防和/或治疗与凝血或血栓栓塞相关的疾病或病症的方法。在另一个方面，本发明提供了一种在受试者中延迟与凝血或血栓栓塞相关的疾病或病症发生的方法。在另一个方面，本发明提供了一种在受试者中降低或抑制与凝血或血栓栓塞相关的疾病或病症复发的方法。以上所述方法包括向有此需要的受试者施用有效量的本发明所述的抗体或其抗原结合片段、载体、宿主细胞、多特异性抗体、缀合物、或者药物组合物。
当本发明的宿主细胞用于以上所述方法时，所述宿主细胞包含如前所述的分离的核酸分子或载体。
在另一个方面，以上所述方法还包括向所述受试者施用第二疗法，所述第二疗法选自抗血小板类药物、抗凝类药物、溶栓药物。
在某些优选的实施方案中，所述第二疗法选自阿司匹林、氯吡格雷、普拉格雷、替格瑞洛、阿昔单抗、依替巴肽、沃拉帕沙、普通肝素、肝素、低分子肝素、华法林、磺达肝癸钠、依度沙班、贝曲西班、利伐沙班、阿哌沙班、达比加群酯、阿加曲班、比伐卢定、链激酶、尿激酶、阿替普酶、尿激酶原及其任意组合。
在某些优选的实施方案中，本发明所述的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体、缀合物、或者药物组合物涉及的与凝血或血栓栓塞相关的疾病或病症选自血栓形成、血栓性中风、心房纤维性颤动、心房纤维性颤动有关的中风预防(SPAF)、深层静脉血栓形成、静脉血栓栓塞、急性冠状动脉综合征(ACS)、缺血性中风、急性肢体局部缺血、慢性血栓栓塞肺高血压、全身栓塞、心肌梗死(MI)、急性心肌梗死(AMI)、稳定型心绞痛、不稳定型心绞痛、冠状动脉介入后的再闭塞和再狭窄、外周动脉闭塞性疾病(PAOD)、肾静脉血栓形成、短暂性脑缺血发作(TIA)、肺血栓栓塞、弥漫性血管内凝血、医疗装置(如导管)引发的血栓栓塞病症、重度全身性炎性反应综合症、转移性癌症、感染性疾病、器官衰竭(如肾衰竭)、体内施用治疗性蛋白质引起的毒性、多发性创伤、缺血再灌注损伤、局部纤维蛋白沉积，成人肺泡蛋白沉积症，关节置换(TKA)手术术前术后的血栓栓塞事件(VTE)，冠心病，心梗后血栓栓塞，非瓣膜房颤患者脑卒中，慢性肾病中的血栓形成及血栓栓塞，经受血液透析的患者及经受体外膜氧化的患者的血栓及血栓栓塞，深静脉血栓形成(DVT)，或肺栓塞(PE)。
本发明的抗体或其抗原结合片段、本发明的药物组合物可以配制成医学领域已知的任何剂型，例如，片剂、丸剂、混悬剂、乳剂、溶液、凝胶剂、胶囊剂、粉剂、颗粒剂、酏剂、锭剂、栓剂、注射剂(包括注射液、注射用无菌粉末与注射用浓溶液)、吸入剂、喷雾剂等。优选剂型取决于预期的给药方式和治疗用途。本发明的药物组合物应当是无菌的并在生产和储存条件下稳定。一种优选的剂型是注射剂。此类注射剂可以是无菌注射溶液。例如，可通过下述方法来制备无菌注射溶液：在适当的溶剂中掺入必需剂量的本发明的重组蛋白，以及任选地，同时掺入其他期望的成分(包括但不限于，pH调节剂，表面活性剂，佐剂，离子强度增强剂，等渗剂、防腐剂、稀释剂，或其任何组合)，随后过滤除菌。此外， 可以将无菌注射溶液制备为无菌冻干粉剂(例如，通过真空干燥或冷冻干燥)以便于储存和使用。此类无菌冻干粉剂可在使用前分散于合适的载体中，例如无菌无热原水。
此外，本发明的抗体或其抗原结合片段可以以单位剂量形式存在于药物组合物中，以便于施用。
本发明的抗体或其抗原结合片段、药物组合物可以通过本领域已知的任何合适的方法来施用，包括但不限于，口服、口腔、舌下、眼球、局部、肠胃外、直肠、叶鞘内、内胞浆网槽内、腹股沟、膀胱内、局部(如，粉剂、药膏或滴剂)，或鼻腔途径。但是，对于许多治疗用途而言，优选的给药途径/方式是胃肠外给药(例如静脉注射，皮下注射，腹膜内注射，肌内注射)。技术人员应理解，给药途径和/或方式将根据预期目的而发生变化。在一个优选的实施方案中，本发明的抗体或其抗原结合片段、药物组合物通过静脉输注或注射给予。
本发明的药物组合物可以包括“治疗有效量”或“预防有效量”的本发明的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体或者缀合物。“预防有效量”是指，足以预防，阻止，或延迟疾病的发生的量。“治疗有效量”是指，足以治愈或至少部分阻止已患有疾病的患者的疾病和其并发症的量。本发明的抗体或其抗原结合片段的治疗有效量可根据如下因素发生变化：待治疗的疾病的严重度、患者自己的免疫系统的总体状态、患者的一般情况例如年龄，体重和性别，药物的施用方式，以及同时施用的其他治疗等等。
在本发明中，可调整给药方案以获得最佳目的反应(例如治疗或预防反应)。例如，可以单次给药，可以在一段时间内多次给药，或者可以随治疗情况的紧急程度按比例减少或增加剂量。
本发明的重组蛋白的治疗或预防有效量的典型非极限范围是0.02～100mg/kg，例如0.1～100mg/kg，0.1～50mg/kg，或1～50mg/kg。应注意的是，剂量可随需要治疗的症状的类型和严重性不同而发生变化。此外，本领域技术人员理解，对于任一特定患者，特定的给药方案应根据患者需要和医生的专业评价而随时间调整；此处给出的剂量范围只用于举例说明目的，而不限定本发明药物组合物的使用或范围。
在本发明中，所述受试者可以为哺乳动物，例如人。
检测方法和试剂盒
本发明的抗体或其抗原结合片段能够特异性结合FXI和/或FXIa(例如人FXI和/或 人FXIa)，从而可用于检测FXI和/或FXIa在样品中的存在或其水平。
因此，在另一个方面，本发明提供了一种试剂盒，其包括本发明的抗体或其抗原结合片段。在某些优选的实施方案中，本发明的抗体或其抗原结合片段带有可检测的标记。在一个优选的实施方案中，所述试剂盒还包括第二抗体，其特异性识别本发明的抗体或其抗原结合片段。优选地，所述第二抗体还包括可检测的标记。
在本发明中，所述可检测的标记可以是可通过荧光、光谱、光化学、生物化学、免疫学、电学、光学或化学手段检测的任何物质。特别优选的是，此类标记能够适用于免疫学检测(例如，酶联免疫测定法、放射免疫测定法、荧光免疫测定法、化学发光免疫测定法等)。这类标记是本领域熟知的，包括但不限于，酶(例如，辣根过氧化物酶、碱性磷酸酶、β-半乳糖苷酶、脲酶、葡萄糖氧化酶等)、放射性核素(例如， 3H、 125I、 35S、 14C或 32P)、荧光染料(例如，异硫氰酸荧光素(FITC)、荧光素、异硫氰酸四甲基罗丹明(TRITC)、藻红蛋白(PE)、德克萨斯红、罗丹明、量子点或花菁染料衍生物(例如Cy7、Alexa 750))、吖啶酯类化合物、磁珠(例如，
Figure PCTCN2020083413-appb-000003
)、测热标记物例如胶体金或有色玻璃或塑料(例如，聚苯乙烯、聚丙烯、乳胶，等)珠、以及用于结合上述标记物修饰的亲和素(例如，链霉亲和素)的生物素。教导该标记物的使用的专利包括，但不限于，美国专利3,817,837；3,850,752；3,939,350；3,996,345；4,277,437；4,275,149；及4,366,241(全部通过引用并入本文)。本发明中涵盖的标记物可通过本领域已知的方法检测。例如，放射性标记可使用摄影胶片或闪烁计算器检测，荧光标记物可使用光检测器检测，以检测发射的光。酶标记物一般通过给酶提供底物及检测通过酶对底物的作用产生的反应产物来检测，及测热标记物通过简单可视化着色标记物来检测。在某些实施方案中，可通过不同长度的接头将如上所述的可检测的标记连接至本发明的抗体或其抗原结合片段，以降低潜在的位阻。
在另一个方面，本发明提供了检测FXI和/或FXIa(例如人FXI和/或人FXIa)在样品中的存在或其水平的方法，其包括使用本发明的抗体或其抗原结合片段的步骤。在一个优选的实施方案中，本发明的抗体或其抗原结合片段还带有可检测的标记。在另一个优选的实施方案中，所述方法还包括，使用带有可检测的标记的试剂来检测本发明的抗体或其抗原结合片段。所述方法可以用于诊断目的，或者非诊断目的(例如，所述样品是细胞样品，而非来自患者的样品)。
在另一个方面，本发明提供了一种检测样品中FXI和/或FXIa(例如人FXI和/或人FXIa)存在或其水平的方法，所述方法包括在允许所述抗体或其抗原结合片段、或者缀合物与FXI和/或FXIa之间形成复合物的条件下，使所述样品与本发明所述抗体或其抗原结 合片段接触，并且检测所述复合物的形成。
在另一个方面，提供了本发明的抗体或其抗原结合片段在制备试剂盒中的用途，所述试剂盒用于检测FXI和/或FXIa(例如人FXI和/或人FXIa)在样品中的存在或其水平。在另一个方面，本发明提供了诊断性或治疗性试剂盒，其包括一个或多个以下本发明能够提供的物质：所述的的抗体或其抗原结合片段、分离的核酸分子、载体、宿主细胞、多特异性抗体、缀合物、或者药物组合物。所述诊断性或治疗性试剂盒还包括使用说明书。
本发明的抗体或抗原结合片段与FXI和/或FXIa的结合亲和力高，且具有极强的特异性。因此，本发明的抗体或抗原结合片段适用于预防和/或治疗与凝血或血栓栓塞相关的疾病或病症。本发明的人源化抗体保留了亲本鼠源抗体的功能和性质。而且本发明的人源化抗体具有较高的人源化程度，从而可安全地施用给人受试者，而不引发免疫原性反应。此外，本发明的抗体或抗原结合片段没有或具有很小的出血风险。因此，本发明的抗体或抗原结合片段具有重大的临床价值。
缩略词及术语定义
CDR        免疫球蛋白可变区中的互补决定区
FR         抗体构架区：抗体可变区中除CDR残基以外的氨基酸残基
VH         抗体重链可变区
VL         抗体轻链可变区
IgG        免疫球蛋白G
Kabat      由Elvin A.Kabat提出的免疫球蛋白比对及编号系统(参见，例如Kabat et al.,Sequences of Proteins of Immunological Interest,5th Ed.Public Health Service,National Institutes of Health,Bethesda,Md.,1991)。
Chothia    由Chothia等人提出的免疫球蛋白编号系统，其是基于结构环区的位置鉴定CDR区边界的经典规则(参见，例如Chothia&Lesk(1987)J.Mol.Biol.196:901-917；Chothia等人 (1989)Nature 342:878-883)。
AbM         AbM CDR定义方式来源于Martin的相关研究(Martin ACR,Cheetham JC,Rees AR(1989)Modelling antibody hypervariable loops:A combined algorithm.Proc Natl Acad Sci USA 86:9268–9272)， 此定义方法整合了Kabat及Chothia两者的部分定义。
IMGT       基于由Lefranc等人发起的国际免疫遗传学信息系统(The international ImMunoGeneTics information
Figure PCTCN2020083413-appb-000004
(IMGT))的编号系统，可参阅Lefranc et al.,Dev.Comparat.Immunol.27:55-77,2003。
mAb        单克隆抗体
EC50       产生50％功效或结合的浓度
IC50       产生50％抑制的浓度
ELISA      酶联免疫吸附测定
PCR        聚合酶链式反应
HRP        辣根过氧化物酶
KD         平衡解离常数
Ka         结合速率常数
Kd         解离速率常数
ADCC       抗体依赖性细胞毒性
CDC        补体依赖细胞毒性
FACS       流式细胞荧光分选
CDR-H1     免疫球蛋白重链可变区中的互补决定区1
CDR-H2     免疫球蛋白重链可变区中的互补决定区2
CDR-H3     免疫球蛋白重链可变区中的互补决定区3
CDR-L1     免疫球蛋白轻链可变区中的互补决定区1
CDR-L2     免疫球蛋白轻链可变区中的互补决定区2
CDR-L3     免疫球蛋白轻链可变区中的互补决定区3
APTT       活化部分凝血活酶时间
CFA        完全弗氏佐剂
EC50       半数最大效应浓度
FACS       流式细胞仪技术
IC50       半数最大抑制浓度
IFA        不完全弗氏佐剂
MFI        平均荧光强度
FXI        人凝血11因子
FXIa       活化人凝血11因子
RLU        相对光单位
在本发明中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本文中所用的细胞培养、生物化学、核酸化学、免疫学等实验室操作步骤均为相应领域内广泛使用的常规步骤。同时，为了更好地理解本发明，下面提供相关术语的定义和解释。
如本文中所使用的，术语“FXI蛋白”、“FXI抗原”及“FXI”可互换使用，且是指各种物种的凝血因子XI蛋白。术语“FXIa蛋白”、“FXIa抗原”及“FXIa”可互换使用，且是指各种物种的活化的凝血因子XI蛋白。术语“FXI”及“FXIa”(及其类似术语)分别包括天然FXI及FXIa蛋白的突变体及变体，所述突变体及变体具有与本发明所述的天然一级结构(氨基酸序列)大体上相同的氨基酸序列。
在本文中，术语“凝血及凝血级联”、“凝血级联模型”及其类似术语是公知的，指凝血途径通过蛋白水解级联最终产生凝血酶，接着使可溶性血纤维蛋白原转化为形成凝块的纤维蛋白。该途径的各种酶以酶原形式(非活性形式)存在于血浆中，其在活化时经历蛋白水解分裂自身前体分子释放活性凝血因子。产生凝血酶的过程可划分为三个阶段：内在及外来途径，及最终共同途径。
如本文中所使用的，术语“抗体”是指，通常由两对多肽链(每对具有一条轻链(LC)和一条重链(HC))组成的免疫球蛋白分子。抗体轻链可分类为κ(kappa)和λ(lambda)轻链。重链可分类为μ、δ、γ、α或ε，并且分别将抗体的同种型定义为IgM、IgD、IgG、IgA和IgE。在轻链和重链内，可变区和恒定区通过大约12或更多个氨基酸的“J”区连接，重链还包含大约3个或更多个氨基酸的“D”区。各重链由重链可变区(VH)和重链恒定区(CH)组成。重链恒定区由3个结构域(CH1、CH2和CH3)组成。各轻链由轻链可变区(VL)和轻链恒定区(CL)组成。轻链恒定区由一个结构域CL组成。恒定结构域不直接参与抗体与抗原的结合，但展现出多种效应子功能，如可介导免疫球蛋白与宿主组织或因子，包括免疫系统的各种细胞(例如，效应细胞)和经典补体系统的第一组分(C1q)的结合。VH和VL区还可被细分为具有高变性的区域(称为互补决定区(CDR))，其间散布有较保守的称为构架区(FR)的区域。各VH和VL由按下列顺序：FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4 从氨基末端至羧基末端排列的3个CDRs和4个FRs组成。各重链/轻链对的可变区(VH和VL)分别形成抗原结合部位。氨基酸在各区域或结构域的分配可遵循IMGT、Kabat、Chothia或AbM等编号系统定义。
在本文中，除非上下文明确指出，否则当提及术语“抗体”时，其不仅包括完整抗体，而且包括抗体的抗原结合片段。
如本文中所使用的，术语“互补决定区”或“CDR”是指抗体可变区中负责抗原结合的氨基酸残基。这些氨基酸残基的精确边界可根据本领域已知的各种编号系统进行定义，例如可按照Kabat编号系统(Kabat et al.,Sequences of Proteins of Immunological Interest,5th Ed.Public Health Service,National Institutes of Health,Bethesda,Md.,1991)、Chothia编号系统(Chothia&Lesk(1987)J.Mol.Biol.196:901-917；Chothia等人(1989)Nature 342:878-883)、IMGT编号系统(Lefranc et al.,Dev.Comparat.Immunol.27:55-77,2003)、或AbM编号系统(Martin ACR,Cheetham JC,Rees AR,Proc Natl Acad Sci USA 86:9268–9272,1989)中的定义。对于给定的抗体，本领域技术人员可以容易地鉴别各编号系统所定义的CDR。并且，不同编号系统之间的对应关系是本领域技术人员熟知的(例如，可参见Lefranc et al.,Dev.Comparat.Immunol.27:55-77,2003)。
如本文中所使用的，术语“构架区”或“FR”残基是指，抗体可变区中除了如上定义的CDR残基以外的那些氨基酸残基。
如本文中所使用的，术语“胚系抗体基因”是由非淋巴细胞编码的免疫球蛋白序列，它没有经历导致表达特异免疫球蛋白的遗传学重排及成熟的过程。本发明的各种实施方案所提供的一个优点来源于一种认识，那就是胚系抗体基因比成熟抗体基因更多地保留了动物物种个体的特征性的重要氨基酸序列结构。因此当被治疗性应用于该物种时，更少地被该物种识别为外源物质。
术语“抗体”不受任何特定的产生抗体的方法限制。例如，其包括，重组抗体、单克隆抗体和多克隆抗体。抗体可以是不同同种型的抗体，例如，IgG(例如，IgG1，IgG2，IgG3或IgG4亚型)，IgA1，IgA2，IgD，IgE或IgM抗体。
如本文中所使用的，术语抗体的“抗原结合片段”是指抗体全长或部分片段的多肽,例如全长抗体的片段的多肽，其保持特异性结合全长抗体所结合的相同抗原的能力，和/或与全长抗体竞争对抗原的特异性结合，其也被称为“抗原结合部分”。通常参见，Fundamental Immunology,Ch.7(Paul,W.,ed.,第2版，Raven Press,N.Y.(1989)， 以其全文通过引用合并入本文，用于所有目的。可通过重组DNA技术或通过完整抗体的酶促或化学断裂产生抗体的抗原结合片段。抗原结合片段的非限制性实例包括Fab、Fab’、F(ab’) 2、Fd、Fv、dAb和互补决定区(CDR)片段、单链抗体(例如，scFv)、嵌合抗体、双抗体(diabody)、线性抗体(linear antibody)、纳米抗体(技术来自Domantis)、结构域抗体(技术来自Ablynx)、和足以具有全长抗体的特异性抗原结合能力的小片段的多肽。工程改造的抗体变体综述于Holliger等,2005；Nat Biotechnol,23:1126-1136中。
如本文中所使用的，术语“全长抗体”意指，由两条“全长重链”或“重链”和两条“全长轻链”或“轻链”组成的抗体。其中，“全长重链”或“重链”是指这样的多肽链，其在N端到C端的方向上由重链可变区(VH)、重链恒定区CH1结构域、铰链区(HR)、重链恒定区CH2结构域、重链恒定区CH3结构域组成；并且，当所述全长抗体为IgE同种型时，任选地还包括重链恒定区CH4结构域。优选地，“全长重链”是在N端到C端方向上由VH、CH1、HR、CH2和CH3组成的多肽链。“全长轻链”或“轻链”是在N端到C端方向上由轻链可变区(VL)和轻链恒定区(CL)组成的多肽链。两对全长抗体链通过在CL和CH1之间的二硫键和两条全长重链的HR之间的二硫键连接在一起。本发明的全长抗体可以来自单一物种，例如人；也可以是嵌合抗体或人源化抗体。本发明的全长抗体包含分别由VH和VL对形成的两个抗原结合部位，这两个抗原结合部位特异性识别/结合相同的抗原。
如本文中所使用的，术语“Fd片段”意指由VH和CH1结构域组成的抗体片段；术语“dAb片段”意指由VH结构域组成的抗体片段(Ward等人,Nature 341:544 546(1989))；术语“Fab片段”意指由VL、VH、CL和CH1结构域组成的抗体片段；术语“F(ab’) 2片段”意指包含通过铰链区上的二硫桥连接的两个Fab片段的抗体片段；术语“Fab’片段”意指还原连接F(ab’) 2片段中两个重链片段的二硫键后所获片段，由一条完整的轻链和重链的Fd片段(由VH和CH1结构域组成)组成。
如本文中所使用的，术语“Fv片段”意指由抗体的单臂的VL和VH结构域组成的抗体片段。Fv片段通常被认为是，能形成完整的抗原结合位点的最小抗体片段。一般认为，六个CDR赋予抗体的抗原结合特异性。然而，即便是一个可变区(例如Fd片段，其仅仅含有三个对抗原特异的CDR)也能够识别并结合抗原，尽管其亲和力可能低于完整的结合位点。
如本文中所使用的，术语“Fc片段”意指，由抗体的第一重链的第二、第三恒定区与第二重链的第二、第三恒定区经二硫键结合而形成的抗体片段。抗体的Fc片段具有多种不同的功能，但不参与抗原的结合。
如本文中所使用的，术语“scFv”是指，包含VL和VH结构域的单个多肽链，其中所 述VL和VH通过接头(linker)相连(参见，例如,Bird等人,Science 242:423-426(1988)；Huston等人,Proc.Natl.Acad.Sci.USA 85:5879-5883(1988)；和Pluckthun，The Pharmacology of Monoclonal Antibodies，第113卷，Roseburg和Moore编，Springer-Verlag，纽约，第269-315页(1994))。此类scFv分子可具有一般结构：NH2-VL-接头-VH-COOH或NH2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成。例如，可使用具有氨基酸序列(GGGGS)4的接头，但也可使用其变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA 90:6444-6448)。可用于本发明的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immunol.31:94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。在一些情况下，scFv的VH与VL之间还可以存在二硫键。如本文中所使用的，术语“di-scFv”是指，由两个scFv连接形成的抗体片段。
如本文中所使用的，术语“双抗体(diabody)”意指，其VH和VL结构域在单个多肽链上表达，但使用太短的连接体以致不允许在相同链的两个结构域之间配对，从而迫使结构域与另一条链的互补结构域配对并且产生两个抗原结合部位(参见，例如,Holliger P.等人,Proc.Natl.Acad.Sci.USA 90:6444-6448(1993)，和Poljak R.J.等人,Structure 2:1121-1123(1994))。
上述各个抗体片段均保持了特异性结合全长抗体所结合的相同抗原的能力，和/或与全长抗体竞争对抗原的特异性结合。
如本文中所使用的，术语“多特异性抗体”是指具有多种不同抗原结合特异性的抗体，包括例如：双特异性抗体,三特异性抗体和四特异性抗体。“双特异性抗体”是指，具有两种不同抗原结合特异性的抗体，其由第一抗体(或其片段)和第二抗体(或其片段)或抗体类似物通过偶联臂所形成的偶联物，偶联的方式包括但不限于化学反应、基因融合，蛋白融合，多肽融合和酶促反应。三特异性抗体是具有三种不同抗原结合特异性的抗体，四特异性抗体是具有四种不同抗原结合特异性的抗体。
如本文中所使用的，“抗体类似物(antibody mimetic)”，指与抗体一样特异性结合抗原，但却没有抗体结构。它们通常是人工肽或蛋白质，摩尔质量约为3至20kDa。例如，锚蛋白重复蛋白(DARPin)和fynomer。经设计的锚蛋白重复蛋白(DARPin)可以与IgG抗体、scFv-Fc抗体片段或其组合相连，如CN104341529A所述。抗IL-17a的fynomer与抗IL-6R抗体结合，如WO2015141862A1所述。
如本文中所使用的，术语“免疫球蛋白”或“Ig”可以指作为抗体起作用的一类蛋白质。由B细胞表达的抗体有时称为抗原受体。包括在这类蛋白质中的五个成员是IgA、IgG、IgM、IgD和IgE，其中IgG是最常见的循环抗体。它是凝集、补体固定和其他抗体反应中最有效的免疫球蛋白，在防御细菌和病毒方面是重要的。
在本文中，获得抗体的技术可使用本领域技术人员已知的常规技术(例如，重组DNA技术或酶促或化学断裂法)从给定的抗体(例如本发明提供的抗体)获得抗体的抗原结合片段(例如，上述抗体片段)，并且以与用于完整抗体的方式相同的方式就特异性筛选抗体的抗原结合片段。
如本文中所使用的，术语“单克隆抗体”、“单抗”、“mAb”具有相同的含义且可互换使用可互换，其是指，来自一群高度同源的抗体分子中的一个抗体或抗体的一个片段，也即，除可能自发出现的自然突变外，一群完全相同的抗体分子。单抗对抗原上的单一表位具有高特异性。多克隆抗体是相对于单克隆抗体而言的，其通常包含至少2种或更多种的不同抗体，这些不同的抗体通常识别抗原上的不同表位。此外，修饰语“单克隆”仅表明该抗体的特征为从高度同源的抗体群中获得，不能理解为需要通过任何特定方法来制备所述抗体。
本发明的单克隆抗体可以通过多种技术进行制备，例如杂交瘤技术(参见，例如Kohler等人.Nature,256:495,1975)，重组DNA技术(参见，例如美国专利申请4,816,567)，或噬菌体抗体库技术(参见，例如Clackson等.Nature352：624-628,1991，或Marks等.J.Mol.Biol.222：581-597,1991)。
例如，可以如下来制备单克隆抗体。首先用免疫原(必要时候添加佐剂)免疫注射小鼠或其它合适的宿主动物。免疫原或佐剂的注射方式通常为皮下多点注射或腹腔注射。可将免疫原预先偶联到某些已知蛋白，如血清白蛋白或大豆胰酶抑制剂上，以增强抗原在宿主内的免疫原性。佐剂可以是弗氏佐剂或MPL-TDM等。动物在接受免疫后，体内将产生分泌特异性结合免疫原的抗体的淋巴细胞。另外，淋巴细胞也可以利用体外免疫获得。收集目的淋巴细胞，并用合适的融合剂，如PEG，使其与骨髓瘤细胞融合以获得杂交瘤细胞(Goding,Monoclonal Antibodies:Principles and Practice,pp.59-103,Academic Press,1996)。上述制备的杂交瘤细胞可以接种到合适的培养液中生长，培养液中优选含有一种或多种能够抑制未融合的、母体骨髓瘤细胞生长的物质。例如，对于缺乏次黄嘌呤鸟嘌呤磷酸转移酶(HGPRT或HPRT)的母体骨髓瘤细胞，在培养液中添加次黄嘌呤、氨基喋呤和胸腺嘧啶(HAT培养基)等物质将可以抑制HGPRT-缺陷细胞的生长。优选的骨髓瘤细胞 应该具有融合率高，抗体分泌能力稳定，对HAT培养液敏感等特征。其中，骨髓瘤细胞首选鼠源骨髓瘤，如MOP-21或MC-11小鼠肿瘤衍生株(THE Salk Institute Cell Distribution Center,San Diego,Calif.USA)，和SP-2/0或X63-Ag8-653细胞株(American Type Culture Collection,Rockville,Md.USA)。另外也有研究报道，利用人骨髓瘤和人鼠异源骨髓瘤细胞株制备人单抗(Kozbor,J.Immunol.,133:3001(1984)；Brodeur et al.,Monoclonal Antibody Production Techniques and Applications,pp.51-63,Marcel Dekker,Inc.,New York,1987)。生长杂交瘤细胞的培养液用于检测针对特异抗原的单抗的产生。测定杂交瘤细胞产生的单抗的结合特异性的方法包括例如，免疫沉淀或体外结合试验，如放射免疫试验(RIA)、酶联免疫吸附试验(ELISA)。例如，可利用Munson等在Anal.Biochem.107:220(1980)描述的Scatchard分析法来测定单抗的亲和力。当确定了杂交瘤产生的抗体的特异性、亲和力和反应性之后，目的细胞株可以通过(Goding,Monoclonal Antibodies:Principles and Practice,pp.59-103,Academic Press,1996)所描述的标准的有限稀释法进行亚克隆化。合适的培养液可以是DMEM或RPMI-1640等。另外，杂交瘤细胞还可以以腹水瘤的形式在动物体内生长。利用传统的免疫球蛋白纯化方法，如蛋白A琼脂糖凝胶、羟基磷灰石层析、凝胶电泳、透析或亲和层析等，可以将亚克隆细胞分泌的单抗从细胞培养液、腹水或血清中分离出来。
还可以通过基因工程重组技术获得单克隆抗体。利用特异性结合单抗重链和轻链基因的核酸引物进行PCR扩增，可以从杂交瘤细胞中分离得到编码单抗重链和轻链基因的DNA分子。将所得的DNA分子插入表达载体内，然后转染宿主细胞(如E.coli细胞、COS细胞、CHO细胞、或其它不产生免疫球蛋白的骨髓瘤细胞)，并在合适的条件下进行培养，可以获得重组表达的目标抗体。
抗体可通过公知的技术，例如使用蛋白A或蛋白G的亲和层析进行纯化。可将特异性抗原(该抗体识别的靶分子)或其抗原表位固定在柱上，并通过免疫亲合层析法来纯化免疫特异性抗体。免疫球蛋白的纯化可参考例如D.Wilkinson(The Scientist,published by The Scientist,Inc.,Philadelphia Pa.,Vol.14,No.8(Apr.17,2000),pp.25-28)。
如本文中所使用的，术语“鼠源抗体”是指，通过将免疫接种过的小鼠的B细胞与骨髓瘤细胞融合，继而筛选出既能无限增殖又能分泌抗体的鼠杂交融合细胞，进而进行筛选、抗体制备和抗体纯化而获得的抗体；或者，由于抗原侵入小鼠体后B细胞分化增殖而形成浆细胞，浆细胞可产生分泌的抗体。
如本文中所使用的，术语“嵌合抗体(Chimeric antibody)”是指，这样的抗体，其 轻链或/和重链的一部分源自一个抗体(其可以源自某一特定物种或属于某一特定抗体类或亚类)，且轻链或/和重链的另一部分源自另一个抗体(其可以源自相同或不同的物种或属于相同或不同的抗体类或亚类)，但无论如何，其仍保留对目标抗原的结合活性(U.S.Patent 4,816,567 to Cabilly et al.；Proc.Natl.Acad.Sci.USA,81:6851 6855(1984))。例如，术语“嵌合抗体”可包括这样的抗体(例如人鼠嵌合抗体)，其中抗体的重链和轻链可变区来自第一抗体(例如鼠源抗体)，而抗体的重链和轻链恒定区来自第二抗体(例如人抗体)。
如本文中所使用的，术语“人源化抗体”是指，经基因工程改造的非人源抗体，其氨基酸序列经修饰以提高与人源抗体的序列的同源性。通常而言，人源化抗体的全部或部分CDR区来自于非人源抗体(供体抗体)，全部或部分的非CDR区(例如，可变区FR和/或恒定区)来自于人源免疫球蛋白(受体抗体)。人源化抗体通常保留了供体抗体的预期性质，包括但不限于，抗原特异性、亲和性、反应性、提高免疫细胞活性的能力、增强免疫应答的能力等。供体抗体可以是有预期性质(例如，抗原特异性、亲和性、反应性、提高免疫细胞活性的能力和/或增强免疫应答的能力)的小鼠、大鼠、兔或非人灵长类动物(例如，食蟹猴)抗体。
人源化抗体既能够保留非人源供体抗体(例如鼠源抗体)的预期性质，又能够有效降低非人源供体抗体(例如鼠源抗体)在人受试者中的免疫原性，因此，是特别有利的。然而，由于供体抗体的CDR与受体抗体的FR之间的匹配问题，人源化抗体的预期性质(例如，抗原特异性、亲和性、反应性、提高免疫细胞活性的能力和/或增强免疫应答的能力)通常低于非人源供体抗体(例如鼠源抗体)。
因此，尽管本领域的研究人员已对抗体的人源化展开了深入的研究，并取得了一些进展(参见例如，Jones et al.,Nature,321:522 525(1986)；Reichmann et al.,Nature,332:323 329(1988)；Presta,Curr.Op.Struct.Biol.,2:593 596(1992)；and Clark,Immunol.Today 21:397 402(2000))，但是，如何对某一供体抗体进行充分的人源化，以使得所产生的人源化抗体既具有尽可能高的人源化程度，又能够尽可能地保留供体抗体的预期性质，现有技术并没有提供详尽的指导。技术人员需要针对具体供体抗体进行摸索、探究和改造，付出大量的创造性劳动才有可能获得，既具有高人源化程度(例如至少75％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％的人源化程度)、又保留具体供体抗体的预期性质的人源化抗体。
在本发明中，为了使人源化抗体尽可能保留供体抗体的性质(包括例如，抗原特异性、亲和性、反应性、提高免疫细胞活性的能力和/或增强免疫应答的能力)，本发明的人源化抗体中构架区(FR)可以既包含人源受体抗体的氨基酸残基，也包含相应的非人源供体抗体的氨基酸残基。
本发明的嵌合抗体或人源化抗体可以根据上述制备的鼠单克隆抗体的序列进行制备。编码重链和轻链的DNA可以从目标鼠杂交瘤中获得，并且使用标准分子生物学技术进行工程改造以包含非鼠(例如人)免疫球蛋白序列。
为制备嵌合抗体，可使用本领域已知的方法将鼠免疫球蛋白可变区连接至人免疫球蛋白恒定区(参见例如Cabilly等人的美国专利No.4,816,567)。例如，将编码VH的DNA可操作的连接至编码重链恒定区的另一DNA分子以获得全长重链基因。人重链恒定区基因的序列是本领域已知的(参见例如Kabat,E.A.等人(1991)Sequences of Proteins of Immunological Interest,Fifth Edition,U.S.Department of Health and Human Services,NIH Publication No.91-3242)，包含这些区的DNA片段可以通过标准PCR扩增获得。重链恒定区可以是IgG1、IgG2、IgG3、IgG4、IgA、IgE、IgM或IgD恒定区，但是通常优选为IgG1或IgG4恒定区。例如，将编码VL的DNA可操作的连接至编码轻链恒定区CL的另一DNA分子以获得全长轻链基因(以及Fab轻链基因)。人轻链恒定区基因的序列是本领域已知的(参见例如Kabat，E.A.等人(1991)Sequences of Proteins of Immunological Interest，Fifth Edition，U.S.Department of Health and Human Services，NIH Publication No.91-3242)，包含这些区的DNA片段可以通过标准PCR扩增获得。轻链恒定区可以是κ或λ恒定区，但通常优选为κ恒定区。
为制备人源化抗体，可以使用本领域已知的方法将鼠CDR区插入人源框架序列(参见Winter的美国专利No.5,225,539；Queen等人的美国专利Nos.5,530,101；5,585,089；5,693,762和6,180,370；以及Lo,Benny,K.C.,editor,in Antibody Engineering:Methods and Protocols,volume 248,Humana Press,New Jersey,2004)。或者，还可以利用转基因动物，其能够在免疫后不产生内源性免疫球蛋白、并且能够产生完整人抗体库。例如，已有报道在嵌合和种系突变小鼠中抗体重链连接区(JH)基因的纯合缺失可以完全抑制了内源性抗体产生，然后将人种系免疫球蛋白基因阵列转移到所述种系突变小鼠中将导致该小鼠在遇到抗原刺激时产生人抗体(参见例如，Jakobovits等，1993，Proc.Natl.Acad.Sci.USA 90：2551；Jakobovits等，1993，Nature362：255-258；Bruggermann等，1993，Year in Immunology 7：33；和Duchosal等，1992，Nature 355： 258)。上述转基因动物的非限制性实例包括，HuMAb小鼠(Medarex,Inc.)，其含有编码未重排的人重链(μ和γ)和κ轻链免疫球蛋白序列的人免疫球蛋白基因微型基因座(miniloci)，加之使内源μ和κ链基因座失活的靶向突变(参见例如Lonberg等人(1994)Nature 368(6474):856-859)；或携带人重链转基因和人轻链转染色体的“KM小鼠TM”(参见专利申请WO02/43478)。其他抗体人源化改造的方法还包括噬菌体展示技术(Hoogenboom等，1991，J.Mol.Biol.227：381；Marks等，J.Mol.Biol.1991，222：581-597；Vaughan等，1996，Nature Biotech 14：309)。
如本文中所使用的，术语“人源化程度”是用于评价人源化抗体中非人源氨基酸残基的数量的指标。人源化抗体的人源化程度例如可通过IMGT网站DomainGapAlign来预测可变区序列与人V结构域的同源性。
如本文中所使用的，术语“同源抗体”指抗体的变体，其包含的重链和轻链可变区所包含的氨基酸序列与本文中所提供的抗体或其抗原结合片段的氨基酸序列同源，且其中所述变体保留了本发明抗FXI和/或FXIa抗体的期望的功能特性。
用于比较的序列比对方法在本领域是熟知的。多种程序和比对算法描述于：Smith TF和Waterman MS,Adv.Appl.Math.,2:482,1981；Higgins DG和Sharp PM,CABIOS5:151,1989。Altschul SF等,Nature Genet.,6:119,1994提供了序列比对方法和同源性计算的详细思路。
如本文中所使用的，术语“特异性结合”是指，两分子间的非随机的结合反应，如抗体和其所针对的抗原之间的反应。特异性结合相互作用的强度或亲和力可以该相互作用的平衡解离常数(KD)或半最大效应浓度(EC50)表示。
两分子间的特异性结合性质可使用本领域公知的方法进行测定。一种方法涉及测量抗原结合位点/抗原复合物形成和解离的速度。“结合速率常数”(ka或kon)和“解离速率常数”(kdis或koff)两者都可通过浓度及缔合和解离的实际速率而计算得出(参见Malmqvist M,Nature,1993,361:186-187)。kdis/kon的比率等于解离常数KD(参见Davies等人,Annual Rev Biochem,1990；59:439-473)。可用任何有效的方法测量KD、kon和kdis值。在某些实施方案中，可以使用生物发光干涉测量法(例如ForteBio Octet法)来测量解离常数。除此以外还可用表面等离子共振技术(例如Biacore)或Kinexa来测量解离常数。
如本文中所使用的，术语“载体(vector)”是指，可将多聚核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸编码的蛋白获得表达时，载体称为表达载体。载 体可以通过转化，转导或者转染导入宿主细胞，使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的，包括但不限于：质粒；噬菌粒；柯斯质粒；人工染色体，例如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC)；噬菌体如λ噬菌体或M13噬菌体及动物病毒等。可用作载体的动物病毒包括但不限于，逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、疱疹病毒(如单纯疱疹病毒)、痘病毒、杆状病毒、乳头瘤病毒、乳头多瘤空泡病毒(如SV40)。一种载体可以含有多种控制表达的元件，包括但不限于，启动子序列、转录起始序列、增强子序列、选择元件及报告基因。另外，载体还可含有复制起始位点。
表达及克隆载体含有使载体能在一或多个所选宿主细胞中复制的核酸序列。通常，在克隆载体中，此序列为使载体能独立于宿主染色体DNA而复制者，且其包括复制起点或自主复制序列。本文所用的术语“表达载体”是指包含重组多核苷酸的载体，其包含与待表达的核苷酸序列有效连接的表达调控序列。表达载体包含用于表达的足够的顺式作用元件(cis-acting elements)；用于表达的其它元件可以由宿主细胞或体外表达系统提供。表达载体包括本领域所有已知的那些，例如粘粒、质粒(例如裸露或包含在脂质体中的)和病毒(例如，慢病毒、逆转录病毒、腺病毒和腺相关病毒)。
如本文中所使用的，术语“宿主细胞”是指，可用于导入载体的细胞，其包括但不限于，如大肠杆菌或枯草菌等的原核细胞，如酵母细胞或曲霉菌等的真菌细胞，如S2果蝇细胞或Sf9等的昆虫细胞，或者如纤维原细胞，CHO细胞，COS细胞，NSO细胞，HeLa细胞，BHK细胞，HEK 293细胞或人细胞等的动物细胞。
如本文中所使用的，术语“同一性”用于指两个多肽之间或两个核酸之间序列的匹配情况。当两个进行比较的序列中的某个位置都被相同的碱基或氨基酸单体亚单元占据时(例如，两个DNA分子的每一个中的某个位置都被腺嘌呤占据，或两个多肽的每一个中的某个位置都被赖氨酸占据)，那么各分子在该位置上是同一的。两个序列之间的“百分数同一性”是由这两个序列共有的匹配位置数目除以进行比较的位置数目×100的函数。例如，如果两个序列的10个位置中有6个匹配，那么这两个序列具有60％的同一性。例如，DNA序列CTGACT和CAGGTT共有50％的同一性(总共6个位置中有3个位置匹配)。通常，在将两个序列比对以产生最大同一性时进行比较。这样的比对可通过使用，例如，可通过计算机程序例如Align程序(DNAstar,Inc.)方便地进行的Needleman等人(1970)J.Mol.Biol.48：443-453的方法来实现。还可使用已整合入ALIGN程序(版本2.0)的E.Meyers和W.Miller(Comput.Appl Biosci.，4:11-17(1988))的算法，使用PAM120权重残基表(weight residue  table)、12的缺口长度罚分和4的缺口罚分来测定两个氨基酸序列之间的百分数同一性。此外，可使用已整合入GCG软件包(可在www.gcg.com上获得)的GAP程序中的Needleman和Wunsch(J MoI Biol.48:444-453(1970))算法，使用Blossum 62矩阵或PAM250矩阵以及16、14、12、10、8、6或4的缺口权重(gap weight)和1、2、3、4、5或6的长度权重来测定两个氨基酸序列之间的百分数同一性。
如本文中所使用的，术语“保守置换”意指不会不利地影响或改变包含氨基酸序列的蛋白/多肽的预期性质的氨基酸置换，通过保守置换氨基酸得到的抗体的变体充分地保留其来源序列的生物学活性，如特异性地与FXI或FXIa结合。例如，可通过本领域内已知的标准技术例如定点诱变和PCR介导的诱变引入保守置换。保守氨基酸置换包括用具有相似侧链的氨基酸残基替代氨基酸残基的置换，例如用在物理学上或功能上与相应的氨基酸残基相似(例如具有相似大小、形状、电荷、化学性质，包括形成共价键或氢键的能力等)的残基进行的置换。已在本领域内定义了具有相似侧链的氨基酸残基的家族。这些家族包括具有碱性侧链(例如，赖氨酸、精氨酸和组氨酸)、酸性侧链(例如天冬氨酸、谷氨酸)、不带电荷的极性侧链(例如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、色氨酸)、非极性侧链(例如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸)、β分支侧链(例如，苏氨酸、缬氨酸、异亮氨酸)和芳香族侧链(例如，酪氨酸、苯丙氨酸、色氨酸、组氨酸)的氨基酸。因此，优选用来自相同侧链家族的另一个氨基酸残基替代相应的氨基酸残基。鉴定氨基酸保守置换的方法在本领域内是熟知的(参见，例如，Brummell等人，Biochem.32:1180-1187(1993)；Kobayashi等人Protein Eng.12(10):879-884(1999)；和Burks等人Proc.Natl Acad.Set USA 94:412-417(1997)，其通过引用并入本文)。
本文涉及的二十个常规氨基酸的编写遵循常规用法。参见例如，Immunology-A Synthesis(2nd Edition,E.S.Golub and D.R.Gren,Eds.,Sinauer Associates,Sunderland,Mass.(1991))，其以引用的方式并入本文中。在本发明中，术语“多肽”和“蛋白质”具有相同的含义且可互换使用。并且在本发明中，氨基酸通常用本领域公知的单字母和三字母缩写来表示。例如，丙氨酸可用A或Ala表示。
如本文中所使用的，术语“药学上可接受的载体和/或赋形剂”是指在药理学和/或生理学上与受试者和活性成分相容的载体和/或赋形剂，其是本领域公知的(参见例如Remington's Pharmaceutical Sciences.Edited by Gennaro AR,19th ed.Pennsylvania:Mack Publishing Company,1995)，并且包括但不限于：pH调节剂，表面活性剂，佐剂， 离子强度增强剂，稀释剂，维持渗透压的试剂，延迟吸收的试剂，防腐剂。例如，pH调节剂包括但不限于磷酸盐缓冲液。表面活性剂包括但不限于阳离子，阴离子或者非离子型表面活性剂，例如Tween-80。离子强度增强剂包括但不限于氯化钠。防腐剂包括但不限于各种抗细菌试剂和抗真菌试剂，例如对羟苯甲酸酯，三氯叔丁醇，苯酚，山梨酸等。维持渗透压的试剂包括但不限于糖、NaCl及其类似物。延迟吸收的试剂包括但不限于单硬脂酸盐和明胶。稀释剂包括但不限于水，水性缓冲液(如缓冲盐水)，醇和多元醇(如甘油)等。防腐剂包括但不限于各种抗细菌试剂和抗真菌试剂，例如硫柳汞，2-苯氧乙醇，对羟苯甲酸酯，三氯叔丁醇，苯酚，山梨酸等。稳定剂具有本领域技术人员通常理解的含义，其能够稳定药物中的活性成分的期望活性，包括但不限于谷氨酸钠，明胶，SPGA，糖类(如山梨醇，甘露醇，淀粉，蔗糖，乳糖，葡聚糖，或葡萄糖)，氨基酸(如谷氨酸，甘氨酸)，蛋白质(如干燥乳清，白蛋白或酪蛋白)或其降解产物(如乳白蛋白水解物)等。
如本文中所使用的，术语“预防”是指，为了阻止或延迟疾病或病症或症状(例如，与凝血或血栓栓塞相关的疾病或病症)在受试者体内的发生而实施的方法。如本文中所使用的，术语“治疗”是指，为了获得有益或所需临床结果而实施的方法。为了本发明的目的，有益或所需的临床结果包括但不限于，减轻症状、缩小疾病的范围、稳定(即，不再恶化)疾病的状态，延迟或减缓疾病的发展、改善或减轻疾病的状态、缓解症状(无论部分或全部)、缓解或改善预后、降低或抑制疾病复发等，无论是可检测或是不可检测的。此外，“治疗”还可以指，与期望的存活期相比(如果未接受治疗)，延长存活期。
如本文中使用的，术语“受试者”是指哺乳动物，例如灵长类哺乳动物，例如人。在某些实施方式中，所述受试者(例如人)患有与凝血或血栓栓塞相关的疾病或病症，或者，具有患有上述疾病的风险。
如本文中所使用的，术语“有效量”是指足以获得或至少部分获得期望的效果的量。例如，预防疾病(例如，与凝血或血栓栓塞相关的疾病或病症)有效量是指，足以预防，阻止，或延迟疾病(例如，与凝血或血栓栓塞相关的疾病或病症)的发生的量；治疗疾病有效量是指，足以治愈或至少部分阻止已患有疾病的患者的疾病和其并发症的量。测定这样的有效量完全在本领域技术人员的能力范围之内。例如，对于治疗用途有效的量将取决于待治疗的疾病的严重度、患者自己的免疫系统的总体状态、患者的一般情况例如年龄，体重和性别，药物的施用方式，以及同时施用的其他治疗等等。
如本文中所使用的，术语“效应子功能(effector function)”是指，那些可归因于抗体Fc区(天然序列Fc区或氨基酸序列变体Fc区)的生物学活性，且其随抗体同种型而 变化。抗体效应子功能的例子包括但不限于：Fc受体结合亲和性、抗体依赖性细胞介导的细胞毒性(ADCC)、补体依赖的细胞毒性(CDC)、抗体依赖性细胞吞噬作用(ADCP)、细胞表面受体(例如B细胞受体)的下调、B细胞活化、细胞因子分泌、抗体和抗原-抗体复合物的半衰期/清除率等。改变抗体的效应子功能的方法是本领域已知的，例如通过在Fc区引入突变来完成。
如本文中所使用的，术语“抗体依赖性细胞介导的细胞毒性(ADCC)”是指，一种细胞毒性形式，免疫球蛋白通过与细胞毒性细胞(例如自然杀伤(NK)细胞、中性粒细胞或巨噬细胞)上存在的Fc受体(FcR)结合，使这些细胞毒性效应细胞特异性结合到抗原附着的靶细胞上，然后通过分泌细胞毒素杀死靶细胞。检测抗体的ADCC活性的方法是本领域已知的，例如可通过测定待测抗体与Fc受体(例如CD16a)之间的结合活性来评价。
如本文中所使用的，术语“补体依赖的细胞毒性(CDC)”是指，通过使补体成分C1q与抗体Fc结合来激活补体级联的细胞毒性形式。检测抗体的CDC活性的方法是本领域已知的，例如可通过测定待测抗体与Fc受体(例如C1q)之间的结合活性来评价。
如本文中所使用的，术语“FXI和/或FXIa介导”是指如下事实：FXI和/或FXIa通过直接或间接活化凝血因子IX(也称为FIX)、凝血因子X(FX)和/或凝血酶和/或通过结合至血小板受体而介导内源凝血途径的活化。
如本文中所使用的，术语“与凝血或血栓栓塞相关的疾病或病症”或类似术语是指凝血途径异常活化或并非天然失活(例如在无治疗性手段下)所导致的病状或疾病。这些病状包括(但不限于)：血栓形成、血栓性中风、心房纤维性颤动、心房纤维性颤动有关的中风预防(SPAF)、深层静脉血栓形成、静脉血栓栓塞、急性冠状动脉综合征(ACS)、缺血性中风、急性肢体局部缺血、慢性血栓栓塞肺高血压、全身栓塞、心肌梗死(MI)、急性心肌梗死(AMI)、稳定型心绞痛、不稳定型心绞痛、冠状动脉介入后的再闭塞和再狭窄、外周动脉闭塞性疾病(PAOD)、肾静脉血栓形成、短暂性脑缺血发作(TIA)、肺血栓栓塞、弥漫性血管内凝血、医疗装置(如导管)引发的血栓栓塞病症、重度全身性炎性反应综合症、转移性癌症、感染性疾病、器官衰竭(如肾衰竭)、体内施用治疗性蛋白质引起的毒性、多发性创伤、缺血再灌注损伤、局部纤维蛋白沉积，成人肺泡蛋白沉积症，关节置换(TKA)手术术前术后的血栓栓塞事件(VTE)，冠心病，心梗后血栓栓塞，非瓣膜房颤患者脑卒中，慢性肾病中的血栓形成及血栓栓塞，经受血液透析的患者及经受体外膜氧化的患者的血栓及血栓栓塞，深静脉血栓形成(DVT)，或肺栓塞(PE)。
导管引发的血栓栓塞病症包括在导管中形成血栓栓塞(例如肿瘤患者中的希克曼导管 (Hickman catheter)，及体外膜氧化(ECMO)的使用过程有可能产生凝块)。
在本文中，表述“预防和/或治疗与凝血或血栓栓塞相关的疾病或病症”可指本发明的抗FXI和/或FXIa抗体或其抗原结合片段可用以预防或治疗的以下病状中的一种或多种：
-怀疑或确诊有心律不整，诸如突发性、持久性或永久性心房纤维性颤动或心房颤动的个体的血栓栓塞；
-心房纤维性颤动中的中风预防(SPAF)，其亚群为经受经皮冠状动脉干预(PCI)的AF患者；
-高出血风险的患者中急性静脉血栓栓塞事件(VTE)治疗及持久继发性VTE预防；
-短暂局部缺血性发作(TIA)或非失能性中风后二级预防及并发窦性节律的心脏衰竭中血栓栓塞事件预防中的大脑及心脏血管事件；
-经受针对心律不整的心脏复律的个体的左心房的凝块形成及血栓栓塞；
-在针对心律不整的切除程序前、期间及后的血栓形成；
-静脉血栓形成，此情况包括(但不排除)治疗及二级预防下部或上部的深层或表面静脉血栓、腹部及胸部静脉的血栓、窦血栓形成及颈静脉血栓形成；
-静脉样导管或起搏器导线中的任何人工表面上的血栓；
-有或无静脉血栓的患者的肺栓塞；
-慢性血栓栓塞性肺高血压(CTEPH)；
-破裂动脉粥样硬化斑上的动脉血栓、动脉内辅具或导管上的血栓及表面上正常的动脉中的血栓，此病状包括(但不限于)急性冠状动脉综合征、ST抬高性心肌梗塞、非ST抬高性心肌梗塞、不稳定绞痛、支架血栓、动脉系统中任何人工表面的血栓及有或无肺高血压的个体的肺部动脉的血栓；
-经受经皮冠状动脉干预(PCI)的患者的血栓形成及血栓栓塞；
-心因性及隐原性中风；
-患有侵入性及非侵入性癌症恶性肿瘤的患者的血栓形成；
-留置导管上的血栓；
-严重疾病患者的血栓及血栓栓塞；
-心脏血栓及血栓栓塞，此包括(但非独占式地)心肌梗塞后的心脏血栓、与诸如心脏动脉瘤、心肌纤维化、心脏增大及功能障碍、心肌炎及心脏中的人工表面的病状有关的心脏血栓；
-有或无心房纤维性颤动的心脏瓣膜病患者的血栓栓塞；
-瓣膜机械或生物辅具上的血栓栓塞；
-在简单或复杂心脏畸形的心脏修复之后具有天然或人工心脏补片、动脉或静脉导管的患者的血栓栓塞；
-膝置换手术、髋置换手术及矫形外科手术、胸部或腹部手术后的静脉血栓及血栓栓塞；
-包括颅内及脊髓干预的神经外科手术后的动脉或静脉血栓；
-先天性或获取性血栓形成倾向，包括(但非独占式地)凝血因子V莱顿、凝血酶原突变、抗凝血酶III、蛋白C及蛋白S缺乏、凝血因子XIII突变、家族纤维蛋白原不良血症、先天性纤维蛋白溶酶原缺乏、凝血因子XI含量增加、镰状细胞疾病、抗磷脂综合征、自身免疫性疾病、慢性肠病、肾病综合征、溶血性尿毒症、骨髓增生疾病、散播性血管内凝血、阵发性夜间血红素尿症及肝素诱导的血小板减少症；
-慢性肾病中的血栓形成及血栓栓塞；及
-经受血液透析的患者及经受体外膜氧化的患者的血栓及血栓栓塞。
如本文中所使用的，术语“药学上可接受的”指当分子本体、分子片段或组合物适当地给予动物或人时，它们不会产生不利的、过敏的或其他不良反应。可作为药学上可接受的载体或其组分的一些物质的具体示例包括糖类(如乳糖)、淀粉、纤维素及其衍生物、植物油、明胶、多元醇(如丙二醇)、海藻酸等。
在本文中，组合疗法包括将本发明涵盖抗FXI和/或FXIa抗体或其抗原结合片段与一或多种另外的第二疗法的活性治疗剂(例如化学治疗剂)或其他预防或治疗模式(例如，抗血小板类药物、抗凝类药物、溶栓药物)组合使用。
第二疗法示例性的抗血小板类药物选自阿司匹林、氯吡格雷、普拉格雷、替格瑞洛、阿昔单抗、依替巴肽、沃拉帕沙或其任意组合。
第二疗法示例性的抗凝类药物选自普通肝素、肝素、低分子肝素、华法林、磺达肝癸钠、依度沙班、贝曲西班、利伐沙班、阿哌沙班、达比加群酯、阿加曲班、比伐卢定或其任意组合。
第二疗法示例性的溶栓药物选自链激酶、尿激酶、阿替普酶或尿激酶原。
在此类组合疗法中，各种活性剂经常具有不同的互补作用机制，组合疗法可能导致协同效应。组合疗法可允许试剂中的一或多种试剂剂量减少，以减少或消除与试剂中之一或多种相关的不良作用。此类组合疗法可对潜在疾病、病症或病状具有协同的治疗或预防作用。
在本文中，“组合”包括可以分开施用的疗法，例如针对单独投药分开调配(例如， 可以在套组中提供)，及可以按单一调配物(亦即“共调配物”)一起施用的疗法。在某些实施方案中，本发明的抗FXI和/或FXIa抗体或其抗原结合片段可依次序施用。在其他实施方案中，抗FXI和/或FXIa抗体或其抗原结合片段可同时施用。本发明的抗FXI和/或FXIa抗体或其抗原结合片段可以与至少一种其他(活性)药剂以任何方式组合使用。
如本文中所使用的，术语“大约”指文中所述数值的正负10％。
中文的语法没有对应英文的单复数规则，所以本公开翻译成英文时，名词前可加上“一个或多个”。
下面将结合附图和实施例对本发明的实施方案进行详细描述，但是本领域技术人员将理解，下列附图和实施例仅用于说明本发明，而不是对本发明的范围的限定。根据附图和优选实施方案的下列详细描述，本发明的各种目的和有利方面对于本领域技术人员来说将变得可实施。
附图说明
图1：杂交瘤上清APTT活性检测
图2A-2B：通过APTT方法检测抗人FXI/FIXa鼠源单克隆抗体的凝血时间
图3：BIOPHEN方法检测抗人FXI/FXIa鼠源单克隆抗体抗凝血功能
图4：抗人FXI/FXIa鼠源单克隆抗体特异性阻断FXI和FXIa的生物学活性
图5：抗人FXI/FXIa人源化抗体APTT抗凝血活性实验
图6：BIOPHEN方法检测抗人FXI/FXIa人源化单克隆抗体抗凝血功能
图7A：ELISA检测抗人FXI/FXIa人源化抗体与FXIa亲和力
图7B：ELISA检测抗人FXI/FXIa人源化抗体与FXI亲和力
图8：抗人FXI/FXIa人源化抗体与对照抗体BAY-1213790竞争结合FXIa检测
图9A：通过测定活化部分凝血活酶时间(APTT)来检测抗人FXI/FXIa人源化抗体在人血中的抗凝活性
图9B：通过测定活化部分凝血活酶时间(APTT)来检测抗人FXI/FXIa人源化抗体在猴血中的抗凝活性
图9C：通过测定活化部分凝血活酶时间(APTT)来检测抗人FXI/FXIa人源化抗体在犬血中的抗凝活性
图9D：通过测定活化部分凝血活酶时间(APTT)来检测抗人FXI/FXIa人源化抗体在 兔血中的抗凝活性
图9E：通过测定活化部分凝血活酶时间(APTT)来检测抗人FXI/FXIa人源化抗体在大鼠血中的抗凝活性
图10：抗人FXI/FXIa人源化抗体加速稳定性检测
图11A：抗人FXI/FXIa人源化抗体食蟹猴体内药效动力学(PD)APTT活性检测
图11B：抗人FXI/FXIa人源化抗体食蟹猴体内药效动力学(PD)PT活性检测
序列信息
本发明涉及的序列的信息描述于下面的表中：
Figure PCTCN2020083413-appb-000005
Figure PCTCN2020083413-appb-000006
具体实施方式
现参照下列意在举例说明本发明(而非限定本发明的范围)的实施例来描述本发明。
除非特别指明，本发明中所使用的分子生物学实验方法和免疫检测法，基本上参照J.Sambrook等人，分子克隆：实验室手册，第2版，冷泉港实验室出版社，1989，以及F.M.Ausubel等人，精编分子生物学实验指南，第3版，John Wiley&Sons,Inc.，1995中所述的方法进行。本领域技术人员知晓，实施例以举例方式描述本发明，且不意欲限制本发明所要求保护的范围。
实施例1.抗人FXI/FXIa鼠源单克隆抗体的制备
采用蛋白免疫方式免疫野生型Balb/c小鼠获得抗人FXI/FXIa鼠源单克隆抗体。每只Balb/c小鼠皮下方式注射CFA(完全弗氏佐剂，厂家：Sigma，货号F5506)乳化25μg人FXIa(厂家：Haematologic Technologies，货号HCXI-0150)和25μg人FXI(厂家：Haematologic Technologies，货号HCXI-0160)进行初次免疫，每两周加强免疫一次，加强免疫采用IFA(不完全弗氏佐剂，厂家：Sigma，货号：F5881)乳化。三次免疫后，通过ELISA检测血清滴度。在融合前3-5天进行加强免疫，选取滴度较高的小鼠用10μg FXIa和10μg FXI腹腔免疫。采用标准的融合流程用PEG融合的方式将小鼠脾脏细胞和Sp2/0-Ag14(ATCC，Cat#CRL-1581)小鼠骨髓瘤细胞进行融合，之后采取HAT(厂家：Sigma，货号：H0262-10VL)加压筛选，14天后进行ELISA筛选。 ELISA筛选具体方法：0.5μg/mL生物素标记的FXI(厂家：Haematologic Technologies，货号：HCXI-0150-B)100μL/孔，室温包被酶标板(厂家：Thermo Fisher Sci.，货号：5129)1小时。使用200μL清洗缓冲液(1×TBS包含0.05％吐温-20)清洗3次,加入100μL杂交瘤上清，37℃孵育1小时。使用200μL清洗缓冲液清洗3次,加入100μL比例为1：8000稀释的Streptavidin-HRP(Pierce,Cat#21130)37℃孵育1小时。使用200μL清洗缓冲液清洗3次,加入100μL的TMB(购自Thermo Fisher Sci.，Cat#TMBW-1000-01)避光显色10分钟,然后加入100μL终止液(购自Thermo Fisher Sci.,Cat#13361-100-10)，酶标仪450nm读数。
通过ELISA筛选了24000个杂交瘤克隆的上清，获得100个能够识别生物素标记的FXI的杂交瘤克隆，转移至24孔板。7-10天后采用APTT功能检测方法测试杂交瘤上清。最优的22个克隆进行有限稀释法进行亚克隆，以获得单克隆杂交瘤。单克隆杂交瘤采用APTT功能检测方法检测抗凝血活性，采用活化部分凝血活酶时间(APTT)试剂盒(Activated Partial Thromboplastin Time Kit，厂家：Thermo Fisher Sci，货号100402)进行检测。具体步骤如下：预热的试管中加入100μL正常人血浆(购自Innovative Research,Cat#IPLA-N),然后加入100μL APTT试剂(购自Thermo Fisher Sci.Cat#100402TS)和100μL检测样品进行混匀，37℃孵育5分钟,然后加入100μL氯化钙(购自Thermo Fisher Sci.Cat#100304，20mM)，测定OD405读数，曲线拟合计算出凝血时间，以Sp2/0-Ag14细胞上清为阴性对照。14E11为阳性对照抗体(参照Aronora专利US8388959B2制备)。APTT实验结果中的倍数的数值是加了实验抗体的样品所测得的凝血时间与未加抗体的对照样品所测得的凝血时间的比值。1倍或以下说明凝血时间不延迟或加快，大于1倍说明凝血时间延长。
如图1所示，APTT一共测试了5个亚克隆杂交瘤上清，其中36G9.10延长了APTT时间，具有显著的抗凝血功能，可以用于进一步的分析，而其它克隆6B6.9、28A8.3、36C3、40F6.9延长凝血时间与阴性对照差异不大。通过同样的筛选获得具有APTT延长持续时间的杂交瘤7B2，用于进一步的分析。
单克隆杂交瘤36G9.10和7B2分别无血清扩大培养至100-150mL。上清通过Protein G填料进行纯化，纯化的鼠源抗体通过HPLC-SEC检测，纯度均大于97％。纯化的鼠源抗体可以用于进一步的功能验证。
实施例2.抗人FXI/FXIa鼠源单克隆抗体的功能鉴定
2.1抗人FXI/FXIa鼠源抗体延长凝血功能测试
采用实施例1中APTT检测方法，在抗体稀释到浓度为2.00、1.00、0.50和0.25μg/mL条件下，比较36G9.10与阳性对照抗体BAY-1213790(参照Bayer专利WO2013167669中M007-H04制备获得)和14E11，PBS缓冲液为阴性对照。
如图2A所示，候选鼠源抗体36G9.10比对照抗体BAY-1213790和14E11在各浓度下均显著延长凝血时间。在抗体浓度5μg/mL条件下，比较7B2与阳性对照抗体14E11，PBS缓冲液为阴性对照，结果如图2B所示，候选鼠源抗体7B2相对于PBS显著延长凝血时间，与阳性对照抗体14E11延长凝血时间相当。
2.2抗人FXI/FXIa鼠源抗体抑制FXIa催化产生FXa作用的活性及其抗凝血功能测定
采用BIOPHEN Factor XIa试剂盒(Hyphen BioMed，货号220412)，按其试剂盒说明书进行测试，通过OD405nm测定para-nitroaniline(pNA)产物的释放进一步确定抗FXI/FXIa抗体抑制FXIa催化产生FXa作用的活性。所有抗体检测浓度为0.25μg/mL，抗FXI/FXIa抗体阻断FXI/FXIa活性功能越强，pNA产物OD405nm信号值越低。
结果如图3所示，36G9.10鼠源抗体比对照抗体BAY-1213790和14E11具有明显更强的抗凝血功能。
2.3抗人FXI/FXIa鼠源单克隆抗体亲和力测试
Octet
Figure PCTCN2020083413-appb-000007
被广泛用于抗体抗原动态亲和力的检测，候选鼠源抗体36G9.10和对照抗体BAY1213790及14E11采用此方法测定与FXIa动态亲和力。具体实验步骤如下：链霉亲和素的探头先与生物素标记的待测抗体结合至应答信号值0.8nm,然后与FXIa蛋白(3.2、1.6、0.8、0.4、0.2、0.1、0.05和0μg/mL)结合5分钟，然后解离7分钟，采用二价分析模型以及全部拟合分析。
如表1所示，36G9.10比对照抗体14E11和BAY-1213790结合速率更快(如Kon数值所示)，而解离速率比BAY-1213790更慢(如Kdis数值所示)，亲和力比对照抗体14E11和BAY-1213790分别强1.7和2.5倍。
表1.抗FXI/FXIa鼠源抗体与FXIa的动态亲和力测定
抗体名称 KD(M) Kon(1/Ms) Kdis(1/s) R 2
14E11 8.03E-10 7.65E+05 6.14E-04 0.9889
BAY-1213790 1.19E-09 9.18E+05 1.09E-03 0.9786
36G9.10 4.80E-10 1.50E+06 7.20E-04 0.9831
2.4抗人FXI/FXIa鼠源抗体特异性阻断FXI和FXIa的生物学活性
为确认鼠源抗体36G9.10特异性阻断FXI和FXIa的生物学活性，采用缺少FXI的人血浆(购自Innovative Research，货号：50-643-396)，通过添加FXI(0.2、0.4、0.8μg/mL),FXIa(0.2、0.4、0.8μg/mL),FXI(0.4μg/mL)和36G9.10(0.4μg/mL)，FXIa(0.4μg/mL)和36G9.10(0.4μg/mL)测定APTT凝血时间。
结果如图4所示，添加FXI或FXIa会显著的缩短FXI缺少的人血浆凝血时间，并呈现剂量依赖，当加入36G9.10鼠源抗体后，FXI和FXIa的凝血的时间明显延长，表明鼠源抗体36G9.10特异性抑制FXI和FXIa的生物学活性。
实施例3.抗人FXI/FXIa鼠源抗体的亚型鉴定及可变区扩增
为了检测候选杂交瘤克隆的抗体亚型，采用Pierce Rapid Isotyping试剂盒(购自Thermo Fisher Sci.Cat#26179)对36G9.10、7B2候选克隆的抗体亚型进行了鉴定。鉴定结果表明候选克隆重链为IgG1亚型，轻链为Kappa亚型。
杂交瘤细胞培养到8000个左右，细胞裂解并采用cDNA反转录试剂盒(购自Thermo Fisher Sci.Cat#18080-200)合成第一链cDNA。采用特殊的引物从cDNA中PCR方式扩增VH和VK基因，PCR产物通过DNA纯化试剂盒(购自Qiagen,Cat#28104)纯化，并连接到TOPO载体上(购自Thermo Fisher Sci.Cat#K457540)。每一个连接反应大概挑取12个克隆进行测序。序列通过Vector NTI 11.5(购自Thermo Fisher Sci.)和Sequencer 5.4.6(购自Genecodes)进行分析,获得抗FXI/FXIa鼠源抗体可变区序列以及CDR序列如序列信息表所示，其中，36G9.10鼠源抗体的重链可变区为SEQ ID NO：1，轻链可变区为SEQ ID NO：2；7B2鼠源抗体的重链可变区为SEQ ID NO：29，轻链可变区为SEQ ID NO：30。进一步，分别构建了36G9.10及7B2的嵌合抗体36G9.10-hz00和7B2-hz00，其是将36G9.10或7B2的重链可变区序列嫁接至突变型人IgG1重链恒定区(N297A突变型)(SEQ ID NO： 21)，将36G9.10或7B2的轻链可变区序列嫁接至人Kappa轻链恒定区(SEQ ID NO:22)而获得。
实施例4.抗人FXI/FXIa鼠源抗体的人源化
采用CDR移植抗体人源化改造方法对鼠源抗体36G9.10，7B2进行人源化改造。简言之，人源化改造涉及以下步骤：把鼠源单克隆抗体的氨基酸序列与人胚系抗体氨基酸序列进行比对，找出同源性高，理化性质较优的序列，作为人胚胎系框架序列；分析考察HLA-DR亲和性，选出亲和力低的人胚胎系框架序列；再将鼠源抗体的六个CDR分别移植到选定的重链及轻链框架序列上。
具体而言，将鼠源抗体36G9.10、7B2的重链和轻链CDR区分别移植到对应的人源化模板的FR框架上。36G9.10的重链人源化模板为人胚系基因序列IGHV1-2*02(参见IMGT登录号X62106)及IGHV1-69-2*01(参见IMGT登录号KF698734),轻链人源化模板人胚系基因序列IGKV1-33*01(参见IMGT登录号M64856)及IGKV1-16*01(参见IMGT登录号J00248)。7B2的重链人源化模板为人胚系基因序列IGHV1-69-2*01(参见IMGT登录号KF698734)，轻链人源化模板为人胚系基因序列IGKV1-39*01(参见IMGT登录号X59315)。
进一步，利用计算机模拟技术，应用分子对接分析可变区及其周边的框架氨基酸序列，考察其空间立体结合方式。通过计算静电力，范德华力，亲疏水性和熵值，分析该鼠源抗体氨基酸序列中可与凝血因子XIa作用以及维护空间构架的关键氨基酸，并在移植后的抗体中，保留这些鼠源的氨基酸。也即，对上述人源化模板的FR区氨基酸残基进行了一系列的回复突变，以使人源化抗体尽可能保留鼠源抗体的抗原结合能力。
根据以上方法，以鼠源抗体36G9.10的CDR为基础，共构建了5株人源化抗体，分别命名为36G9.10-hz43、36G9.10-hz73、36G9.10-hz74、36G9.10-hz92、36G9.10-hz93；其中，各抗体的重链恒定区均为人IgG1重链恒定区(N297A突变型)(SEQ ID NO：21)。以鼠源抗体7B2的CDR为基础，构建了人源化抗体7B2-hz11，重链恒定区均为突变型人IgG1重链恒定区(N297A突变型)(SEQ ID NO：21)。抗体36G9.10-hz73、36G9.10-hz74、36G9.10-hz43、36G9.10-hz92、36G9.10-hz93以及7B2hz11的轻链恒定区序列为SEQ ID NO：22，均不具有ADCC和CDC效应。
上述人源化抗体的可变区及恒定区氨基酸序列如表2所示。
表2.抗人FXI/FXIa人源化抗体可变区及恒定区氨基酸序列
Figure PCTCN2020083413-appb-000008
实施例5.抗人FXI/FXIa抗体的亲和力测定
使用Octet
Figure PCTCN2020083413-appb-000009
测定嵌合和人源化抗体的亲和力。主要测定步骤为：首先将嵌合和人源化的抗体(浓度为0.3μg/mL)分别固定到AHC(anti-human-Fc)传感器上,然后以起始浓度3.2μg/mL对FXI进行1：2梯度稀释，测定嵌合和人源化抗体的结合解离速率。通过Octet数据分析软件分析获得的数据。
结果如表3所示，显示嵌合抗体36G9.10-hz00及人源化抗体36G9.10-hz43，36G9.10-hz73，36G9.10-hz74，36G9.10-hz92，36G9.10-hz93的亲和力KD均强于阳性对照BAY-1213790。
表3.抗人FXI/FXIa人源化抗体结合人FXI的动态亲和力测定
Figure PCTCN2020083413-appb-000010
实施例6.抗人FXI/FXIa嵌合及人源化抗体APTT抗凝血活性、抑制FXIa催化产生FXa活性及其抗凝血功能测定
采用APTT凝血实验试剂盒对人源化后的抗体进行抗凝血活性检测，具体检测方法见实施例1。结果如图5所示，通过4次测定计算平均值及标准差，嵌合抗体36G9.10-hz00， 人源化抗体36G9.10-hz43，36G9.10-hz73，36G9.10-hz74，36G9.10-hz92，36G9.10-hz93凝血延长时间均大于阳性对照抗体14E11和BAY-1213790。
采用Biophen Factor XIa试剂盒(购自Aniara Cat#220412)，对人源化后的抗体进行抗凝血活性检测，具体方法见实施例2。
检测结果如图6所示，嵌合抗体36G9.10-hz00，人源化抗体36G9.10-hz43，36G9.10-hz73，36G9.10-hz74，36G9.10-hz92，36G9.10-hz93，抗体14E11和BAY-1213790均能够有效地减少FXa的产生，抗体36G9.10-hz43，36G9.10-hz73，36G9.10-hz92，36G9.10-hz93相比对照抗体14E11和BAY-1213790更有效地减少FXa的产生，表明其具有更优越的抗凝活性。
实施例7.抗人FXI/FXIa人源化抗体与FXI/FXIa的亲和力测定
采用ELISA法检测36G9.10-hz73与人FXIa亲和力，具体步骤如下：用CBS包被液(称取0.32g Na 2CO 3、0.59g NaHCO 3，去离子水溶解，定容至200ml)稀释FXIa抗原(Haematologic Technologies，HCXIA-160)至1μg/mL，100μL每孔包被FXIa抗原，4℃过夜；第二天弃去孔中液体，用300μL PBS清洗一次；加入100μL PBS(含2％BSA，BOVOGEN，BSAS 1.0)，37℃封闭2小时；用PBS(含2％BSA)稀释36G9.10-hz73及BAY-1213790抗体(10μg/mL起始，4倍稀释，12个浓度点)，取100μL加入对应的孔中，37℃孵育2小时；300μL PBST清洗3次；用PBS(含2％BSA)按1:10000比例稀释HRP标记的羊抗人二抗(购自Jackson，109-035-00)，取100μL加入对应的孔中，37℃孵育1小时；300μL PBST清洗5次；加入100μL TMB显色液(购自BioPanda，TMB-S-004)至对应的孔中，室温显色20分钟；加入50μL 2N H 2SO 4终止，酶标仪(购自MD，SpectraMax M2)OD450nm读数并导入Graphpad Prism进行曲线拟合。
实验结果如图7A所示，36G9.10-hz73与FXIa亲和力EC50为2.488ng/mL，BAY-1213790与FXIa亲和力EC50为6.163ng/mL，36G9.10-hz73优于BAY-1213790。
采用ELISA法检测36G9.10-hz73与人FXI亲和力，用CBS包被液稀释FXI抗原(从义翘神州购买PMD-F11质粒，克隆至PLVX-TRES-PURO载体并转染293F细胞表达获得)至1μg/mL，100μL每孔包4℃包被过夜，其余步骤如前文所示，抗体起始浓度为0.37μg/mL，3倍稀释，9个浓度点。
实验结果如图7B所示，36G9.10-hz73与FXI亲和力EC50为9.68ng/mL，BAY-1213790不与FXI结合。36G9.10-hz73同时中和FXI和FXIa，能发挥更好的抗凝血功能。
实施例8.抗人FXI/FXIa抗体与对照抗体竞争结合FXIa检测
为了确定36G9.10-hz73与BAY-1213790、14E11是否识别FXIa同一表位，采用竞争ELISA方法进行检测。具体步骤如下：用CBS包被液稀释FXIa抗原至1μg/mL，100μL每孔包被FXIa抗原，4℃过夜；第二天弃去孔中液体，用300μL PBS清洗一次；加入100μL PBS(含2％BSA)，37℃封闭2小时；用PBS(含2％BSA)稀释生物素标记的36G9.10-hz73抗体至10ng/mL，并以此为母液稀释BAY-1213790、14E11抗体至10μg/mL取100μL加入对应的孔中，并以10μg/mL 36G9.10-hz73抗体作为阳性对照，以只含10ng/mL生物素标记的36G9.10-hz73抗体作为阴性对照，并设空白对照，37℃孵育2小时；300μL PBST清洗3次；用PBS(含2％BSA)按1:3000比例稀释HRP-Streptavidin二抗(购自Proteintech，SA00001-0)，取100μL加入对应的孔中，37℃孵育1小时；300μL PBST清洗5次；加入100μL TMB显色液(购自BioPanda，TMB-S-004)至对应的孔中，室温显色20分钟；加入50μL 2N H 2SO 4终止，酶标仪(购自MD，SpectraMax M2)OD450nm读数并导入Graphpad Prism进行作图。
实验结果如图8所示，BAY-1213790、14E11均不与36G9.10-hz73竞争结合FXIa，表明前两者与36G9.10-hz73结合FXIa的不同表位。
实施例9.抗人FXI/FXIa抗体抑制FXIa对底物的催化作用
1988年Shun-ichiro KAWABATA等筛选出若干FXIa的特异性荧光标记底物，用于体外灵敏检测人FIXa的酶活(详见Eur.J.Biochem.172,17-25(1988))。因此通过检测人FXIa对特异性荧光底物(I-1575，Bachem)的催化裂解来测定人FXIa活性及抗人FXI/FXIa人源化抗体对FXIa的有效中和作用。具体步骤如下：用含有50mM Tris/HCl、100mM NaCl、5mM CaCl 2和0.1％BSA的缓冲液将人FXIa稀释至1nM，并以此为母液梯度稀释36G9.10-hz73及BAY-1213790抗体，20μg/mL起始，4倍稀释，14个浓度点；取稀释好的抗体10μL每孔加入384孔板(购自Coring，4514)对应孔中，放置于37℃孵育1小时；孵育后每孔加入10μL浓度为2μM的荧光底物I-1575，混匀后立即上机，用酶标仪连续读取360/465nm下的荧光数值，并导入Graphpad Prism进行曲线拟合。
实验结果如表4所示，36G9.10-hz73抗体能够有效抑制FXIa对荧光底物的催化作用，IC50为26.215ng/mL，BAY-1213790IC50为69.96ng/mL，36G9.10-hz73优于BAY-1213790。
表4.抗人FXI/FXIa人源化抗体抑制FXIa对荧光底物的催化作用
抗体名称 IC50值(ng/mL)
36G9.10-hz73 26.215±3.365(n＝2)
BAY-1213790 69.96±7.44(n＝2)
实施例10.通过测定活化部分凝血活酶时间(APTT)来检测抗人FXI/FXIa抗体的抗凝活性
抗凝血浆中加入APTT试剂后，启动内源性凝血途径，使XI激活为XIa，靶向FXIa的抗体能够抑制FXIa的活性，从而延长APTT，因此采用测定APTT来检测抗人FXI/FXIa人源化抗体的抗凝活性。具体步骤如下：分别取人、猴、犬、兔、大鼠静脉血，每个种属取2至3个样本，每个样本取4管血样(每管1.8ml)，用3.2％柠檬酸钠抗凝，2500×g、4℃离心10分钟后，取血浆4℃储存备用(每个样本血浆合并)；将待测抗体用生理盐水稀释，1500μg/mL起始，3个浓度点，作为10×待测抗体母液；高浓度时样品检测体系为150μl，取135μl血浆，再加入15μl待测抗体母液(即，待测抗体母液进行10倍稀释)，然后用全自动凝血分析仪(购自希森美康CA1500)检测APTT。低浓度时样品检测体系为75μl，取67.5μl血浆，再加入7.5μl待测抗体母液(即，待测抗体母液进行10倍稀释)，然后用全自动凝血分析仪检测APTT。
实验结果如图9A所示，4个待测抗体36G9.10-hz73、BAY-1213790、BMS-962212(参考J Med Chem.2017Dec 14；60(23):9703-9723.doi:10.1021/acs.jmedchem.7b01171.Epub 2017Nov 17制备)、14E11在人血浆中均能延长APTT，36G9.10-hz73药效最佳，6μg/mL即可使APTT有2.2倍的延长，优于其它三者。如图9B-9E所示，36G9.10-hz73仅在猴血浆中延长APTT凝血时间,而BAY-1213790在猴、兔血浆中延长APTT凝血时间，14E11在猴、兔、大鼠血浆中延长APTT凝血时间，表明36G9.10-hz73与BAY-1213790、14E11的种属交叉不一样，推测36G9.10-hz73结合FXI/FXIa的抗体表位与BAY-1213790、14E11不同。
凝血酶原时间(PT)检测主要反映外源性凝血系统状况,PT实验结果中的倍数的数值是加了实验抗体的样品所测得的凝血时间与未加抗体的对照样品所测得的凝血时间的比值。1倍或以下说明凝血时间不延迟或加快，大于1倍说明凝血时间延长。
采用上文中相同处理方法通过全自动凝血分析仪检测36G9.10-hz73、BAY-1213790、BMS-962212、14E11对PT影响。检测结果如表5所示，所有样品在5个种属血浆中，与PBS 对照，浓度至150μg/mL(1μM)也都不延长PT(倍数表示)，表明其对外源性凝血无影响，没有增加出血的风险。
表5.抗人FXI/FXIa人源化抗体PT活性检测
抗体名称 人 猴 犬 兔 大鼠
36G9.10-hz73 0.96±0.04 1.00±0.01 1.03±0.01 0.99±0.01 0.99±0.01
BAY-1213790 0.95±0.05 1.00±0.01 1.02±0.01 0.99±0.01 0.99±0.01
14E11 0.95±0.05 / / 1.00±0.01 1.00±0.01
BMS-962212 0.97±0.06 0.99±0.01 1.01±0.01 1.00±0.00 1.00±0.01
实施例11.抗人FXI/FXIa抗体加速稳定性检测
将36G9.10-hz73抗体用20mM His-HCl(盐酸-组氨酸缓冲液)(含0.03％Tween-20，pH5.5)稀释至浓度11.5mg/mL，分别置于40℃、25℃放置14天、28天后，采用实施例4中APTT测定方法检测加速后样品抗凝活性，并通过SEC检测加速后抗体纯度。
实验结果如图10及表6所示，40℃、25℃放置14天、28天对36G9.10-hz73抗体抗凝活性及纯度无明显影响。
表6.抗人FXI/FXIa人源化抗体加速稳定性检测
放置条件 SEC检测纯度(％) APTT检测(EC50，nM)
0天 99.4 18.36
25℃-28天 99.8 17.36
40℃-14天 97.9 20.33
40℃-28天 94.4 26.89
实施例12.抗人FXI/FXIa抗体药代动力学(PK)及药效动力学(PD)检测
为了检测36G9.10-hz73在体内的PK及PD，采用单次静脉注射(IV)或皮下注射(SC)给予食蟹猴不同剂量的36G9.10-hz73抗体，并于不同时间点取血测PK及APTT活性。具体给药分组及剂量如表7所示，其中单次静脉注射或皮下给药体积为2mL/kg，静脉注射部位为四肢静脉，皮下注射部位为颈背部。
表7.抗人FXI/FXIa人源化抗体PK、PD检测给药方案
组别 剂量(mg/kg) 给药方式 动物数 动物性别
1 1 静脉注射 2 1雄+1雌
2 3 静脉注射 3 1雄+2雌
3 3 皮下注射 3 2雄+1雌
完成所有时间点采血以后，以36G9.10-hz73抗体作为标准品，采用实施例7中ELISA方法绘制抗体浓度标准曲线，并在相同条件下以此标准曲线测定每个时间点36G9.10-hz73抗体的血药浓度，最后将测得的血药浓度导入Graphpad Prism进行曲线拟合，计算36G9.10-hz73在食蟹猴体内的PK。
同时在每次采血以后，立即采用实施例10中方法检测APTT，最后将所有时间点数据导入Graphpad Prism进行曲线拟合，计算36G9.10-hz73在食蟹猴体内的PD。
PK检测结果如表8所示，静脉注射3mg/kg 36G9.10-hz73抗体在食蟹猴体内半衰期为290.15小时，皮下注射3mg/kg 36G9.10-hz73抗体在食蟹猴体内半衰期为188.02小时。皮下注射3mg/kg 36G9.10-hz73抗体生物利用度为94％±2％(n＝2)。
表8.抗人FXI/FXIa人源化抗体PK测定
给药方式 半衰期(小时) AUC(0-t,h*μg/mL)
静脉注射-1mg/kg 355.37 3997.79
静脉注射-3mg/kg 290.15 5035.86
皮下注射-3mg/kg 188.02 9581.64
PD检测结果表明36G9.10-hz73用于静脉注射和皮下给药均能达到很好的延长APTT的效果。如图11A所示，两个静脉注射剂量组量效关系明确，3mg/kg的皮下注射给药方式延长APTT效果稍优于静脉注射，其在1008小时仍有约1.3倍的APTT延长效果；如图11B所示，三个剂量组均不延长PT，表明对外源性凝血无影响。因此36G9.10-hz73抗体具有潜在的不引起出血的风险的临床优势。
尽管本发明的具体实施方式已经得到详细的描述，但本领域技术人员将理解：根据已经公布的所有教导，可以对细节进行各种修改和变动，并且这些改变均在本发明的保护范围之内。本发明的全部分为由所附权利要求及其任何等同物给出。

Claims (30)

  1. 特异性结合FXI和/或FXIa的抗体或其抗原结合片段，所述抗体或其抗原结合片段包含：
    (a)如下的三个重链互补决定区(CDRs)：如SEQ ID NOs:1、15、16、17、29、31任一项所示的重链可变区(VH)所含的CDR-H1、CDR-H2以及CDR-H3；和/或
    如下的三个轻链互补决定区(CDRs)：如SEQ ID NOs:2、18、19、20、30、32任一项所示的轻链可变区(VL)所含的CDR-L1、CDR-L2以及CDR-L3；
    或，
    (b)如下的三个重链CDRs：(a)中所述的CDR-H1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-H3或与其相比含有氨基酸突变的变体；和/或
    如下的三个轻链CDRs：(a)中所述的CDR-L1或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L2或与其相比含有氨基酸突变的变体，(a)中所述的CDR-L3或与其相比含有氨基酸突变的变体；
    其中(b)中所述的三个重链CDRs和/或三个轻链CDRs中至少一个CDR,与(a)中相应的CDR相比含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加(例如1个，2个或3个氨基酸的置换、缺失或添加)；优选地，所述的置换是保守置换；
    优选地，所述CDR根据Kabat，IMGT，Chothia或AbM编号系统定义；
    优选地，所述抗体或其抗原结合片段还包括来自人或鼠的免疫球蛋白的构架区(FRs)；
    优选地，所述抗体或其抗原结合片段结合人FXI和/或人FXIa。
  2. 权利要求1所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (1)下述重链可变区(VH)和/或轻链可变区(VL)，其中CDR按IMGT编号系统定义：
    (1a)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：3的CDR-H1，序列为SEQ ID NO：4的CDR-H2，序列为SEQ ID NO：5的CDR-H3；和/或，
    包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：6的CDR-L1，序列为SEQ ID NO：7的CDR-L2，序列为SEQ ID NO：8的CDR-L3；
    或
    (1b)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：33的CDR-H1， 序列为SEQ ID NO：34的CDR-H2，序列为SEQ ID NO：35的CDR-H3；和/或，
    包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：36的CDR-L1，序列为SEQ ID NO：37的CDR-L2，序列为SEQ ID NO：38的CDR-L3；
    (2)下述重链可变区(VH)和/或轻链可变区(VL)，其中CDR按AbM编号系统定义：
    (2a)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：9的CDR-H1，序列为SEQ ID NO：10的CDR-H2，序列为SEQ ID NO：11的CDR-H3；和/或，
    包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：12的CDR-L1，序列为SEQ ID NO：13的CDR-L2，序列为SEQ ID NO：14的CDR-L3；
    或
    (2b)包含如下3个CDRs的重链可变区(VH)：序列为SEQ ID NO：39的CDR-H1，序列为SEQ ID NO：40的CDR-H2，序列为SEQ ID NO：41的CDR-H3；和/或，
    包含如下3个CDRs的轻链可变区(VL)：序列为SEQ ID NO：42的CDR-L1，序列为SEQ ID NO：43的CDR-L2，序列为SEQ ID NO：44的CDR-L3；
    或
    (3)下述重链可变区(VH)和/或轻链可变区(VL)，其中，所述重链可变区(VH)和/或轻链可变区(VL)与(1a)、(1b)、(2a)或(2b)任一所述的重链可变区和/或轻链可变区相比，至少一个CDR含有氨基酸突变，所述氨基酸突变为一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个或3个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换为保守置换；
    优选地，所述抗体或其抗原结合片段的VH和/或VL中包括来自人或鼠的免疫球蛋白的构架区(FRs)；
    优选地，所述抗体或其抗原结合片段结合人FXI和/或人FXIa。
  3. 权利要求1或2所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)SEQ ID NOs：1、15、16、17任一项所示的VH，和/或,SEQ ID NOs：2、18、19、20任一项所示的VL；或
    (b)SEQ ID NOs：29、31任一项所示的VH，和/或,SEQ ID NOs：30、32任一项所示的VL；
    或者，所述抗体或其抗原结合片段所包含的重链可变区(VH)与(a)或(b)任一组中的 VH相比，其重链可变区(VH)具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性；和/或，所述抗体或其抗原结合片段所包含的轻链可变区(VL)与(a)或(b)任一组中的VL相比，其轻链可变区(VL)具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性；
    或者，所述抗体或其抗原结合片段所包含的重链可变区(VH)与(a)或(b)任一组中的VH相比，其重链可变区(VH)具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；和/或，所述抗体或其抗原结合片段所包含的轻链可变区(VL)与(a)或(b)任一组中的VL相比，其轻链可变区(VL)具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换是保守置换。
  4. 权利要求1-3任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)SEQ ID NO：1所示序列的VH和SEQ ID NO：2所示序列的VL；
    (b)SEQ ID NO：15所示序列的VH和SEQ ID NO：18所示序列的VL；
    (c)SEQ ID NO：15所示序列的VH和SEQ ID NO：20所示序列的VL；
    (d)SEQ ID NO：16所示序列的VH和SEQ ID NO：18所示序列的VL；
    (e)SEQ ID NO：17所示序列的VH和SEQ ID NO：19所示序列的VL；
    (f)SEQ ID NO：17所示序列的VH和SEQ ID NO：18所示序列的VL；
    (g)SEQ ID NO：29所示序列的VH和SEQ ID NO：30所示序列的VL；或
    (h)SEQ ID NO：31所示序列的VH和SEQ ID NO：32所示序列的VL；
    或者，所述抗体或其抗原结合片段所包含的重链可变区(VH)和轻链可变区(VL)与(a)至(h)任一组中的VH和VL相比，其重链可变区(VH)具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性；和/或，其轻链可变区(VL)具有至少70％、至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性；
    或者，所述抗体或其抗原结合片段所包含的重链可变区(VH)和轻链可变区(VL)与(a)至(h)任一组中的VH和VL相比，其重链可变区(VH)具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；和/或，其轻链可变区(VL)具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)；优选地，所述的置换是保守置换。
  5. 权利要求1-4任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段是鼠源抗体、嵌合抗体或人源化抗体。
  6. 权利要求1-5任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段进一步包含：
    (a)人免疫球蛋白的重链恒定区(CH)或其变体，所述变体与其所源自的野生型序列相比具有一个或多个氨基酸的置换、缺失或添加或其任意组合(例如，至多20个、至多15个、至多10个、至多5个、4个、3个，2个或1个氨基酸的置换、缺失或添加或其任意组合)；和/或
    (b)人免疫球蛋白的轻链恒定区(CL)或其变体，所述变体与其所源自的野生型序列相比具有一个或多个氨基酸的置换、缺失或添加或其任意组合(例如，至多20个、至多15个、至多10个、至多5个、4个、3个，2个或1个氨基酸的置换、缺失或添加或其任意组合)；
    优选地，所述重链恒定区是IgG重链恒定区，例如IgG1、IgG2、IgG3或IgG4重链恒定区；
    优选地，所述抗体或其抗原结合片段包含选自下列的重链恒定区：
    (1)人IgG1重链恒定区；或，
    (2)人IgG4重链恒定区；
    优选地，所述抗体或其抗原结合片段包含如SEQ ID NO：21所示的重链恒定区(CH)或其变体，所述变体与SEQ ID NO：21相比具有至多20个氨基酸的保守置换(例如，至多20个、至多15个、至多10个、至多5个、4个、3个，2个或1个氨基酸的置换、缺失或添加或其任意组合)；
    优选地，所述轻链恒定区是κ轻链恒定区；
    优选地，所述抗体或其抗原结合片段包含如SEQ ID NO：22所示的轻链恒定区(CL)或其变体，所述变体与SEQ ID NO：22相比具有至多20个氨基酸的保守置换(例如，至多20个、至多15个、至多10个、至多5个、4个、3个，2个或1个氨基酸的置换、缺失或添加或其任意组合)；
    更优选的，所述抗体或其抗原结合片段包含如SEQ ID NO：21所示的重链恒定区(CH)和如SEQ ID NO：22所示的轻链恒定区(CL)。
  7. 权利要求1-6任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包含：
    (a)重链，其包含选自下列的氨基酸序列：
    (i)包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的序列；
    (ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
    (iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；和/或
    轻链，其包含选自下列的氨基酸序列：
    (iv)包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的序列；
    (v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
    (vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
    或
    (b)重链，其包含选自下列的氨基酸序列：
    (i)包含SEQ ID NO：31所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的 序列；
    (ii)与(i)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
    (iii)与(i)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；和/或
    轻链，其包含选自下列的氨基酸序列：
    (iv)包含SEQ ID NO：32所示的VH和SEQ ID NO：22所示的轻链恒定区(CL)的序列；
    (v)与(iv)所示的序列相比具有一个或几个氨基酸的置换、缺失或添加或其任意组合(例如1个，2个，3个，4个或5个氨基酸的置换、缺失或添加或其任意组合)的序列；或
    (vi)与(iv)所示的序列具有至少80％、至少85％、至少90％、至少91％、至少92％、至少93％、至少94％、至少95％、至少96％、至少97％、至少98％、至少99％、或100％的同一性的序列；
    优选地，(ii)或(v)中所述的置换是保守置换。
  8. 权利要求1-7任一项所述的抗体或其抗原结合片段，其中，所述抗体选自如下任一组：
    (a)包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链；
    (b)包含SEQ ID NO：15所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：20所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链；
    (c)包含SEQ ID NO：16所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链；
    (d)包含SEQ ID NO：17所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的 重链，和，包含SEQ ID NO：19所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链；
    (e)包含SEQ ID NO：17所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：18所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链；
    (f)包含SEQ ID NO：31所示的VH和SEQ ID NO：21所示的重链恒定区(CH)的重链，和，包含SEQ ID NO：32所示的VL和SEQ ID NO：22所示的轻链恒定区(CL)的轻链。
  9. 权利要求1-8任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段选自ScFv、Fab、Fab’、(Fab’) 2、Fv片段、二硫键连接的Fv(dsFv)、和双抗体(diabody)。
  10. 权利要求1-9任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段带有标记；
    优选地，所述抗体或其抗原结合片段带有可检测的标记，例如酶(例如辣根过氧化物酶)、放射性核素、荧光染料、发光物质(如化学发光物质)或生物素。
  11. 权利要求1-10任一项所述的抗体或其抗原结合片段，其中所述抗体或其抗原结合片段具有以下特性中的至少一项：
    (a)以小于约100nM，例如小于约10nM、1nM、0.1nM或更低的KD结合FXI和/或FXIa(例如，人FXI和/或人FXIa)；优选地，所述KD通过生物薄膜干涉技术(BLI)测得；
    (b)以小于约500nM，例如小于约100nM、10nM、1nM、0.9nM、0.8nM、0.7nM、0.6nM、0.5nM、0.4nM、0.3nM、0.2nM、0.1nM或更小的EC50结合FXI和/或FXIa(例如，人FXI和/或人FXIa)；优选地，所述EC50通过流式细胞技术或细胞竞争ELISA技术测得；
    (c)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa与底物的结合，从而延长凝血时间；
    (d)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或 FXIa对底物的催化作用；
    (e)所述抗体或其抗原结合片段与FXI和/或FXIa的结合不影响外源性凝血；
    (f)所述抗体或其抗原结合片段具有降低的ADCC和/或CDC活性；
    (g)所述抗体或其抗原结合片段不具有ADCC和/或CDC活性；
    (h)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa各自二聚体的形成；
    (i)所述抗体或其抗原结合片段与FXI和/或FXIa的结合抑制或阻断FXI和/或FXIa与高分子量激肽原(HK)形成复合物；
    (j)所述抗体或其抗原结合片段结合至FXI和/或FXIa的催化结构域，和/或诱导其构象变化；
    (k)所述抗体或其抗原结合片段抑制或阻断FXI和/或FXIa与血小板受体结合；或
    (l)(a)-(k)的任意组合。
  12. 分离的核酸分子，其编码权利要求1-11任一项所述的抗体或其抗原结合片段、其重链和/或轻链、或其重链可变区和/或轻链可变区。
  13. 权利要求12所述的分离的核酸分子，其包含编码抗体重链可变区的核酸分子，和/或编码抗体轻链可变区的核酸分子，其中，
    所述编码抗体重链可变区的核酸分子具有选自下列的核苷酸序列：
    (a)如SEQ ID NO:23或27所示的核苷酸序列，
    (b)与(a)所述的核苷酸序列基本上相同的序列(例如，与(a)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或
    (c)与(a)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列；
    和/或，
    所述编码抗体轻链可变区的核酸分子具有选自下列的核苷酸序列：
    (d)如SEQ ID NO:24或28所示的核苷酸序列，
    (e)与(d)所述的核苷酸序列基本上相同的序列(例如，与(d)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或更高同一性的序列，或具有一个或更多个核苷酸取代的序列)，或
    (f)与(d)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列；
    优选地，所述编码抗体重链可变区的核酸分子具有如SEQ ID NO:23所示的核苷酸序列，和/或所述编码抗体轻链可变区的核酸分子具有如SEQ ID NO:24所示的核苷酸序列；
    优选地，所述编码抗体重链可变区的核酸分子具有如SEQ ID NO:27所示的核苷酸序列，和/或所述编码抗体轻链可变区的核酸分子具有如SEQ ID NO:28所示的核苷酸序列。
  14. 权利要求12-13任一项所述的分离的核酸分子，其包含编码抗体重链的核酸分子，和/或编码抗体轻链的核酸分子，其中，
    所述编码抗体重链的核酸分子具有选自下列的核苷酸序列：
    (a)如SEQ ID NO:25所示的核苷酸序列，
    (b)与(a)所述的核苷酸序列基本上相同的序列(例如，与(a)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或100％同一性的序列，或具有一个或更多个核苷酸取代的序列)，或
    (c)与(a)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列；
    和/或，
    所述编码抗体轻链的核酸分子具有选自下列的核苷酸序列：
    (d)如SEQ ID NO:26所示的核苷酸序列，
    (e)与(d)所述的核苷酸序列基本上相同的序列(例如，与(d)所述的核苷酸序列相比，具有至少大约85％、90％、95％、99％或100％同一性的序列，或具有一个或更多个核苷酸取代的序列)，或
    (f)与(d)所述的核苷酸序列相差不超过3、6、15、30或45个核苷酸的序列；
    优选地，所述编码抗体重链的核酸分子具有如SEQ ID NO:25所示的核苷酸序列，和/或所述编码抗体轻链的核酸分子具有如SEQ ID NO:26所示的核苷酸序列。
  15. 载体，其包含权利要求12-14任一项所述的分离的核酸分子；优选地，所述载体为克隆载体或表达载体。
  16. 宿主细胞，其包含权利要求12-14任一项所述的分离的核酸分子或权利要求15所述的载体。
  17. 制备权利要求1-11任一项所述的抗体或其抗原结合片段的方法，其包括，在允许所述抗体或其抗原结合片段表达的条件下，培养权利要求16所述的宿主细胞，和从培养的宿主细胞培养物中回收所述抗体或其抗原结合片段。
  18. 多特异性抗体，其包含权利要求1-11任一项所述的特异性结合FXI和/或FXIa的抗体或其抗原结合片段，以及另外的抗体或其抗原结合片段，或抗体类似物；
    优选地，所述多特异性抗体是双特异性抗体或三特异性抗体或四特异性抗体。
  19. 缀合物，其包括权利要求1-11任一项所述的特异性结合FXI和/或FXIa的抗体或其抗原结合片段以及偶联部分，其中所述偶联部分为可检测的标记，如放射性同位素、荧光物质、发光物质、有色物质或酶，或者所述偶联部分为治疗剂；
    可选地，所述治疗剂为抗血小板类药物、抗凝类药物、或溶栓药物；
    可选地，所述治疗剂治疗剂通过连接子与权利要求1至11任一项所述的特异性结合FXI和/或FXIa的抗体或其抗原结合片段结合。
  20. 药物组合物，其含有权利要求1-11任一项所述的抗体或其抗原结合片段、权利要求12-14任一项所述的分离的核酸分子、权利要求15所述的载体、权利要求16所述的宿主细胞、权利要求18所述的多特异性抗体、或者权利要求19所述的缀合物，以及药学上可接受的载体和/或赋形剂；
    优选地，药物组合物还包含另外的药学活性剂，例如抗血小板类药物、抗凝类药物或溶栓药物；
    更优选地，所述另外的药学活性剂是阿司匹林、氯吡格雷、普拉格雷、替格瑞洛、阿昔单抗、依替巴肽、沃拉帕沙、普通肝素、肝素、低分子肝素、华法林、磺达肝癸钠、依度沙班、贝曲西班、利伐沙班、阿哌沙班、达比加群酯、阿加曲班、比伐卢定、链激酶、尿激酶、阿替普酶、尿激酶原，或其任意组合。
  21. 权利要求20所述的药物组合物，其中所述的药物组合物中的抗体或其抗原结合片段的有效剂量足以在受试者中引起至少一项以下生物学活性：
    (a)结合至FXI和/或FXIa的催化结构域，和/或诱导其构象变化；
    (b)抑制或阻断FXI和/或FXIa与底物结合；
    (c)抑制或阻断FXI和/或FXIa与血小板受体结合；
    (d)抑制或阻断FXI和凝血因子XIIa(FXIIa)结合，从而抑制或阻断FXI转变为有活性的FXIa；
    (e)抑制或阻断FXIa和凝血因子FIX结合，从而抑制或阻断FIX转变为有活性的FIXa；
    (f)抑制或阻断FXI和/或FXIa介导的内源凝血途径的活化；
    (g)抑制或阻断FXI和/或FXIa在血栓形成中的活性；
    (h)延长FXI和/或FXIa介导的凝血时间；
    (i)抑制血栓形成；
    (j)预防和/或治疗FXI和/或FXIa介导的与凝血或血栓栓塞相关的病症或疾病；或
    (k)(a)-(j)的任意组合。
  22. 如权利要求20或21所述的药物组合物，其还包含第二抗体或编码所述的第二抗体的核酸，其中所述的第二抗体是识别FXI或FXIa不同表位的另一抗体，或者是特异性结合选自以下受体或配体的抗体：凝血酶(thrombin)、抗纤维蛋白溶酶(Antiplasmin)、因子十二(Factor XII)、因子八(Factor VIII)、因子七(Factor VII)、因子十(Factor X)、因子九(Factor IX)、因子二(Factor II)、组织因子(Tissue Factor)、P-选择素及其配体、L-选择素及其配体，或以上抗体的任意组合。
  23. 一种试剂盒，其包括权利要求1-11任一项所述的抗体或其抗原结合片段、或权利要求15所述的载体、或权利要求16所述的宿主细胞、或者权利要求18所述的多特异性抗体、权利要求19所述的缀合物、或者权利要求20-22任一项所述的药物组合物，以及可选地使用说明书。
  24. 权利要求1-11任一项所述的抗体或其抗原结合片段、或权利要求12-14任一项所述的分离的核酸分子、或权利要求15所述的载体、或权利要求16所述的宿主细胞、或者权利要求18所述的多特异性抗体、权利要求19所述的缀合物、权利要求20-22任一项所述的药物组合物在制备用于预防和/或治疗与凝血或血栓栓塞相关的疾病或病症的药物中的用途。
  25. 权利要求1-11任一项所述的抗体或其抗原结合片段、或权利要求12-14任一项所述的分离的核酸分子、或权利要求15所述的载体、或权利要求16所述的宿主细胞、或者权利要求18所述的多特异性抗体、权利要求19所述的缀合物、或者权利要求20-22任一项所述的药物组合物在制备药物中的用途，所述药物用于至少一项以下用途：
    (a)结合至FXI和/或FXIa的催化结构域，和/或诱导其构象变化；
    (b)抑制或阻断FXI和/或FXIa与底物结合；
    (c)抑制或阻断FXI和/或FXIa与血小板受体结合；
    (d)抑制或阻断FXI和凝血因子XIIa(FXIIa)结合，从而抑制FXI转变为有活性的FXIa；
    (e)抑制或阻断FXIa和凝血因子FIX结合，从而抑制FIX转变为有活性的FIXa；
    (f)抑制或阻断FXI和/或FXIa介导的内源凝血途径的活化；
    (g)抑制或阻断FXI和/或FXIa在血栓形成中的活性；
    (h)延长FXI和/或FXIa介导的凝血时间；
    (i)抑制血栓形成；
    (j)预防和/或治疗FXI和/或FXIa介导的与凝血或血栓栓塞相关的疾病或病症；或
    (k)(a)-(j)的任意组合。
  26. 根据权利要求24或25所述的用途，其中所述的与凝血或血栓栓塞相关的疾病或病症选自：血栓形成、血栓性中风、心房纤维性颤动、心房纤维性颤动有关的中风预防(SPAF)、深层静脉血栓形成、静脉血栓栓塞、急性冠状动脉综合征(ACS)、缺血性中风、急性肢体局部缺血、慢性血栓栓塞肺高血压、全身栓塞、心肌梗死(MI)、急性心肌梗死(AMI)、稳定型心绞痛、不稳定型心绞痛、冠状动脉介入后的再闭塞和再狭窄、外周动脉闭塞性疾病(PAOD)、肾静脉血栓形成、短暂性脑缺血发作(TIA)、肺血栓栓塞、弥漫性血管内凝血、医疗装置(如导管)引发的血栓栓塞病症、重度全身性炎性反应综合症、转移性癌症、感染性疾病、器官衰竭(如肾衰竭)、体内施用治疗性蛋白质引起的毒性、多发性创伤、缺血再灌注损伤、局部纤维蛋白沉积，成人肺泡蛋白沉积症，关节置换(TKA)手术术前术后的血栓栓塞事件(VTE)，冠心病，心梗后血栓栓塞，非瓣膜房颤患者脑卒中，慢性肾病中的血栓形成及血栓栓塞，经受血液透析的患者及经受体外膜氧化的患者的血栓及血栓栓塞，深静脉血栓形成(DVT)，或肺栓塞(PE)。
  27. 一种用于在受试者中预防和/或治疗与凝血或血栓栓塞相关的疾病或病症、和/或延迟与凝血或血栓栓塞相关的疾病或病症发生、和/或降低或抑制与凝血或血栓栓塞相关的疾病或病症复发的方法，所述方法包括向有此需要的受试者施用有效量的权利要求1-11任一项所述的抗体或其抗原结合片段、或权利要求12-14任一项所述的分离的核酸分子、或权利要求15所述的载体、或权利要求16所述的宿主细胞、或者权利要求18所述的多特异性抗体、权利要求19所述的缀合物、或者权利要求20-22任一项所述的药物组合物，所述受试者是哺乳动物；优选的，所述受试者是人。
  28. 权利要求27所述的方法，其还包括向所述受试者施用第二疗法，所述第二疗法包括施用选自抗血小板类药物、抗凝类药物、溶栓药物中的一种或多种的第二药物；
    优选地，所述第二药物选自阿司匹林、氯吡格雷、普拉格雷、替格瑞洛、阿昔单抗、依替巴肽、沃拉帕沙、普通肝素、肝素、低分子肝素、华法林、磺达肝癸钠、依度沙班、贝曲西班、利伐沙班、阿哌沙班、达比加群酯、阿加曲班、比伐卢定、链激酶、尿激酶、阿替普酶、尿激酶原，或其任意组合。
  29. 权利要求27或28所述的方法，其中所述与凝血或血栓栓塞相关的疾病或病症选自:血栓形成、血栓性中风、心房纤维性颤动、心房纤维性颤动有关的中风预防(SPAF)、深层静脉血栓形成、静脉血栓栓塞、急性冠状动脉综合征(ACS)、缺血性中风、急性肢体局部缺血、慢性血栓栓塞肺高血压、全身栓塞、心肌梗死(MI)、急性心肌梗死(AMI)、稳定型心绞痛、不稳定型心绞痛、冠状动脉介入后的再闭塞和再狭窄、外周动脉闭塞性疾病(PAOD)、肾静脉血栓形成、短暂性脑缺血发作(TIA)、肺血栓栓塞、弥漫性血管内凝血、医疗装置(如导管)引发的血栓栓塞病症、重度全身性炎性反应综合症、转移性癌症、感染性疾病、器官衰竭(如肾衰竭)、体内施用治疗性蛋白质引起的毒性、多发性创伤、缺血再灌注损伤、局部纤维蛋白沉积，成人肺泡蛋白沉积症，关节置换(TKA)手术术前术后的血栓栓塞事件(VTE)，冠心病，心梗后血栓栓塞，非瓣膜房颤患者脑卒中，慢性肾病中的血栓形成及血栓栓塞，经受血液透析的患者及经受体外膜氧化的患者的血栓及血栓栓塞，深静脉血栓形成(DVT)，或肺栓塞(PE)。
  30. 一种检测样品中FXI和/或FXIa存在或其水平的方法，包括在允许所述抗体或其抗原结合片段与FXI和/或FXIa之间形成复合物的条件下，使所述样品与权利要求1-11 任一项所述抗体或其抗原结合片段、或者权利要求19所述的缀合物接触，和检测所述复合物的形成。
PCT/CN2020/083413 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途 WO2020211674A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US17/310,957 US20220162338A1 (en) 2019-04-16 2020-04-06 Anti-fxi/fxia antibody and use thereof
JP2021548201A JP2022528595A (ja) 2019-04-16 2020-04-06 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
EP20791510.9A EP3957652A4 (en) 2019-04-16 2020-04-06 ANTI-FXI/FXIA ANTIBODIES AND THEIR USE
KR1020217026020A KR20210151774A (ko) 2019-04-16 2020-04-06 항-FXI/FXIa 항체 및 그 용도
CN202311157496.9A CN117186232A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途
CN202080014807.4A CN113474374A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910303627 2019-04-16
CN201910303627.7 2019-04-16

Publications (1)

Publication Number Publication Date
WO2020211674A1 true WO2020211674A1 (zh) 2020-10-22

Family

ID=72838014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/083413 WO2020211674A1 (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Country Status (6)

Country Link
US (1) US20220162338A1 (zh)
EP (1) EP3957652A4 (zh)
JP (1) JP2022528595A (zh)
KR (1) KR20210151774A (zh)
CN (2) CN113474374A (zh)
WO (1) WO2020211674A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131213A1 (zh) * 2022-01-05 2023-07-13 上海迈晋生物医药科技有限公司 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
WO2013167669A1 (en) 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
CN104341529A (zh) 2013-07-26 2015-02-11 三星电子株式会社 带有DARPin的双特异性嵌合蛋白
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016207858A1 (en) * 2015-06-26 2016-12-29 Novartis Ag Factor xi antibodies and methods of use
WO2018116255A1 (en) * 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021129189A (ru) * 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
BR112018069283A2 (pt) * 2016-03-23 2019-01-22 Prothix Bv anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos
JP7110199B2 (ja) * 2016-12-23 2022-08-01 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体による処置法
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4366241B1 (zh) 1980-08-07 1988-10-18
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
WO2013167669A1 (en) 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
CN104341529A (zh) 2013-07-26 2015-02-11 三星电子株式会社 带有DARPin的双特异性嵌合蛋白
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016207858A1 (en) * 2015-06-26 2016-12-29 Novartis Ag Factor xi antibodies and methods of use
WO2018116255A1 (en) * 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
"Antibody Engineering: Methods and Protocols", vol. 248, 2004, HUMANA PRESS
ALFTHAN ET AL., PROTEIN ENG, vol. 8, 1995, pages 725 - 731
ALTSCHUL SF ET AL., NATURE GENET., vol. 6, 1994, pages 119
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
BRUGGERMANN ET AL., YEAR IN IMMUNOLOGY, vol. 7, 1993, pages 33
BRUMMELL ET AL., BIOCHEM, vol. 32, 1993, pages 1180 - 1187
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
D. WILKINSON: "The Scientist", vol. 14, 17 April 2000, THE SCIENTIST, INC., pages: 25 - 28
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473
DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17
EUR. J. BIOCHEM., vol. 172, 1988, pages 17 - 25
F.M. AUSUBEL ET AL.: "Short Protocols in Molecular Biology", 1995, MACK PUBLISHING COMPANY
HIGGINS DGSHARP PM, CABIOS, vol. 5, 1989, pages 151
HOLLIGER ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381 - 597
HU ET AL., CANCER RES, vol. 56, 1996, pages 3055 - 3061
HUDSON, CURR. OPIN. IMMUNOL., vol. 11, 1999, pages 548 - 557
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
J MED CHEM., vol. 60, no. 23, 17 November 2017 (2017-11-17), pages 9703 - 9723
J. SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
JAKOBOVITS ET AL., NATURE, vol. 361, 1993, pages 186 - 187
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 6448
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 596
KABAT, EA ET AL.: "Sequences of Proteins of Immunological Interest, Fifth Edition", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KOBAYASHI ET AL., PROTEIN ENG, vol. 12, no. 10, 1999, pages 879 - 884
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77
LITTLE ET AL., IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402
LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859
MARTIN ACR, CHEETHAM JC,REES AR: "Modelling antibody hypervariable loops: A combined algorithm", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 9268 - 9272, XP000165667, DOI: 10.1073/pnas.86.23.9268
MARTIN ACRCHEETHAM JCREES AR, PROC NATL ACAD SCI USA, vol. 86, 1989, pages 9268 - 9272
MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, vol. 24, 1992, pages 107 - 117
MUNSON ET AL., ANAL. BIOCHEM., vol. 107, 1980, pages 220
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
POLJAK RJ ET AL., STRUCTURE, vol. 113, 1994, pages 1121 - 1123
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROOVERS ET AL., CANCER IMMUNOL, 2001
See also references of EP3957652A4
SMITH TFWATERMAN MS, ADV.APPL.MATH., vol. 2, 1981, pages 482
VAUGHAN ET AL., NATURE BIOTECH, vol. 14, 1996, pages 309 - 103
ZILBERMAN-RUDENKO J: "Coagulation factor XI promotes distal platelet activation and single platelet connsumpation in the bloodstream under shear flow", ARTERIOSCLER THROMB VASC BIOL, vol. 36, no. 3, March 2016 (2016-03-01), pages 510 - 517

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131213A1 (zh) * 2022-01-05 2023-07-13 上海迈晋生物医药科技有限公司 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Also Published As

Publication number Publication date
EP3957652A4 (en) 2023-06-21
JP2022528595A (ja) 2022-06-15
CN113474374A (zh) 2021-10-01
CN117186232A (zh) 2023-12-08
US20220162338A1 (en) 2022-05-26
EP3957652A1 (en) 2022-02-23
KR20210151774A (ko) 2021-12-14

Similar Documents

Publication Publication Date Title
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
ES2672267T3 (es) Anticuerpo del factor tisular humano y usos del mismo
KR102448456B1 (ko) 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도
US20200384106A1 (en) Novel anti-human gpvi antibodies and uses thereof
TW201728602A (zh) 抗凝固因子ｘｉ抗體
BR112012028306A2 (pt) anticorpos para proteína 6 relacionada com lipoproteína de baixa densidade (lrp6) e seus fragmentos, seu uso, ácidos nucléicos, vetores, bem como composições farmacêuticas e combinações
CN107531797B (zh) 凝血酶抗体、其抗原结合片段及医药用途
US20230391869A1 (en) Inhibition of platelet aggregation using anti-human gpvi antibodies
JPWO2015125904A1 (ja) 新規抗ヒトｐａｉ−１抗体
WO2021254481A9 (zh) 抗Claudin18.2抗体以及其用途
WO2020211674A1 (zh) 抗FXI/FXIa抗体及其用途
TW202214701A (zh) 抗ＦＸＩ／ＦＸＩａ抗體、其抗原結合片段及醫藥用途
JP2022523007A (ja) 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用
CN112442127A (zh) 针对tfpi的单克隆抗体
JP7454106B2 (ja) 新規な抗ａ２ａｐ抗体およびその使用
US20240101709A1 (en) Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
WO2019096294A1 (zh) 凝血酶抗体、其抗原结合片段及医药用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20791510

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021548201

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020791510

Country of ref document: EP

Effective date: 20211116